

INDEX

1. AN INTRODUCTION TO THE CANNABIS PLANT
 - 1.1 *The Different Forms of Cannabis*
 - 1.2 *The Botany of Cannabis sativa*
 - 1.3 *A Short History of Cannabis*
 - 1.4 *Chemical Constituents of Cannabis*

2. CANNABINOIDS
 - 2.1 *Cannabinoids Defined*
 - 2.2 *Biosynthesis of the Cannabinoids*
 - 2.2.1 *The acidic cannabinoids*
 - 2.2.2 *Occurrence of short-chain cannabinoids and other homologues*
 - 2.3 *A Phytochemical Classification of Cannabinoids*
 - 2.4 *Chromatographic Analysis of Cannabinoids*
 - 2.4.1 *Decarboxylation*
 - 2.4.2 *Microscopy*
 - 2.4.3 *Color reactions*
 - 2.4.4 *Thin-layer chromatography*
 - 2.4.5 *Gas chromatography*
 - 2.4.6 *High-performance liquid chromatography*
 - 2.4.7 *Other techniques*
 - 2.4.8 *Spectroscopic and chromatographic data*

3. SITES AND MECHANISMS OF ACTION OF CANNABINOIDS
 - 3.1 *The Cannabinoid Receptors: CB1 and CB2*
 - 3.2 *The Endocannabinoid System*
 - 3.3 *Pharmacokinetics of the Cannabinoids (ADME)*
 - 3.4 *Structure-Activity Relationships of Cannabinoids*
 - 3.5 *Administration Forms*

4. BIOLOGICAL EFFECTS OF THE CANNABINOIDS
 - 4.1 *Delta-9-Tetrahydrocannabinol (THC)*
 - 4.2 *Cannabidiol (CBD)*

- 4.3 *Delta-8-Tetrahydrocannabinol (Delta-8-THC)*
- 4.4 *Cannabigerol (CBG)*
- 4.5 *Cannabinol (CBN)*
- 4.6 *Cannabichromene (CBC)*
- 4.7 *Tetrahydrocannabivarin (THCV)*
- 4.8 *The Acidic Cannabinoids*

5. NON-CANNABINOID CONSTITUENTS OF CANNABIS

- 5.1 *Terpenoids*
 - 5.5.1 *Biosynthesis and composition of Cannabis essential oils*
 - 5.1.2 *Biological effects of terpenoids*
- 5.2 *Flavonoids*
 - 5.2.1 *Biosynthesis of flavonoids in cannabis*
 - 5.2.2 *Biological effects of flavonoids*
 - 5.2.3 *Therapeutic potential*
- 5.3 *Hemp Oil*
 - 5.3.1 *Production methods*
 - 5.3.2 *Composition of hemp oil*
 - 5.3.3 *Therapeutic potential*
 - 5.3.4 *Cannabinoid contamination of hemp oil products*
- 5.4 *Other Components Found in Cannabis*
 - 5.4.1 *Alkaloids and nitrogenous compounds*
 - 5.4.2 *Non-cannabinoid phenols*
 - 5.4.3 *Stilbenoids*
 - 5.4.4 *Lignanamides and phenolic amides*

6. CANNABIS AS A MEDICINE

- 6.1 *Therapeutic Potential of Cannabinoids*
- 6.2 *Current Status of Cannabinoid Medicines*
- 6.3 *Approaches for Further Development*
 - 6.3.1 *Improving the biological availability of cannabinoids*
 - 6.3.2 *Selective activation of cannabinoid receptors*
 - 6.3.3 *Modulating the endocannabinoid system*
 - 6.3.4 *Interaction with other neurotransmitter pathways*

7. PRACTICAL ASPECTS OF CANNABIS RESEARCH

7.1 *Legal Aspects*

7.2 *Availability of Plant Materials and Reference Standards*

7.3 *Social aspects*

8. REFERENCES

1. AN INTRODUCTION TO THE CANNABIS PLANT

Almost no plant has been studied as much as the Cannabis plant (*Cannabis sativa* L.); more than 10.000 papers have been published describing various aspects of Cannabis as a biologically active plant. Nonetheless, it is hard to think of a medical topic that can so strongly divide the research community as the medicinal use of Cannabis. It may even be stated that Cannabis is the most controversial plant in the history of mankind. But imagine *Cannabis sativa* would be discovered today, growing in some remote spot of the world, it would be hailed as a wonder of nature; a new miracle plant with the potential to treat anything ranging from headaches to neurological disorders to cancer. Still, the potential of Cannabis was largely ignored until the discovery of the human endocannabinoid system, about a decade ago. Nowadays it is known that many of our own body functions are controlled by Cannabis-like substances in our brain, immune system and other organs.

But Cannabis plants are interesting to human society in more ways. As a fiber plant, Cannabis produces some of the best and most durable fibers of natural origin, historically used to produce ropes and sails for sea-ships, paper, banknotes and even the first Levi's jeans. Modern applications include dashboards for exclusive cars and insulation for houses. The oil of the hempseed was found to be well balanced in regards to the ratio of omega-3 and -6 fatty acids for human nutrition, and can be used as a sustainable alternative to fish-oil. Furthermore, the oil is ideal as an ingredient for body oils and lipid-enriched creams.

The medicinal use of Cannabis has a very long history. However, the availability of alternative treatments, absence of quality control, and sociopolitical pressure led to a decline in the medical use of Cannabis by the beginning of the 20th century. As a result, in the last decades its medicinal potential continues to be disputed. But despite its illegality, people have continued to obtain Cannabis on the black market for self-medication.

At least one bioactivity of Cannabis is undisputed: the psycho-active effect of delta-9-tetrahydrocannabinol, usually abbreviated as THC, is one of the best studied biological activities in the world. As a result, the attention has shifted from the Cannabis plant as a whole, to its main psycho-active component. Interestingly, THC, a terpenophenolic compound, contains no nitrogen atom and therefore is not an alkaloid, which is rare amongst the psychotropically active compounds. Furthermore, therapeutically used THC is among the most non-polar compounds used in medicine today. Chemically, THC belongs to a group of closely related compounds known as cannabinoids, and they are considered the main

bioactive components of Cannabis. Up to date, already 70 different cannabinoids have been described, several of which were found to be bioactive in one or more ways.

Cannabis has the potential to evolve into useful and much needed new medicines, but this is seriously obstructed by its classification as a dangerous narcotic. But as shown in the case of the poppy plant (*Papaver somniferum*) and the opiates derived from it (e.g. morphine, codeine), the distinction between a dangerous drug of abuse and a medicine can be made by proper, unbiased and well conducted research, combined with a rational approach. Relevant biological activities, as shown by thorough research in the lab, and finally confirmed through properly conducted clinical trials, are the best guarantee for the future of Cannabis as a medicine. The information presented in this chapter should help researchers of various disciplines to understand the current scientific status of the Cannabis plant and its constituents.

1.1 *The Different Forms of Cannabis*


Together with coffee and tobacco, Cannabis is the most commonly used psychoactive drug worldwide, and it is the single most popular illegal drug. Worldwide over 160 million people are using Cannabis regularly and these numbers are still rising.¹ With such high popular demand, it is not surprising that Cannabis and its products are known under a large variety of names. Some of the most widely used ones are defined here.

The commonly used term *marijuana* or *marihuana* traditionally describes the Cannabis plant when used as a recreational drug, and is frequently associated with the negative effects or social impact of the drug. *Weed* is another name for Cannabis when used as a recreational drug. When the term *hemp* is used, it usually refers to the use of Cannabis as a source of fiber, making the term fiber-hemp therefore somewhat superfluous. Because of the inexact and unscientific nature of these terms, they will not be used in this chapter. Instead, the proper scientific name *Cannabis* will be consistently used to describe the plant *Cannabis sativa* L. in all its varieties.

When talking about Cannabis for either recreational, medicinal or scientific use, what is usually referred to are the female flowers (also known under the Latin name *Flos*), being the most potent part of the plant. The dried resin obtained from these flowers is generally known as *hash*, or *hashish*, although a large variety of names exist throughout the world. This resin is the source of the most important bioactive components of the Cannabis plant, the *cannabinoids*, which will be the main focus throughout this chapter.

Finally, *dronabinol* is another name for the naturally occurring (-)-*trans*-isomer of THC, often used in a medical context in the scientific and political literature, and adopted by the World Health Organization.

Figure 1: *Cannabis sativa* L. A female plant in full bloom. Photo used with permission by Bedrocan BV, The Netherlands.



1.2 The Botany of *Cannabis sativa*

The basic material of all Cannabis products is the plant *Cannabis sativa* L (figure 1). It is an annual, usually dioecious, more rarely monoecious, wind-pollinated herb, with male and female flowers developing on separate plants. It propagates from seed, grows vigorously in open sunny environments with well drained soils, and has an abundant need for nutrients and water. It can reach up to 5 meters (16 feet) in height in a 4-6 month growing season. However, in modern breeding and cultivation of recreational Cannabis, the preferred way to propagate the plants is by cloning, using cuttings of a so-called mother plant. As this term indicates, female plants are used for this purpose, as they produce significantly higher amounts of psychoactive compounds than the male plants.

The sexes of Cannabis are anatomically indistinguishable before they start flowering, but after that, the development of male and female plants varies greatly. Shorter days, or more accurately longer nights, induce the plant to start flowering.² The female plant then produces several crowded clusters of individual flowers (flowertops); a large one at the top of the stem and several smaller ones on each branch, while the male flowers hang in loose clusters along a relatively leafless upright branch. The male plants finish shedding pollen and die before the seeds in the female plants ripen four to eight weeks after being fertilized. A large female can produce over one kilogram of seed. If the seed survives, it may germinate the next spring.

According to current botanical classification, Cannabis belongs, only with *Humulus* (hops), to the small family of *Cannabinaceae* (also *Cannabaceae* or *Cannabidaceae*).^{3,4,5} Despite this close relationship, cannabinoids (see section 2.1) can only be found in *Cannabis sativa*. In the genus *Humulus*, even in grafting experiments between Cannabis and *Humulus*, no cannabinoids have been found,^{6,7} but instead a variety of so-called bitter-acids, such as humulone, adhumulone and cohumulone are produced. The close relationship between both plant species is clearly shown by the fact that the compounds (cannabinoids and bitter-acids, respectively) are both derived from similar biosynthetic pathways (see section 2.2). Furthermore, both are excreted as a resinous mixture by glandular hairs, mainly found on female flowers.

The current systematic classification of Cannabis is:⁸

Division	Angiosperms
Class	Dicotyledon
Subclass	Archichlamydeae
Order	Urticales
Family	Cannabinaceae
Genus	<i>Cannabis</i>
Species	<i>sativa</i> L.

Because of centuries of breeding and selection, a large variation of cultivated varieties (or cultivars) has been developed. Already, more than 700 different cultivars have been described⁹ and many more are thought to exist. As a result, there has been extensive discussion about further botanical and chemotaxonomic classification. So far, several classifications of Cannabis have been proposed. Originally, this was a classification into *Cannabis sativa* L., *C. indica* Lam and *C. ruderalis* Janisch^{10,11,12} or *Cannabis sativa* L. ssp. *Sativa* and ssp. *Indica*.^{13,14,15} However, it is becoming commonly accepted that Cannabis is monotypic and consists only of a single species *Cannabis sativa*, as described by Leonard Fuchs in 16th century.^{16,17,18,19}

To solve the controversy in a biochemical way, a first chemical classification was done by Grlic,²⁰ who recognized different ripening stages. Fetterman *et al.*²¹ described different phenotypes based on quantitative differences in the content of main cannabinoids and he was the first to distinguish the drug- and fiber- type. Further extension and perfection of this approach was subsequently done by Small and Beckstead,²² Turner *et al.*²³, and Brenneisen and Kessler.²⁴ However, it was found that a single plant could be classified into different phenotypes, depending on its age. Although these chemotaxonomic classifications do not strictly define the contents of main cannabinoids for each chemotype, it does provide a practical tool for classification. A final validation of Cannabis classification awaits further chemotaxonomic and genetic research.

For forensic and legislative purposes, the most important classification of Cannabis types is that into the fiber-type and the drug-type. The main difference between these two is found in the content of the psychotropically active component Δ^9 -tetrahydrocannabinol (THC), and its acidic precursor tetrahydrocannabinolic acid (THCA, see section 2.2): a high content of THC+THCA classifies as drug-type Cannabis, while a low THC+THCA content (below 0.2 -

0.3% of dry weight) is found in fiber-type Cannabis. All Cannabis varieties presently used for medicinal purposes belong to the drug-type, because of their high content of the biologically active THC. But although fiber-type Cannabis is currently not used for medicinal or recreational purpose, it does contain components that have been found to be biologically active, most notably the cannabinoid cannabidiol (CBD). This indicates that the distinction between the two types may have limited relevance for medicinal research into Cannabis.

1.3 A Short History of Cannabis

Cannabis most likely originates from Central Asia, as archeological evidence indicates it was cultivated in China for food and fiber already 10,000 years ago. Even in ancient Egyptian mummies clues have been found for the use of Cannabis as food or medicine.²⁵ In fact, Cannabis is one of the oldest known medicinal plants and is described in almost every ancient handbook on plant medicine, most commonly in the form of a tincture or a tea.^{26,27} Some religions were closely related with the properties of the Cannabis plant. For example, in Hindu legend Cannabis is believed to be the favorite food of the god Shiva, because of its energizing properties. As Cannabis spread from Asia towards the West, almost every culture came into contact with this miracle plant. Nowadays, varieties of Cannabis can be found in all temperate and tropical zones, except in humid, tropical rainforests.²⁸

Despite the fact that Cannabis was grown on a large scale in many countries, the abuse as a narcotic remained uncommon in Western countries until relatively recently. People were largely unaware of the psychoactive properties of Cannabis and it is unlikely that early cultivars, selected mainly for their seed or fiber qualities, contained significant amounts of the psychoactive THC. The medicinal use of Cannabis was only introduced in Europe around 1840, by a young Irish doctor, William O'Shaughnessy, who served for the East India Trading Company in India, where the medicinal use of Cannabis was widespread. Unlike the European fiber Cannabis, these Indian varieties did contain a reasonable amount of bioactive cannabinoids. In the following decades the medicinal use of Cannabis knew a short period of popularity both in Europe and the United States. At the top of its popularity, more than 28 different medicinal preparations were available with Cannabis as active ingredient, which were recommended for indications as various as menstrual cramps, asthma, cough, insomnia, support of birth labor, migraine, throat infection and withdrawal from opium use.²⁷

However, because no tools existed for quality control it was impossible to prepare a standardized medicine, so patients often received a dose that was either too low, having no

effect, or too high, resulting in serious side effects. Moreover, Cannabis extract was not water-soluble and could therefore not be injected (in contrast to e.g. the opiates), while oral administration was found to be unreliable because of its slow and erratic absorption. Because of such drawbacks the medicinal use of Cannabis increasingly disappeared in the beginning of the twentieth century, and in 1937 Cannabis was removed from the US pharmacopoeia, a move that was followed by most other Western countries.²⁷ Isolation and structure elucidation of the first pure active substances from Cannabis was not achieved until the 1960s.²⁹

Only since the flower-power-time of the 1960s, the smoking of Cannabis as a recreational drug has become a widely known phenomenon in the Western world. From then on, import of stronger varieties from the tropics, combined with a growing expertise in breeding and cultivation, led to a steady increase in psychoactive potency. Contemporary recreational Cannabis has increasingly become a high-tech crop, grown indoors under completely artificial conditions. An extensive review on the history of cannabis and its uses by humans has recently been published.³⁵⁵

Table 1: An overview of compounds identified in cannabis.

Compound class	Compounds identified
terpenoids	>120
cannabinoids	>70
hydrocarbons	50
sugars and related compounds	34
nitrogenous compounds	27
non-cannabinoid phenols	25
flavonoids	23
fatty acids	22
simple acids	21
amino acids	18
simple ketones	13
simple esters and lactones	13
simple aldehydes	12
proteins, glycoproteins and enzymes	11
steroids	11
elements	9
simple alcohols	7
pigments	2
vitamin	1

1.4 Chemical Constituents of Cannabis


With about 538 known constituents, Cannabis is one of the chemically best studied plants.¹³⁵ But because most of these constituents have not yet been properly characterized for biological activity, the Cannabis plant could be called a "neglected pharmacological treasure trove".³⁶ Extensive reviews of Cannabis constituents are available in the literature.^{4,27,32} The most important classes are listed in table 1. Most interesting among these constituents are those found in the secretions of the head cells of glandular hairs (trichomes) distributed across the surface of the Cannabis plant. Although trichomes can be found all over the male and female plants, they are particularly concentrated on the bracts that support the female inflorescence. Solitary resin glands, consisting of one or two dozen cells, most often form at the tips of slender trichome stalks which form as extensions of the plant surface, as shown in figure 2. The resin excreted by the glands contains a variety of constituents, any of which might play a role in the biological activities of the Cannabis plant. Among these are terpenoids, flavonoids and cannabinoids. Resin collects under a thin waxy membrane surrounding the secretory head cells. In these extracellular resin pockets, the secreted compounds are segregated from the secretory cells, protecting it from both oxidative degradation and enzymatic change. A layer of abscission cells at the base of each secretory head allows the gland to be easily removed.³³ The adaptational significance of the resin glands remains speculative. Although the resin gives a certain defense against insect and fungal attack, Cannabis crops are still vulnerable to attack by a wide variety of pests, particularly under greenhouse conditions. Certainly, the intoxicating effects of Cannabis resin have increased Cannabis predation by humans, as well as encouraged its domestication, thus dramatically widening its distribution. It has been shown that the cannabinoids cannabigerolic acid (CBGA) and tetrahydrocannabinolic acid (THCA) induce cell death via apoptosis in some plant cells as well as insect cells.³⁴ Furthermore, formation of THCA was found to be linked to hydrogen peroxide formation which may contribute to self-defense of the Cannabis plant. These results strongly suggest that cannabinoids act as plant defense compounds, which is a common function of plant secondary metabolites.³⁵

The compounds described in table 1 all have been identified as a constituent of some preparation of Cannabis: herbal plant material, whole extracts and chromatographic fractions, or illicit material such as hashish. In many cases, the material used has been obtained from an uncontrolled source (e.g. materials confiscated by authorities) and its quality can not be guaranteed. It is therefore not certain how many compounds, identified from such materials,

should be considered as artifacts, resulting from oxidation, and enzymatic, thermal or other degradation. In fact, even THC itself is not produced by the metabolism of the Cannabis plant but rather is formed by thermal decarboxylation (loss of CO₂) of THCA. Further degradation of THC results in formation of cannabinol (CBN) or delta-8-THC. Also many terpenoids are known to be susceptible to degradation upon storage or extraction. As such, the chemical composition of any given Cannabis preparation depends not only on its biosynthetic composition, but also on factors such as age, conditions of storage, and method of extraction. Any biological activity claimed for such preparations should therefore be considered with some care.

Cannabinoids, terpenoids, flavonoids, and fatty acids (hemp oil) comprise the most interesting classes of biologically active compounds from Cannabis. They will be discussed in detail in sections 2 and 5, and constituents in these classes that deserve more scientific attention will be highlighted. Several less significant classes of secondary metabolites found in Cannabis will be discussed shortly in section 5.4.

Figure 2: Microscope photograph and drawing of a cannabis resin gland, with secretory head cells visible underneath the transparent cannabinoid- and terpenoid-rich resin.
Source: drawing from Hashish!, by R. Clarke. Los Angeles: Red Eye Press, 1998. Reprinted with permission.




2. CANNABINOIDS

Cannabinoids are considered to be the main biologically active constituents of the Cannabis plant, and they can be found nowhere else in nature (for an exception, see section 2.2). The majority of biological activities attributed to Cannabis have so far been linked cannabinoids, and more specifically to THC. The naturally occurring cannabinoids form a complex group of closely related compounds of which currently 70 are known and well described.^{4,32,135} New cannabinoids, although present in very minor quantities, have been discovered very recently. These include at least eleven new cannabinoid esters and a number of other cannabinoid structures.^{40,322} However, because their presence has not yet been confirmed by further studies, they will not be discussed in this chapter.

Cannabinoids can be divided into 10 main structural types (figure 3). All other compounds that do not fit into the main types are grouped as miscellaneous.

Figure 3: The structural types of cannabinoids found in *Cannabis sativa* L.




2.1 Cannabinoids Defined

Until the 1980s, the term cannabinoids represented by definition the group of typical terpenophenolic C₂₁ compounds present in *Cannabis sativa*, their carboxylic acids, analogs, and transformation products. But from this rather restricted pharmacognostic definition, considerable expansion is now required. A modern definition will put more emphasis on synthetic chemistry and on pharmacology, and would also include related structures or compounds that affects cannabinoid receptors. This, however, creates several chemical subcategories of cannabinoids. The term "cannabinoids" now represents the whole set of endogenous, natural, and synthetic ligands of the cannabinoid receptors, belonging to a wide variety of chemical families. The plant-derived cannabinoids are now often termed *phytocannabinoids*. When the word cannabinoids is used in this book chapter, the naturally occurring phytocannabinoids are meant, unless indicated otherwise. It should be emphasized that not all phytocannabinoids bind to the cannabinoid receptors.

The first cannabinoid was isolated in 1940.⁴¹ Chemical analysis indicated it to be an alcohol, so it obtained the rather straightforward name cannabinol (CBN, C₂₁H₂₆O₂). It was, however, found to be inactive as a psychoactive compound. Chemically, the (phyto)cannabinoids belong to the terpenophenols, which are common in nature. Cannabinoids are accumulated in the glandular hairs (see section 1.4), where they typically make up more than 80% of the subcuticular secretion. In general all plant parts can contain cannabinoids, except for the seeds. The traces of cannabinoids found in seeds are most likely a result of contamination with Cannabis resin from the flowers.^{17,42} Essentially there are no qualitative differences in cannabinoid spectrum between plant parts, only quantitative differences.^{21,43} The highest cannabinoid concentrations (in % of dry weight plant material) can be found in parts of the flowers and fruits. In the foliage leaves the content is lower, and in the stems and, even more so, the roots the content is very low.⁴⁴ Cannabis grown outdoors generally has lower levels of cannabinoids when compared to indoor grown plants. When grown under artificial, high yielding conditions, Cannabis flowering parts can be obtained with a resin content of up to 25-30%, mainly consisting of THCA, the acidic precursor of THC (see section 2.2).


Figure 4: Structures of the cannabinoids most commonly found in cannabis plant materials. All cannabinoids have the (6aR,10aR)-orientation, according to the chemical numbering shown in figure 5.




2.2 Biosynthesis of the Cannabinoids

The cannabinoids most commonly detected in Cherbai cannabis materials are shown in figure 4. For the chemical numbering of cannabinoids 5 different nomenclature systems have been used so far,⁴⁵ but the most commonly used system nowadays is the dibenzopyran numbering, which is also adopted by Chemical Abstracts. In Europe the monoterpenoid system based on *p*-cymene has also been widely used. As a result, the major cannabinoid delta-9-THC is sometimes described as delta-1-THC in older manuscripts. In this chapter, the dibenzopyran numbering is consistently used, therefore THC is fully described as (-)-*trans*- Δ^9 -tetrahydrocannabinol (figure 5).

Figure 5: Two most commonly used numbering systems for the cannabinoids. The dibenzopyran system is used in this chapter.



Dibenzopyran-numbering



Monoterpene-numbering based on *p*-cymene

It is often said that cannabinoids are unique compounds only found in cannabis. However, in *Helichrysum umbraculigerum* Less., a species from the family Compositae, the presence of CBGA, CBG and analogous to CBG was reported.³⁶⁴ Moreover, in liverworts from *Radula* species the isolation of geranylated bibenzyls analogous to CBG was reported³⁶⁵, suggesting homology of genes from the cannabinoid pathway in at least some other species.

2.2.1 The acidic cannabinoids

In all biosynthetic pathways for cannabinoids that were postulated until 1964, CBD or CBDA was regarded as key intermediate, which was supposedly built from a monoterpene, and olivetol or olivetolic acid, respectively. However, Gaoni and Mechoulam⁴⁶ showed that CBG is the common precursor of cannabinoids, biosynthesized through the condensation of geranyldiphosphate, and olivetol or olivetolic acid. Subsequently, they concluded that CBD, THC and CBN all derive from CBG and differ mainly in the way this precursor is cyclized.^{47,48,49,50} A further improvement of our understanding of cannabinoid biosynthesis came when Shoyama *et al.*^{51,52} concluded that neither the free phenolic (non-carboxylic acid) forms of the cannabinoids nor CBNA were produced by the living plant. Instead, they postulated a biosynthetic pathway based on geraniol and a polyketoacid, resulting in the production of the acidic cannabinoids. The same conclusion was reached by Turner and Hadley⁵³ after study of African Cannabis types.


It is now known that cannabinoids are produced by the metabolism of the plant in the form of carboxylic acids, where the substituent at position 2 is a carboxyl moiety (-COOH).⁵² Incorporation studies with ¹³C-labeled glucose have confirmed that geranyl diphosphate (GPP) and olivetolic acid (OA) are specific intermediates in the biosynthesis of cannabinoids.^{54,55} The first specific biosynthetic step is the condensation of GPP with OA into CBGA, catalyzed by the prenylase enzyme geranylpyrophosphate:olivetolate geranyl transferase (GOT).⁵⁴ Further biosynthetic pathways finally became clear by identification and subsequent cloning of the genes responsible for the conversion of CBGA to THCA, CBDA and CBCA, respectively.^{56,57,58} Further oxidation of THCA leads to formation of CBNA, which should therefore be considered an artifact. (figure 6).

The terpenoid GPP is derived from the deoxyxylulose phosphate/methyl-erythritol phosphate (DOXP/MEP) pathway.^{55,323} About the biosynthesis of OA not much is known yet, but it has been proposed that a polyketide synthase (PKS) could be involved.³²³ However, a PKS specifically yielding OA has not been found to date. Interestingly, OA itself has never been isolated from plant material, possibly indicating it to be a very short-lived intermediate.

Mahlberg and Kim³⁴⁸ reported that glandular trichomes are exclusively specialized to synthesize high amounts of cannabinoids and that other tissues contain only very low amounts. These authors distinguished three types of glandular trichomes in cannabis, with different localization, morphology, and cannabinoid content. Cannabinoids are deposited in the non-cellular, secretory cavity of glandular trichomes. However, after confirming the presence of

the central precursor CBGA, as well as THC synthase activity in the secretory cavity, it was suggested that this is not only the site of cannabinoid accumulation, but also of cannabinoid biosynthesis.³⁴

Figure 6: General overview of the biosynthesis of cannabinoids and putative routes. Reprinted with permission.³²³



2.2.2 Occurrence of short-chain cannabinoids and other homologues

Most commonly, the acidic cannabinoids produced by plant metabolism contain a pentyl side chain, derived from the OA moiety. Cannabinoids with propyl side chains result if GPP condenses with divarinic acid instead of OA, into cannabigerovarinic acid (CBGVA). The three known cannabinoid synthase enzymes are not selective for the length of the alkyl side chain, and will convert CBGVA into the propyl homologues of CBDA, THCA and CBCA (de Meijer 2009). All chain lengths from -methyl to -pentyl have been found in naturally occurring


cannabinoids, probably all arising from the incorporation of shorter chain homologues of OA. The side chain is important for the affinity, selectivity and pharmacological potency for the cannabinoids receptors

Many other minor acidic cannabinoids have been identified over the years, including monomethyl and other types of esters.^{136,322} The biosynthetic pathways explaining this variation have been studied.³²³

2.3 A Phytochemical Classification of Cannabinoids

Cannabinoids are produced by the metabolism of the plant in the form of carboxylic acids as discussed in section 2.2. However, a range of other types of cannabinoids have been detected in Cannabis. For a clear phytochemical discussion of the cannabinoids, they can most conveniently be divided in three groups: acidic cannabinoids; neutral cannabinoids; and artifacts. This practical classification of the cannabinoids is shown in figure 7.

Figure 7: A practical way to categorize the relationships between the major cannabinoids found in herbal cannabis. Three different groups may be distinguished: 1) cannabinoids produced by biosynthesis of the plant; 2) cannabinoids resulting from natural decarboxylation of acidic cannabinoids; 3) degradation products resulting from various influences, such as UV-light, oxidation or isomerization. Arrows indicate the routes of conversion.



An important distinction that can be made within the group of cannabinoids is between so-called acidic and neutral cannabinoids. Consequently, in fresh plant material almost no neutral


cannabinoids can be found, but theoretically all cannabinoids are present in this acidic form. These can be converted into their decarboxylated analogs under the influence of light, heat or prolonged storage, by losing the relatively unstable carboxyl-group in the form of carbon dioxide.⁵⁹ For the purpose of this chapter, the original plant-derived carboxylic acids will be indicated as 'acidic' cannabinoids, while their decarboxylated counterparts are indicated as 'neutral' cannabinoids, even though the presence of the phenolic moiety in the neutral cannabinoids may of course classify them as acids as well.

The group of the acidic cannabinoids includes a large number of structures. The most common types of acidic cannabinoids found in a typical drug-type Cannabis plant are tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabigerolic acid (CBGA) and cannabichromenic acid (CBCA). These acids can be converted to their neutral counterparts by decarboxylation to form delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG) and cannabichromene (CBC), respectively. An example of this conversion is shown in figure 8.

The group of cannabinoids that occur as a result of degradative conditions deserve some special attention, because their presence is largely the result of variable and unpredictable conditions during all stages of growing, harvest, processing, storage and use. As a result, a well-defined Cannabis preparation may change rapidly into a product with significantly different biological effects. Degradation of THC results in formation of CBN and delta-8-THC, while THCA can further degrade into CBNA.⁴ Particularly in samples that have been stored for an extended period, CBN can be found in relatively large amounts. The isomerization of delta-9-THC to delta-8-THC is well documented and occurs particularly at elevated temperature, where the equilibrium is towards the delta-8 isomer.^{49,50,61} The cannabinoids CBL and CBLA arise by exposure of CBC and CBCA, respectively, to UV-radiation, leading to crosslinking of two double bonds in the molecule.⁶²

Although a large variety of cannabinoids is known, this doesn't mean that all cannabinoids are detectable in all Cannabis products. They were identified over several decades of Cannabis research, studying many different Cannabis products and different and sometimes rare types of Cannabis plants from a variety of origins and qualities. There can be an enormous variation in their quantitative ratios. The different chemical types of cannabinoids have been well described.^{4,60} Understanding how the cannabinoids are (chemically) related to each other is important when studying Cannabis samples, as degradation and changes in the cannabinoid profile might occur as a result of storage or breeding conditions, variations in preparation of medicines, heating etc.

Figure 8: decarboxylation of cannabinoids converts acidic cannabinoids to their neutral counterparts. The conversion of THCA to THC is shown as an example.



2.4 Chromatographic Analysis of Cannabinoids

Instrumental methods are most often used for the identification, classification (e.g., fiber type, drug type), and individualization (e.g., source tracing) of *Cannabis* plants and products. Because of the complex chemistry of *Cannabis*, separation techniques, such as GC or liquid chromatography, often coupled with MS, are necessary for the acquisition of the typical chemical profiles and the sensitive, specific, qualitative, and/or quantitative (e.g., THC potency) determination of *Cannabis* constituents. However, especially for screening purposes and on-site field testing, noninstrumental techniques like thin-layer chromatography (TLC) and color reactions may be helpful, too.

Only a few of the cannabinoids, and predominantly THC, have been tested for their biological and clinical activities. For these pure compounds, specific analytical procedures can be easily developed. However, studies on cannabinoid biosynthesis and localization in *Cannabis sativa* L. requires accurate identification of the whole cannabinoid profile in fresh plant tissues. Also, increasingly *in vitro* and *in vivo* studies are being conducted with whole *Cannabis* preparations, either as raw plant materials (e.g. powdered flower tops) or as extracts.^{106,107,108,109} The bio-activities found for such preparations are possibly the result of the acidic cannabinoids,¹⁰² and consequently a method must be available to identify and quantify neutral as well as acidic cannabinoids present in the plant materials used.

For the study of cannabinoids, the analytical methods that are available have been extensively reviewed by Raharjo.¹¹⁰ By far the most commonly used chromatographic methods have been high-performance liquid chromatography (HPLC) and gas chromatography (GC).

In the end, the only way researchers can communicate about Cannabis in a clear way is by using reliable and standardized methods to understand the composition of various Cannabis preparations. Only using the total THC-content to characterize different Cannabis varieties is not sufficient to understand the complex biological effects of this plant. Ideally, a comprehensive overview of the cannabinoid content (i.e. the chemical fingerprint) of Cannabis preparations used in studies should therefore be a standard part of scientific reports on the effects of Cannabis.

2.4.1 Decarboxylation

Owing to the thermal lability of the acidic cannabinoids, indirect methods have been widely used for their determination. These indirect methods are based on decarboxylation of the acids and subsequent high-performance liquid chromatographic (HPLC) determination of the neutral cannabinoids formed. But although decarboxylation occurs naturally over time, during storage of cannabinoids, it is difficult to perform a quantitative decarboxylation under experimental conditions. When performing the thermal decarboxylation of cannabinoid acids in either the presence or absence of organic solvents in an open reactor, an optimum temperature at which the velocity of the decarboxylation would be high enough and simultaneous evaporation of neutral cannabinoids would not occur could not be found.⁵⁹ Consequently, it is not possible in this manner to obtain an amount of neutral cannabinoids equivalent to that of the cannabinoid acids from which they were decarboxylated. During the decarboxylation on different sorbent surfaces, the evaporation of cannabinoids was hindered by sorptive effects, but simultaneous side-reactions occurred, causing chemical changes of the neutral cannabinoids.⁵⁹

2.4.2 Microscopy

Identifying a plant sample as *Cannabis sativa* L. may be done simply by using macroscopic and microscopic evaluation of the intact plant material. The botanical identification of plant specimens consists of physical examination of the intact plant morphology and habit (leaf shape, male and female inflorescences, etc.) followed by the microscopical examination of leaves for the presence of cystolith hairs (as shown in figure 2). The very abundant trichomes, which are present on the surface of the fruiting and flowering tops of Cannabis, are the most

characteristic features to be found in the microscopic examination of herbal Cannabis products.¹³⁶

2.4.3 *Color reactions*

The most common color spot tests include those developed by Duquenois and its modifications. A study of 270 different plant species and 200 organic compounds has shown that the Duquenois–Levine modification is most specific.³⁶⁰ The fast blue B salt test is the most common color reaction for the visualization of TLC patterns (see below) but may also be used as spot test on a filter paper.³⁵⁶

It must be stressed that positive reactions to color tests are only presumptive indications of the possible presence of Cannabis products or materials containing Cannabis products. A few other materials, often harmless and uncontrolled by national legislation or international treaties, may react with similar colors to the test reagents.¹³⁶

2.4.4 *Thin-layer chromatography*


One- and two-dimensional TLC is suited for the acquisition of qualitative cannabinoid profiles from plant material. Both normal-phase and reversed-phase TLC methods have been described.¹¹⁴ For selective visualisation of cannabinoids, the TLC plate can be sprayed with 0.5% fast blue B salt (o-dianisidine-bis-(diazotized)-zinc double salt) in water, followed by 0.1 M NaOH.³⁵⁶ For quantitation, instrumental TLC coupled to densitometry is necessary. High-pressure TLC and overpressured layer chromatography have been developed for the reproducible and fast determination and isolation of neutral and acidic cannabinoids.³⁵⁷⁻³⁵⁹

2.4.5 *Gas chromatography*

The use of GC, commonly coupled to flame ionization detection (FID) or mass (MS)-detection, permits the analysis of a large variety of cannabinoids with very high resolution. However, derivatization is necessary (e.g., silylation or methylation) when information about cannabinoid acids, the dominating cannabinoids in the plant, is required.¹³⁶ Because it is hard to perform a quantitative derivatization for all components in a complex mixture, GC analysis may have only limited value when studying the authentic composition of Cannabis products.

GC/MS is the method of choice for creating Cannabis profiles and signatures (chemical fingerprints), a tool for attributing the country of origin, the conditions of cultivation (indoor, outdoor), and so on. A representative GC-FID chromatogram is shown in figure 9a.

Figure 9a: A typical GC chromatogram (FID-detection) obtained according to reference 114. Column: Durabond fused silica capillary column (30 m x 0.25 mm inner diameter) coated with DB-1 at a film thickness of 0.1 μm , (J&W scientific Inc., Rancho Cordova, CA). The oven temperature was programmed from 100°C to 280°C at a rate of 10°C/min.




2.4.6 High-performance liquid chromatography

HPLC has made it possible to simultaneously detect cannabinoids in both the acid and neutral forms, without the need of derivatization. By making use of a UV- or photodiode-array detector (PDA), cannabinoids can be efficiently analyzed without causing degradation of sample components. Thus, HPLC has become the method of choice for most laboratories. A representative HPLC chromatogram is shown in figure 9b.

However, analysis of all major cannabinoids in a typical Cannabis extract is not easily achieved, because of the complex composition resulting in chromatographic overlap of peaks. To overcome this problem, the use of mass-detection (LC-MS) to distinguish between overlapping chromatographic peaks is becoming increasingly important.^{113,114}


Validated HPLC methods exist for the analysis of cannabinoids according to the American USP or German DAC guidelines. However, these were specifically developed for the analysis of impurities in highly pure preparations of THC, either derived from synthetic (USP method) or natural source (DAC method). They were not intended, and hence not validated, for use with whole Cannabis plant materials. Also, to our knowledge, none of these methods have been validated according to ICH guidelines; the pharmaceutical standards for adequate validation of analytical methods.

Figure 9b: A typical HPLC chromatogram (228nm) obtained according to ref 114. Column: Waters XTerra MS C₁₈ (2.1 x 150mm, 3.5µm); Eluent: Methanol/Water gradient with linear increase of methanol from 65 to 100 % over 25 minutes; Flow-rate 1.5 ml/min.; Detection: UV@228nm. The baseline was not corrected for the influence of the methanol gradient.



More recently, a fully validated pharmacopoeia method was developed for the quality control of Cannabis produced for the Dutch medicinal Cannabis program.³⁰ This Ultra-Performance LC (UPLC) method has been validated according to ICH guidelines and is suitable for the analysis of a wide range of authentic cannabinoids in herbal Cannabis. A representative UPLC chromatogram is shown in figure 9c.

Figure 9c: A typical UPLC chromatogram obtained using the following method:
 Column: Waters C₁₈ analytical column (1.7µm, 2.1x150 mm). Eluent: acetonitrile/water/0.1% formic acid. 0-6min. isocratic 70% acetonitril, 6-10.5min. gradient to 100% acetonitril, 10.5-11 min. hold at 100% acetonitril. Flow-rate: 0.3 ml/min.; Detection wavelength: UV@228 nm.
 a: CBDA; b: CBGA; c: CBG; d: CBD; e: CBN; f: THC; g: delta-8-THC; h: CBNA; k: CBC; l: THCA; m: CBCA



2.4.7 Other techniques

Occasionally, new methods are explored for the analysis of cannabinoids. The applicability of capillary electrochromatography with photodiode array UV detection for the analysis of phytocannabinoids has been demonstrated.¹¹¹ Also supercritical fluid chromatography has been studied,¹¹² but with limited success. Supercritical fluid chromatography is characterized by shorter analysis times than GC or HPLC and does not require derivatization.

2.4.8 Spectroscopic and chromatographic data

A final important factor in the effective analysis of phytocannabinoids is the availability of reliable spectroscopic and chromatographic data. Although such data have been published for most known cannabinoids during isolation and identification experiments (see Turner *et al.*⁴ for an overview), they were scattered over a huge amount of scientific papers. In 2005,

Hazekamp *et al.*¹¹⁴ determined chromatographic and spectroscopic data for 16 different phytocannabinoids as well as 2 human metabolites under standardized conditions. Spectroscopic analyses performed were UV-absorbance, infra-red spectral analysis, (GC-) mass spectrometry and spectrophotometric analysis. Also the fluorescent properties of the cannabinoids were presented. Chromatographic data includes relative retention times in HPLC, GC and TLC. In a similar standardized fashion, the complete ¹H- and ¹³C-NMR assignments of several major cannabinoids have been summarized.¹⁴⁰

3. SITES AND MECHANISMS OF ACTION OF CANNABINOID

The majority of studies on the biological effects of Cannabis constituents have been done with cannabinoids. No other class of Cannabis compounds received anything near as much attention. The reason for this is clear: cannabinoids are unique to the Cannabis plant, while all the other classes of compounds can also be found elsewhere in nature. Therefore the majority of this chapter is dedicated particularly to the cannabinoids. And among the cannabinoids, virtually all studies have focused on the effects of THC. So almost by necessity, this section will focus on THC to discuss what is known about the receptor-binding, metabolism and other mechanisms involved in understanding the biological effects of cannabinoids. However, other cannabinoid constituents will be discussed where possible, based on the literature available.

In general, biological effects take place through activation of receptors, so it needs no explanation that the psychoactive effects of THC led to the hunt for specific binding sites. Analogs of THC, chemically modified and radiolabelled, served as a tool for the identification of cannabinoid receptor CB1 in the rat brain, soon followed by discovery of the CB2 receptor. These findings prompted the search for endogenous ligands, which was guided by the chemical concept that, by homology to the highly lipophilic THC, physiological cannabinoid receptor ligands were to be looked for among endogenous lipids rather than the more polar peptides like the endorphins.

It is now known that cannabinoid receptors can be found in most parts of the brain, as well as in the immune system and a variety of other organs. Their distribution seems to explain many of the observed effects of Cannabis consumption. Such a variety of effects was concisely summarized by DiMarzo *et al.*¹⁸⁶ endocannabinoids make you “feel less pain, control your movement, relax, eat, forget (posttraumatic), sleep and protect your neurons”. The activation of the endogenous cannabinoid system could represent a crucial and important component for each of these functions. The endocannabinoid system that is responsible for our physiological response to Cannabis use is analogous to the morphine-endorphin system. Interestingly, crosstalk between the two systems has been shown.¹⁸⁷

In this section, we look into the sites and mechanisms of action of the cannabinoids. After describing the discovery of Cannabis receptors, the endocannabinoids will be discussed. The understanding of this endogenous system explains the effects of Cannabis on human physiology, which will be further clarified by looking in more detail at THC. Information on absorption, distribution, metabolism and elimination will help to explain the possible role of

synergy and interaction between Cannabis components. Finally, the effect of administration forms on the observed biological effects of cannabinoids is discussed.

3.1 *The Cannabinoid Receptors: CB1 and CB2*

The cannabinoid receptors are a class of receptors under the G-protein coupled receptor superfamily. Their ligands are known as cannabinoids or endocannabinoids depending on whether they come from external or internal (endogenous) sources, respectively. Cannabinoid receptors have a protein structure defined by an array of seven transmembrane-spanning helices with intervening intracellular loops and a C-terminal domain that can associate with G proteins of the $G_{i/o}$ family.³¹⁰

Until the discovery of specific Cannabis receptors, the biochemical mode of action of cannabinoids was much disputed. Because of their lipophilic character, cannabinoids can penetrate cellular membranes by simple diffusion. Therefore, possible explanations for cannabinoid activity initially included unspecific membrane binding resulting in fluidity- and permeability changes of neural membranes, the inhibition of acetylcholine-synthesis, an increase in the synthesis of catecholamines, and an interaction with the synaptosomal uptake of serotonin.^{193,194} However, it was established in the mid 1980s that cannabinoid activity is highly stereoselective,¹⁹⁰ indicating the existence of a receptor-mediated mechanism.

The first reliable indications that cannabinoids act through receptors came when it was shown that cannabinoids can act as inhibitors of the adenylate cyclase second messenger pathway in brain tissue and neuroblastoma cell lines. This activity was dose-dependent, stereospecific, and could be modulated by pertussis toxin.^{92,202-205} Finally, a stereospecific G-protein-coupled cannabinoid receptor was found and cloned.²⁰⁶ It was named 'Cannabinoid-Binding receptor type 1' or CB1. The CB1 receptor is most clearly localized in the central nervous system, therefore it is often called the 'central receptor', but it is also found in certain peripheral organs and tissues, such as lungs, liver and kidneys.³²⁵ CB1 receptors are thought to be the most widely expressed G-protein coupled receptors in the brain. Activation leads to inhibition of adenylate cyclase activity.²⁰⁷ The CB1 receptor also modulates ion channels, inducing, for example, inhibition of N- and P/Q-type voltage-sensitive Ca^{2+} channels and activation of G-protein inwardly rectifying K^+ channels. Besides these well-established cannabinoid receptor-coupled events, cannabinoid receptors have also been shown to modulate several signaling pathways that are more directly involved in the control of cell proliferation and survival, including extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38

mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K)/Akt, focal adhesion kinase (FAK), and the ceramide pathway.²⁰⁸

Subsequently, a second cannabinoid receptor (CB2) was found with a possible role in immunological processes.²⁰⁹ The CB2 receptor was first described as a peripheral GPCR receptor, mainly localized in the immune system, therefore it is often called the 'peripheral receptor'. However, it appears nowadays that the situation is more complex, as CB2 expression was also reported to be present in neurons of the brain.²¹⁰ It is primarily expressed by immune tissues such as leukocytes, spleen and tonsils, and it shows a different selectivity than centrally acting CB1. So far, the physiological roles of CB2 receptors are proving more difficult to establish, but at least one seems to be the modulation of cytokine release.²¹¹ Recently, it has been recognized that CB2 may play a functionally relevant role in the CNS, mediated through microglial cells.²¹²


The cannabinoid signaling system is teleologically millions of years old, as it has been found in mammals, fish, and invertebrates down to very primitive organisms such as the hydra.²¹⁶ Surprisingly, the protein sequences of CB1 and CB2 show only about 45% homology. There are indications that CB receptors are evolutionary related to the vanilloid receptors.²¹⁷ The vanilloid TRVR1 receptor (transient receptor potential vanilloid VR1 receptor) can be activated by the fatty acid amide compound capsaicin. Based on chemical similarities between capsaicin and endocannabinoids (see section 3.2), it was hypothesized that TPVR1 and proteins of the endocannabinoid system share common ligands. This was indeed confirmed when it was demonstrated that the endocannabinoid anandamide activates TRPV1 receptors.²¹³ Also it was found in isolated blood vessel preparations that some endocannabinoids can activate vanilloid receptors on sensory neurons,²¹⁴ which raises the possibility that endocannabinoids are endogenous agonists for vanilloid receptors.²¹⁵ These receptors might therefore be putatively regarded as CB3 receptors.

There is mounting evidence of novel receptors expressed in endothelial cells and in the CNS that have cannabimimetic and therapeutic effects independent of the mechanisms described above.²¹⁸ In 2007, the binding of several cannabinoids to a GPCR (GPR55) in the brain was described.²¹⁹ These receptors are more likely to be functionally than structurally related, as there is currently no evidence for additional cannabinoid receptors in the human genome. However, not all of the effects of cannabinoids can be explained by receptor-mediated effects, and it is believed that at least some effects are non-specific and caused through membrane perturbation.^{220,221}

3.2 The Endocannabinoid System

Based on the observation that all natural cannabinoids are highly lipid-soluble, an attempt was made to isolate endogenous ligands for the cannabinoid receptors from fatty tissues of animals. Finally, a single compound could be isolated from brain tissue of pigs, with a high affinity for the CB1 receptor. It was chemically identified as arachidonic acid ethanolamide, and named anandamide, from the Sanskrit for "eternal bliss."¹⁹⁹ A few years later, a related compound was isolated from canine gut with an affinity for both cannabinoid receptors; 2-arachidonyl glycerol (2-AG).²²² Structures of these two compounds are shown in figure 10. In recent years, a variety of compounds with endocannabinoid activity have been isolated or synthesized,^{223,224} interestingly all having an eicosanoid-related structure. Cannabinoid receptors and their endogenous ligands together constitute what is referred to as the endogenous cannabinoid, or endocannabinoid, system.

Figure 10: Structures of the two major endocannabinoids



The endocannabinoid system is now known to be a ubiquitous neuromodulatory system with wide-ranging actions. It comprises cannabinoid receptors, endogenous cannabinoids, and enzymes responsible for their production, transport, and degradation. The endocannabinoid system can be found even in very primitive organisms, indicating it has a fundamental role in basic physiology. There are currently two main families of endocannabinoids that have been extensively characterized. The first are amides of arachidonic acid and ethanolamide; the typical example of this family is anandamide. The second family includes glycerol esters related to 2-AG. The synthetic pathways for both families of endocannabinoids are complex, but well reviewed.^{225,226}

There are several pathways known for synthesis and degradation of endocannabinoids, so there appears to be a high redundancy. Basically, endocannabinoids exist intracellularly as precursors in the plasma membrane of neurons as part of certain phospholipids. They are produced on demand by distinct biochemical pathways involving phospholipases C and D, as well as other enzymes. These events are triggered by the enhancement of intracellular calcium concentrations that follow cell depolarization or the mobilization of intracellular calcium stores subsequent to stimulation of protein-coupled receptors from the G_q/G_{11} family. Accordingly, the enzymes catalyzing anandamide and 2-AG are calcium-sensitive. After formation, endocannabinoids are transported across the cell-membrane for interaction with their extracellular binding sites on cannabinoid receptors.^{225,226}

Endocannabinoids serve as extracellular retrograde messengers, with characteristics very different from other neurotransmitters such as acetylcholine, GABA or dopamine. Endocannabinoids are described as retrograde transmitters because they most commonly travel backwards against the usual synaptic transmitter flow: they are released from the postsynaptic cell and act on the presynaptic cell, where the target receptors are densely concentrated. Like the endorphins, endocannabinoids exert a homeostatic function. But because of their chemical (non-water soluble) nature, they cannot travel unaided for long distances in the aqueous medium surrounding the cells from which they are released. Therefore, endocannabinoids do not typically function like hormones, which can affect cells throughout the body, but instead they act as local (autocrine or paracrine) mediators. Activation of the cannabinoid receptors temporarily reduces the amount of conventional neurotransmitter released, thereby controlling the incoming synaptic signal. The ultimate effect of this process depends on the nature of the transmitter that is controlled, which itself depends on the function of the tissue where the cannabinoid receptors are expressed. Simply said, endocannabinoids produced by a certain neuron, are modulators of the flow of other neurotransmitters produced by that same neuron.

Degradation is an important mechanism to regulate endocannabinoid activity, as the duration of endocannabinoid effect is dependant on the localization of the degrading enzymes.²²⁶ The degradation system involves reuptake into the presynaptic cell, followed by rapid hydrolysis of the amide or ester bonds. How endocannabinoids move from the extracellular space to the interior of a cell for degradation remains unclear, but there is indirect evidence for specific proteins facilitating the membrane transport.²²⁷ 2-AG exhibits higher selectivity and efficacy for CB1 and CB2 receptors than anandamide, which also interacts with non-cannabinoid receptor targets. Therefore, it is not surprising that the levels of the two compounds are

regulated in different ways. However, the main enzyme that inactivates both anandamide and 2-AG (and others) by hydrolysis, is fatty acid amide hydrolase (FAAH). It was isolated after the synthesis of inhibitors of endocannabinoid degradation, which were then used for affinity chromatography purification of the degrading enzyme.²²⁸ 2-AG is also inactivated by monoacylglycerol lipase (MAGL).

Interestingly, in *Arabidopsis thaliana* a functional homolog of the mammalian FAAH has been cloned,²²⁹ and fatty acid ethanolamines with high homology to anandamide have been discovered in several plant species.²³⁰ These findings provide support at the molecular level for a conserved mechanism between plants and animals for the metabolism of N-acylethanolamines.

3.3 Pharmacokinetics of the Cannabinoids (ADME)

Cannabinoid pharmacokinetic research has been especially challenging due to low analyte concentrations in serum, rapid and extensive metabolism, and physicochemical characteristics that hinder the separation of drugs of interest from biological matrices, and from each other. Although many other administration forms have been developed (see section 3.5 on administration forms), oral administration, often in the form of synthetic THC (Marinol), has been most extensively studied.

Although the metabolic fate of THC is well known,²⁷ not much has been reported on the other cannabinoids. After oral administration, THC is almost completely absorbed (90-95%); however, due to first-pass metabolism by the liver and high lipid solubility, 90 percent or more of orally administered THC never reaches sites of activity in the body in its native form.^{231,232} THC and its metabolites are extensively protein bound in the blood (ca. 97%) and rapidly distributed to highly vascularized tissues and the brain. Serum concentrations peak at approximately 0.5 to 4 hours after oral dosing, and decline over several days. After oral administration, THC has an onset of action of approximately 1-2 hours and duration of psychoactive effects is 4-6 hours after administration.

In humans, plasma THC concentration profiles are similar after smoking or intravenous administration, with prompt onset and steady decline. Metabolism occurs mainly in the liver by microsomal hydroxylation, and oxidation catalyzed by enzymes of the P450 complex. Nearly 100 metabolites have been identified for THC alone. Besides the liver, other tissues like the heart and lungs are also able to metabolize cannabinoids, albeit to a lesser degree. The two major metabolites of THC are 11-hydroxy-THC (11-OH-THC) and 11-nor-9-carboxy-

THC (11-COOH-THC). 11-OH-THC is the most important psychotropic metabolite, being about twice as psychoactive as THC, and it has a similar kinetic profile as the parent molecule.⁷² In contrast, 11-COOH-THC has no psychotropic activity. Most of the 11-COOH-THC is finally converted into its glucuronide form, with a glucuronic acid moiety linked to the carboxylic group. This is the major form of THC excreted into urine. When THC is inhaled through smoking or vaporizing, it avoids first-pass metabolism, and conversion to 11-hydroxy-THC and further metabolites takes place much slower.⁷²

Metabolism is the major route for the elimination of THC from the body. The elimination is biphasic; there is a rapid distribution phase (initial half-life about 4 hours), believed to be due to the highly lipophilic nature of the drug and redistribution into lipid-rich tissues, and a terminal half-life of around 25 to 30 hours for THC and 11-OH-THC. Plasma half-life for 11-COOH-THC may be even as long as 25-75 hours.^{343,344}

Only negligible amounts of THC are excreted in unchanged form; less than 5% of an oral dose is recovered unchanged in the feces. Most of the absorbed dose (65-80%) is excreted as metabolites in the feces and a lesser amount is secreted in the urine (20-35%). Among the metabolites, 11-COOH-THC is a major one identified in both urine and feces, both in its native form and in the form of its glucuronide. Because of its large volume of distribution (approx. 10 L/kg), THC and its metabolites may be excreted at low levels for prolonged periods of time. Following single dose administration, low levels of THC metabolites have been detected for more than 5 weeks in the urine and feces.³⁴⁴

For the other cannabinoids, only the metabolism of CBD and CBN has been described to some extent.²³³ An important aspect of CBD is that it inactivates certain types of cytochromes, which may be important because serious drug-drug interactions may occur in the case that cannabidiol is co-administered with drugs that are metabolized mainly by the enzyme system containing these P450 isozymes.²³⁴

So far, virtually nothing was reported on ADME of the major cannabinoid THCA. In a case-study (unpublished data by the author) it was found that the oral consumption of 30 mg pure THCA did not lead to psychotropic effects and no THC-metabolites could be detected in urine by a standardized GC-MS detection method for THC. So despite their structural similarity, the metabolism of THCA seems to be quite distinct from THC.

3.4 Structure-Activity Relationships of Cannabinoids

There is a central problem in the discussion about making Cannabis or THC medicinally available: the curative properties of Cannabis/THC are mediated mainly by the same receptors that cause its unwanted psychoactive side effects. So, just as for other psychoactive drugs (e.g. morphine, benzodiazepines) the accepted medicinal applications are limited. As a result, a major goal of cannabinoid research nowadays is to separate beneficial from unwanted effects by means of medicinal chemistry, studying structure-activity relationships (SAR). The same approach is also used to develop agonists or antagonists with a high selectivity for only one of the cannabinoid receptors.

The absolute configuration of naturally occurring THC is *trans*-(6aR,10aR), resulting in a (-) specific rotation. The preparation of the *cis*-(+)-enantiomer of THC, and subsequent pharmacological comparison to its natural counterpart, gave a decisive argument for the stereospecificity of the binding, and thereby reinforcing the cannabinoid-receptor interaction hypothesis. Since this discovery, cannabinoids have been extensively studied to understand the relationships between their structure and affinity for the Cannabis-receptors. For this purpose, a very large number of synthetic derivatives have been made and systematically tested for receptor binding on CB1 and CB2.

Large numbers of compounds have been studied for the structure activity relationship of both known CB receptors. But in addition to CB1 and CB2 receptors, pharmacological studies have strongly suggested the existence of other cannabinoid receptor subtypes²⁶⁵, the most likely candidate being the vanilloid TRVR1 receptor (see section 3.1). This essentially means that all available cannabinoids produced for SAR studies could be tested again for binding affinity to this receptor. This may lead to new clues about the mechanism of action for certain bioactivities of cannabinoids.

Classical cannabinoids and endocannabinoids are both agonists of the CB receptors, but due to the different structural features of CB1 and CB2, their structural activity relationship is not entirely similar. The CB1 receptor has been proposed to exist in two different conformational states; one where it is bound to the secondary system (by G proteins) and one in which it is uncoupled.²⁶⁴ Agonists of the CB1 receptor bind to the precoupled stage activating the receptor, while antagonists bind to the receptor without activating it. Because antagonists prevent endogenous cannabinoids from binding, activation is interrupted. Inverse agonists bind to the uncoupled receptor, blocking it and avoiding precoupling of the receptor.

The structure activity relationship of classical cannabinoids and endocannabinoids has been studied intensively, and several reviews have been published.²⁶⁶⁻²⁷¹ The major cannabinoids THC²²² and delta-8-THC²⁷² bind to the CB1 receptor with moderate affinity and do not show specificity for either. CBN however, does show a slight specificity for the CB2 receptor.²⁷³ It should be noted that values published for CB-receptor affinity may be strongly dependent on type of tissue and animal species used in the study. Although rat CB1 is 97% homologous with human CB1, critical differences do exist.³⁴⁹ Also the type of agonist to be displaced has an influence on the value of K_i reported. As a result, binding efficiencies reported in the literature often show a range of values. An overview is presented by Pertwee³⁶⁷, and a summary is presented in table 2.

Table 2: Range of reported K_i values for the major phytocannabinoids, according to Pertwee.³⁶⁷

<i>Phytocannabinoid</i>	<i>CB1 K_i (nM)</i>	<i>CB2 K_i (nM)</i>
THC	5.05 - 80.3	3.13 - 75.3
delta-8-THC	44 - 47.6	39.3 - 44
THCV	46.6 - 75.4	62.8
CBN	120.2 - 1130	96.3 - 301
CBD	4350 - 27 542	2399 - 4200
CBG	440	337

By introducing a large variety of chemical modifications, four pharmacophores have so far been identified for the classical cannabinoids prototype. They are listed below. For chemical numbering of carbon-positions, see figure 5.

1) An alkyl-substituent at C-3:

An alkyl group on the C-3 aromatic position seems necessary for binding affinity to the CB receptors, and in the phytocannabinoids this sidechain ranges from the most commonly observed pentyl (C_5H_{11}), down to methyl (CH_3). Changes in the alkyl group of natural cannabinoids lead to wide variations in affinity and selectivity for the cannabinoid receptors. It is now well established that introduction of a dimethylalkyl sidechain greatly increases affinity²⁷⁹, suggesting that introduction of a branched substituent enhances the affinity of CB receptor ligands. The best substituents found so far are 1,1-dimethylheptyl or 1,2-dimethylheptyl.^{272,274} One of the strongest CB1 agonists ever made falls into this class:

HU210. It has a binding affinity to CB1 of up to 800 times more potent than THC, but without the psychoactive effects.³²⁴

Sometimes, varying the sidechain may also lead to surprising results: the propyl analog of THC, naturally occurring in the Cannabis plant, is an antagonist of both CB1 and CB2 receptors with fairly high affinity, instead of a weak agonist, as was expected based on its structural similarity to THC.⁹⁶

2) A hydroxyl-substituent at C-1:

The phenolic hydroxyl group at C-1 has to be freely available for significant CB₁ binding. Removal of this hydroxyl, or conversion into a methoxy group (i.e. esterification) leads to selective CB2 binding affinity.²⁷² A possible explanation for the inactivity of the acidic cannabinoids in receptor binding may be the occurrence of hydrogen-bonding between the adjacent hydroxyl and carboxyl groups.

3) The substituent at C-9/C-11:

The methyl group at C-9 is not an absolute requirement for binding affinity. Introduction of a hydroxyl group at C-11 was in fact shown to increase affinity of THC as well as delta-8-THC for both CB1 and CB2 receptors.²⁷⁵ The 11-hydroxy substituent is present in the primary metabolite of THC, 11-hydroxy-THC, which has a more potent psychoactive effect than THC. Further oxidation (to aldehydes or carboxylic acids) eliminates the psychoactive effect but induces analgesic and anti-inflammatory properties. Ajulemic acid (a carboxylic acid) and Nabilone (an aldehyde) are examples of synthetic analogs of THC developed for clinical use (see section 6.2).

4) An aliphatic hydroxyl at C-6:

The hydroxyl-group attached to C-6 should be bound to an optimal chain length of three carbon atoms.²⁷⁶ In the structure of THC, this pharmacophore is part of ring B (see figure 5, carbon# 6, 12 and 13). In contrast, in the structure of CBD these aliphatic carbons are spatially separated from the hydroxyl, and consequently CBD does not bind to either cannabinoid receptor.

There are several structural similarities between endocannabinoids and classical cannabinoids that bind to the CB receptors: both classes have a polar head group and a hydrophobic chain with a terminal n-pentyl group. More specifically, the pentyl side chain in cannabinoids is

present in the endocannabinoids as the last five carbons of the fatty acid chain, and the OH at the C-3 position might correspond to the polar hydroxyl end of the endocannabinoids. Furthermore, the relative distances between these functional groups are comparable due to the ring system in cannabinoids, which can be mimicked by the four double bonds in the endocannabinoids.²⁷⁷ The fatty acid acyl chain of endocannabinoids should be 20 to 22 carbons long, with at least three homoallylic double bonds.²⁸⁰ It is proposed that the acyl chain can assume more than one conformation and that flexibility is necessary in order to mimic the tricyclic core of the classical cannabinoids.²⁸¹ Recently, evidence was also presented for common binding sites to the CB receptors.²⁷⁸

The knowledge obtained from these SAR studies has played a crucial role in the development of some of the cannabinoids in clinical use, as described in section 6.2.

3.5 Administration Forms

Studies with Cannabis or Cannabis-based preparations have been performed with a large variety of administration forms, ranging from pulmonary (smoking and vaporizing), to sublingual, topical, and oral preparations (tea, milk decoctions, and baked products). A common factor of all administration forms of (herbal) Cannabis is a heating step, which is essential for conversion of the acidic cannabinoids into their pharmacologically more active neutral counterparts. Depending on the administration form, many changes to the original profile of compounds may occur by e.g.: the extent of heating (decarboxylation of acidic cannabinoids), the type of storage (e.g. tea is stored differently from Cannabis-cigarettes), degradation, loss by evaporation (e.g. terpenoids), and metabolism. As a result, a different spectrum of compounds is finally entering the bloodstream, and consequently a different type and duration of effects may be observed.

Smoking and oral administration are the two most commonly studied administration forms in clinical trials. The few studies that have directly compared the two forms of THC delivery show smoking to be more effective than oral administration.²³⁶⁻²³⁸ Inhalation of THC avoids the first-pass effect but causes a rapid peak in blood levels accompanied by a spike in psychoactivity. A dose of 2-5 milligrams of THC consumed through smoking reliably produces blood concentrations above the effective level within a few minutes.^{241,242} As a result, Cannabis smoking is a convenient method of administration, allowing self-titration of the desired effects. However, inhalation of toxic compounds during Cannabis smoking poses a serious hazard. This risk is not thought to be due to cannabinoids, but rather to noxious

pyrolytic byproducts.^{243,244} Consequently, the shortcomings of smoked Cannabis have been widely viewed as a major obstacle for approval of crude (herbal) Cannabis as a medicine by public health authorities.²⁴⁵ Nevertheless, inhaling is about equal in efficiency to intravenous injection, while considerably more practical.^{246,247} Smoking cannabis in the presence of tobacco can almost double the release of THC into the smoke, compared to smoking pure cannabis. The mechanism for this is however still unclear.³⁴⁵

Cannabis vaporization or volatilization is a technique aimed at suppressing irritating respiratory toxins by heating Cannabis to a temperature where active cannabinoid vapors are formed, but below the point of combustion where pyrolytic toxic compounds are released. Vaporization offers patients who use medicinal Cannabis the advantages of the pulmonary route of administration, i.e.: rapid delivery into the bloodstream, ease of self-titration and concomitant minimizing the risk of over- and under-dosing, while avoiding the respiratory disadvantages of smoking. A few studies have been performed in recent years showing that vaporizing can be considered an efficient way of administration of Cannabis as well as pure cannabinoids,⁹⁹ resulting in bioavailability of THC comparable to smoking.²⁴⁸

In contrast, despite its convenient use, oral THC is notoriously unreliable in its effects.²³⁹ Drawbacks of this administration route include its large variability in bioavailability, and extensive first-pass metabolism. The onset of effects is slow, precluding effective individual titration. In a study performed with orally administered THC, two hours after oral administration of 10-15 milligrams, 84 percent of subjects had no measurable level of THC in their blood. After 6 hours, 57 percent still had none.²⁴⁰

When Cannabis is consumed in the form of a decoction, it is often referred to as 'tea'. Although Cannabis tea is a relatively popular administration form for self-medication among medicinal users, virtually no standardized studies have been performed with it. However, a recent study⁹⁸ showed Cannabis tea to be a robust and reproducible administration form for cannabinoids, with relatively high levels of acidic cannabinoids present.

As a result of the factors described above, the choice of administration form can have a major influence on the observed biological effects. For example, early studies indicated that oral doses of THC were no more effective than codeine for pain, and produced a significant amount of dysphoric effects.^{249,250} Thus it was believed that THC could only produce analgesia at doses that were high enough to cause behavioral side effects, and therefore was dropped as potential analgesic.²⁵¹ However, when using the parenteral or systemic route, THC and other synthetic cannabinoid compounds have demonstrated potent analgesic effects up to ten times that of morphine in animal models of acute and neuropathic pain.²⁵²⁻²⁵⁵

4. BIOLOGICAL EFFECTS OF THE CANNABINOIDS

Virtually all studies on the biological activities of cannabinoids have been performed on the neutral cannabinoids. This may be an inheritance from the time when Cannabis was mainly studied to answer questions about social and health risks associated with its recreational use. However, it is now becoming increasingly clear that the acidic cannabinoids may have biological activities of their own, because obviously, there are other routes of administration than smoking, and some of these indeed contain significant amounts of the acidic cannabinoids.

It would be impossible here to give a comprehensive overview of all described bioactivities of the (phyto)cannabinoids, in particular for THC. However, they have been well reviewed in a number of papers and books.^{27,63,65} Only the most important or remarkable biological activities will be discussed here, while their clinical implications will be described in more detail in section 6.1 of this chapter.

4.1 *Delta-9-Tetrahydrocannabinol (THC)*

THC is the pharmacologically and toxicologically most relevant constituent of the Cannabis plant, producing a myriad of effects in animals and humans. A frequently used way to review the biological effects of THC is by distinguishing central from peripheral effects, reflecting the classical physiological distribution of the cannabinoid binding receptors CB1 (the 'central' receptor) and CB2 (the 'peripheral' receptor), as discussed in section 3.1. However, the exact mechanism of action of cannabinoids is not exactly clear, as CB1-receptors are increasingly found outside the CNS,³²⁵ while CB2 receptors are now known to be present in the nervous system, for example in rat microglial cells and other brain associated cells during inflammation.⁶⁷

In a toxicological sense, the CB1 mediated central effects of THC are most important, because they are directly related to the psychological effects of Cannabis use. The most conspicuous psychological effects of THC in humans have been divided into four groups⁶⁹: affective, sensory, somatic, and cognitive. In fact, most documented cannabinoid effects are mediated by the central cannabinoid receptor, and behavioral effects caused by Cannabis or THC are generally consistent with the anatomical distribution of the cannabinoid receptors, in particular CB1 in the brain. However, neuroprotective properties in ischemia and hypoxia are examples of some known receptor-independent actions of THC and other cannabinoids.

Furthermore, both THC (CB1 and CB2-binding) and CBD (non-binding) potentiate the extinction of conditioned incentive learning, indicating that screening of receptor binding does not necessarily show the potential of cannabinoids.⁶⁸

The best-established palliative effect of THC is the inhibition of chemotherapy-induced nausea and vomiting, mainly in cancer patients. Today, oral capsules containing dronabinol (Marinol) or its synthetic analogue Nabilone (Cesamet) are approved for this purpose (see section 6.2). Also herbal Cannabis has been shown to reduce nausea in the majority of users, when ingested or inhaled. The effect of THC on nausea and vomiting has confirmed in clinical trials.^{326,327} It is however unclear how Cannabis or THC compare to the more recently developed, and very efficient serotonin (5HT₃) receptor antagonists for the treatment of nausea. Other potential palliative effects of THC in cancer patients include appetite stimulation and pain inhibition.

THC increases the metabolic rate in the brains of animals and humans,⁷¹ and it decreases body temperature, but only at high doses. The increase in heart rate observed after THC administration is clearly dose-dependent and closely associated with THC plasma concentrations. As a result, cardiovascular problems are generally considered a contraindication for the medicinal use of Cannabis or THC. The results of a well-designed clinical trial using inhaled THC suggest that the increase in heart rate is not mediated by brainstem centers but is established by a direct effect of THC on the heart.⁷² In the same study a wide array of CNS and non-CNS parameters were monitored after administration. THC had clear dose-dependent effects on postural stability, and body sway was found to be a very reliable indicator of THC blood levels. The high densities of CB1-receptors found in the basal ganglia, cerebellum, amygdala and forebrain, may explain these observations.

In particular in inexperienced users, THC can induce unpleasant effects including anxiety, panic, and paranoia. There are suggestions that in a small number of cases THC is capable of precipitating psychosis, involving delusions and hallucination.⁷³ If these disorders exist they seem to be rare, because they most likely require very high doses of THC, the prolonged use of highly potent forms of Cannabis, or a pre-existing genetic vulnerability.³⁴⁶ The causal link between cannabis use and development of psychosis has not been definitely proven, because of the large amount of parameters to be considered. However, there is enough reason to be precautious and communicate these 'suspicions' in a fair and balanced way. Although the psychological effects caused by THC or Cannabis are a major drawback in their medical applications, many physical effects are already achieved below the threshold of psychological effects.

The effect that THC decreases intraocular pressure and improves blood circulation in the eye was found serendipitously as part of a study that tried to find easy physiological markers to screen drivers for driving under the influence of drugs. As a result, a variety of studies have targeted THC and other cannabinoids as potential new drugs in the treatment of glaucoma, the leading cause of irreversible blindness. The neuroprotective properties of THC may also be useful in this respect, leading to a dual-effect in the protection of the retina and optic nerve.⁷⁴ Anticonvulsant effects have been described for psychotropic as well as non-psychotropic cannabinoids, including: THC, CBD, CBN, 11-OH-THC and delta-8-THC. THC relaxes muscles, and has hypokinetic and anticonvulsant effects. This is one of the major reasons THC is studied as a treatment for multiple sclerosis, and it also may have significance in epilepsy.

THC exerts an atropine-like effect on salivary secretion resulting in dry mouth. It also causes bronchodilation, comparable to the standard drug salbutamol.³⁴⁷ This indicates there is a potential for THC-like substances to treat asthma. However, no recent studies have been performed in this field.

Receptors of the CB2 type are present on white blood cells, and affect the immune system, which may be a reason why Cannabis is often used as self-medication by immunocompromised individuals. THC is now considered an immunomodulator, capable of either enhancing or suppressing the function of a range of immune cells. These effects may be modulated by other constituents present in Cannabis.⁶⁶ Many described anti-inflammatory effects of THC and other cannabinoids are probably mediated by complex interactions with the immune system.

In early studies, THC was suggested to be mutagenic or carcinogenic. But in fact, an increasing number of studies are showing its anti-cancer properties.⁷⁵ Currently there is convincing evidence that THC may play a role in the treatment of several types of cancer. In addition to apoptosis and inhibition of proliferation, THC might exert its antitumor effects by inhibiting tumor angiogenesis and metastasis. However, there is some controversy here: although THC has antiproliferative effect in tumors expressing cannabinoid receptors, those with low or no expression suffer increased growth and metastasis due to THC-induced suppression of the antitumor immune response.⁷⁶ More research is needed to clearly identify the therapeutic role of THC in cancer treatment.

A promising recent discovery is that THC relaxes the colon and reduces the colonic motility and tone after a meal.³²⁸ This points out the potential for CB receptors to modulate colonic motor function in intestinal disease such as irritable bowel syndrome or Crohn's disease.

An important aspect of the evaluation of THC effects is that it may have a biphasic effect, causing opposite effects at high versus low concentrations. For example, in hefty doses, THC may protect the brain against various types of damage, whereas in tiny doses, potentially adverse effects would come through.⁷⁷ The potentially adverse doses would be much lower than those normally obtained from smoking a joint. However, a large dose inevitably becomes a small one as the body slowly clears it out. This may explain the many conflicting results obtained in clinical studies on THC and Cannabis: many studies use low concentrations of THC in order to prevent possible psychological effects in test subjects. Inadvertently these low doses may cause exactly those adverse effects the study tries to prevent.⁷⁷

4.2 *Cannabidiol (CBD)*

CBD is, together with CBG, the major non-psychoactive cannabinoid found in Cannabis. It is the principal cannabinoid present in fiber-type Cannabis (in the form of its carboxylic acid CBDA), a plant that is easily available to researchers, in contrast to the strictly controlled drug-type Cannabis varieties. Second to THC, the pharmacological effects of CBD have been best studied of all cannabinoids. It has powerful anti-oxidant properties, more potent than ascorbate and α -tocopherol. Also it has notable anti-inflammatory and immunomodulatory effects.⁸⁰ Furthermore, sedating, hypnotic, antiepileptic, and antidystonic effects have been described. Also, CBD is a modulator of some types of opioid-receptors,⁸¹ and can modulate sleep in rats.⁸²

CBD was found to have anti-anxiety effects.⁷⁸ In a clinical trial, oral administration of 400 mg of CBD resulted in decreased anxiety and increased mental sedation in test subjects.⁸³ It was concluded that CBD possesses anxiolytic properties, possibly mediated by an action on limbic and paralimbic brain areas, where it reduced regional cerebral blood flow. These anxiolytic properties might prove useful in psychiatry. Possibly the most significant conclusion of this study is that a dose as high as 400 mg of CBD had no adverse effects. CBD was furthermore found to have anti-psychotic benefits.⁷⁹

A prominent effect of CBD was found in a variety of cancer studies. In a mouse model of metastatic breast cancer CBD reduced the aggressiveness of breast cancer cells, by inhibiting a crucial protein for cancer development.⁸⁴ The study concluded that CBD represents the first nontoxic exogenous agent that can significantly inhibit metastatic breast cancer cells leading to the down-regulation of tumor aggressiveness. Currently there is a limited range of options in treating certain aggressive forms of cancer. CBD offers the hope of a non-toxic therapy that

could achieve significant results without any of the painful side effects associated with standard therapy. Both *in vitro* and *in vivo*, CBD was able to produce a significant anti-tumor activity on glioma cells. This antiproliferative effect of CBD was shown to be correlated to induction of apoptosis, which suggests a possible application of CBD as an antineoplastic agent. Effects were partially prevented by a (non-psychoactive) CB2 receptor antagonist, suggesting a role for CB2 in cancer treatment.⁸⁵

In another study performed on a panel of tumor cell lines with a variety of plant-derived cannabinoids, CBD was the most potent inhibitor of cancer cell growth, with significantly lower potency in noncancer cells. A cannabidiol-rich Cannabis extract was equipotent to CBD, whereas CBG and CBC followed in the rank of potency.⁸⁶ It was suggested that the observed effect was due to the capability of CBD to induce apoptosis via cannabinoid receptors, or cannabinoid/vanilloid receptor-independent elevation of intracellular Ca^{2+} and reactive oxygen species. These data support the further testing of CBD and cannabidiol-rich extracts for the potential treatment of cancer.

In many Cannabis varieties CBD is present in significant amounts.⁸⁹ However, only since a few years there is serious attention for THC/CBD interaction and this is mostly in studies on multiple sclerosis. Earlier studies focusing on the effect of THC alone have generally shown the use of Cannabis to be ineffective in many disease models, and such negative results unfortunately helped to shape the controversy in the discussion on the moral and ethical sides of Cannabis use in multiple sclerosis and other diseases.⁹⁰ It is known that CBD inhibits the metabolism of THC, by blocking its conversion to the more psychoactive 11-hydroxy-THC by cytochrome P450 3A11.⁸⁷ Possibly this is the reason why CBD is known to antagonize the psychotropic effects of THC.⁸⁸ Even though higher doses of THC are capable of inducing psychotic problems in some users, CBD seems to have an anti-psychotic effect, its presence balancing the negative impact of THC consumption.²⁶ This property of CBD is exploited in the cannabis-based medicine Sativex (discussed in section 6.2).

4.3 *Delta-8-Tetrahydrocannabinol (Delta-8-THC)*

Delta-8-THC is a positional isomer of delta-9-THC with a similar pharmacological profile and slightly lower psychoactive potency. Even though delta-8-THC has been very important for SAR studies on the classical cannabinoids, not many bioactivity studies have been done with the pure compound. It is probably not produced by plant metabolism, but rather it is an artifact caused by degradation of THC (section 2.3). In very low concentrations (0.001 mg/kg

in mice, i.p. injection) it increased food consumption, more than THC, while performance and activity of the animals were similar.³²⁹ This low dose is equivalent to about 0.1mg for an average human, an amount that could easily be formed by degradation of THC during the smoking of Cannabis (or be already present in aged plant material). Consequently, it could, at least partially, be responsible for the “munchies”, a popular name for Cannabis induced increase in appetite.

In a rat study, it was found that behavioral suppression by delta-8-THC was mediated by activation of the arachidonic acid cascade via the CB1 receptor.⁹¹ This may be a useful model to study the amotivational syndrome in humans.

4.4 *Cannabigerol (CBG)*

CBG is one of the major cannabinoids found in most Cannabis varieties. It has shown relevant antibiotic effects,³³¹ and could decrease intraocular pressure.³³⁰ CBG has been called ‘inactive’ when compared to THC, but it has slight affinity for CB1 receptors, approximately equal to that of CBD.⁹² Like CBD, it has analgesic and anti-inflammatory properties, indicating that there is scope for developing cannabinoid-drugs which do not have the psychoactive properties of THC.³³⁶ In one study,⁹³ cannabigerol was evaluated for antitumor efficacy against mouse skin melanoma cells and showed a significant *in vivo* activity using an MTT based cell viability assay.

Of several cannabinoids tested, CBG had the strongest potency to inhibit platelet aggregation.³³² However, in recent years no further studies have been reported on the biological activities of CBG.

4.5 *Cannabinol (CBN)*

In 1940, CBN was the first cannabinoid to be isolated and purified from Cannabis. Although CBN is not produced by the metabolism of the plant, it is easily formed from THC by degradation during drying, storing, and consumption (heating) of Cannabis products. As a result, it may play a significant role in several effects attributed to Cannabis consumption. It is a very weakly psychotropic cannabinoid, whose effect is only measurable after intravenous administration. Cannabinol has significant anticonvulsant, sedative and other pharmacological activities likely to interact with the effects of THC.³³⁵ It was shown to decrease heart rate without affecting coronary blood flow,³³³ to decrease intestinal motility,³³⁴ and to inhibit

platelet aggregation.³²⁹ Furthermore, CBN is a downregulator of NF- κ B, thereby counteracting the effects of THC, which increases NF- κ B.⁹⁴

4.6 *Cannabichromene (CBC)*

This cannabinoid has hardly been studied at all. However, in most *Cannabis* varieties analyzed, CBC (in the form of CBCA) can be detected in significant amounts. CBC was shown to have sedative effects. By itself it has only a low analgesic effect in mice, but it increased the analgesic action of THC when administered together.³³⁷ A *Cannabis* extract rich in CBC altered Behavioral Despair on the Mouse Tail Suspension test of depression.⁹⁵

4.7 *Tetrahydrocannabivarin (THCV)*

Tetrahydrocannabivarin (THCV) is structurally similar to THC, except for a shortened sidechain: it has a propyl (C₃) sidechain instead of a pentyl (C₅), and for a long time it was thought to be a slightly less potent little brother of THC, exhibiting similar properties. However, quite unexpectedly, there is evidence that THCV is a CB1 and CB2 receptor antagonist.⁹⁶ Although the mechanism of action is not yet fully understood, a very recent study suggest that THCV, alongside standard CB1 receptor antagonists, has therapeutic potential to combat diseases involving cerebellar dysfunction and hyperexcitability, such as epilepsy.⁹⁷

4.8 *The Acidic Cannabinoids*

Isolated in 1955, CBDA was the first discovered cannabinoid acid, while CBCA was isolated from *Cannabis* in 1968.¹⁰³ Up to date, only sporadic reports have been made on CBCA or CBDA, and rarely have the pure compounds been used for evaluation of biological activity. As an exception to this rule, pure CBDA was found to display a potent antimicrobial effect.³³⁸ In a study examining the composition of hemp seed oil and its potential as an important source of nutrition, it was observed that extracts containing higher concentrations of CBDA displayed more pronounced antimicrobial activity.¹⁰⁴ Because nowadays it is known that seeds do not produce cannabinoids, the observed levels of CBDA must have resulted from external contamination of seeds by the hemp flowers surrounding it.

Not much is known about the biological effects or human metabolism of the acidic cannabinoids, but older studies at least indicate that the most common acidic cannabinoid, THCA, is not psychoactive in monkeys.¹⁰⁰ CB receptor binding assays indicate that the acidic cannabinoids, as well as their esters, are not binding. In the more potent varieties of cannabis, THCA may be present in levels up to more than 20% of dry weight. However, a quantified, highly pure standard of THCA, as needed for analytical research as well as studies on biological effects, has not been available until recent years.¹⁰¹ As a result, the potential value of THCA as an immuno-modulating agent has only been discovered very recently.¹⁰² Further studies on the biological activities of THCA, and on clinical formulation of this compound, are currently under way.

The acidic cannabinoids are biosynthesized by specialized trichomes, and stored extracellularly, which may indicate they are cytotoxic. Therefore the toxicity of CBGA and THCA, in suspension-cultured Cannabis cells and tobacco BY-2 cells, was compared with that of olivetolic acid, the phenolic moiety in cannabinoids³⁴. In 10-day-old suspension-cultured cells of *C. sativa*, 24 h treatment with CBGA and THCA at 50 μ M caused 100% cell death as demonstrated by trypan blue staining, whereas olivetolic acid did not have any effect on the cells. The same study also showed that both CBGA and THCA induced apoptosis not only in plant cells but also in insect (*Spodoptera frugiperda*, Sf9) cells, suggesting that cannabinoids may act as plant defense compounds. Since cannabinoid-producing glandular trichomes are distributed in physically fragile young tissues of the Cannabis plant, THCA and CBGA, and possibly other acidic cannabinoids, would protect these tissues from predators such as insects. This was the first report suggesting the physiological importance of THCA and CBGA as apoptosis-inducing defense compounds.

In a later study, it was observed that besides THCA, also CBCA has the ability to induce necrotic cell death via mitochondrial dysfunction in the leaf cells of the Cannabis plant itself.¹⁰⁵

5. NON-CANNABINOID CONSTITUENTS OF CANNABIS

Besides some major cannabinoids, no constituents derived from Cannabis plant material have been developed for medical use. Nevertheless, there are several constituents or even whole classes of compounds that may play a significant role in the observed effect of some Cannabis-based preparations. Many of these preparations are a part of self-medication by patients, but they have not been studied in controlled experiments.

Cannabis contains a large number as well as a significant amount of terpenoids. These compounds can be easily evaporated and are consequently inhaled by smoking. Smoke of Cannabis contains a high level of carcinogens, tar and obnoxious gases (such as CO). However, smoking of Cannabis (without tobacco) does not seem to be associated with lung-disease. In contrast, there are even positive effects reported on asthma. It is thought that the positive properties of the terpenoids are at least partially responsible for this. Indeed, several terpenoids identified in Cannabis have known anti-inflammatory, anti-apoptosis or neuroprotective effects (discussed in more detail in section 5.1). Furthermore, Cannabis terpenoids and flavonoids may increase cerebral blood flow, enhance cortical activity, and kill respiratory pathogens.³⁷

Plants offer a wide range of chemical diversity and have been a growing domain in the search for effective cannabinoid receptor ligands.³¹⁸ An increasing number of natural compounds from other species is found to bind to the CB receptors. An exciting discovery was that certain isobutyl analogs of anandamide from *Echinacea* species constitute a new class of cannabinomimetics, which specifically engage and activate CB2.^{315,316} More recently, the ubiquitous sesquiterpene beta-caryophyllene was found to bind to CB2.³¹⁷ Relatively high concentrations of this compound can be found in many plant species, including Cannabis.

The examples mentioned above illustrate the limitations of focussing solely on the cannabinoids. Even though many cannabis constituents are found ubiquitous in other species, many of them have only been poorly characterized. At the same time, we have strong indications that the biological activities ascribed to Cannabis use cannot be explained by the presence of cannabinoids alone. The following sections will therefore list the most relevant non-cannabinoid constituents found in Cannabis. For a complete overview of compounds found in Cannabis materials, see ^{4,32,136}


5.1 Terpenoids

Terpenoids make up a large percentage of the essential oil of *Cannabis sativa* L. To date more than 120 terpenoids have been found in Cannabis, including 58 monoterpenoids, 38 sesquiterpenoids, one diterpenoid, two triterpenoids and four other terpenoids. Two excellent reviews have been published summarizing these compounds and how they were identified.^{4,32}

Terpenoids display a wide range of biological activities and hence may play a role in some of the pharmacological effects of various Cannabis preparations.

While cannabinoids are odorless, the volatile mono- and sesquiterpenoids are the compounds that give Cannabis its distinct smell. The sesquiterpenoid β -caryophyllene-epoxide (figure 11), for example, is the main compound that search-dogs are trained to recognize.¹¹⁵ Only one unusual terpenoid can be found in Cannabis: the monoterpenoid *m*-mentha-1,8(9)-dien-5-ol. All others can be found ubiquitously in nature. For this reason the terpenoids of Cannabis did not receive much scientific interest, until it was found that the terpenoid profile of Cannabis products can help in determining the origin of Cannabis in custom seizures.¹¹⁶

Figure 11: Two special terpenoids found in cannabis



5.1.1 Biosynthesis and composition of Cannabis essential oils

The terpenoids in Cannabis are frequently extracted from herbal material by steam distillation or vaporization. Typical yields of the terpene essential oils from fresh plant material range from 0.05-0.29% (v/w).³⁷ The essential oil of Cannabis is mainly composed of mono- and sesquiterpenoids with monoterpenoids dominating. Since self-administered Cannabis plant

material is usually consumed as an (air)-dried product, the change in terpenoid content and concentration in relation to the fresh plant material is important to note. It has been reported that the essential oil content of a Cannabis plant changed from 0.29% essential oil (v/w) in the fresh product to 0.8% (v/w) after one week of drying, as a result of water loss. Following storage at room temperature for up to 3 months in a paper bag the total essential oil was then reduced to 0.57% (v/w). Furthermore it was observed in the essential oil that the relative percentage of monoterpenoids decreased while the relative percentage of sesquiterpenoids increased.¹¹⁷

Environmental conditions such as plant density, harvest time, pollination, and climate conditions may all play a role in composition and yield of Cannabis essential oils.¹¹⁸ The cultivar of the plant also plays a role in the terpenoid composition. A study that analyzed the terpenoids of 157 different strains of Cannabis from various known origins found statistically significant differences in terpenoid composition. Even though these differences were not always indicative of what chemotaxonomic type the Cannabis strains belonged to, it may play a role in differential medicinal effects.¹¹⁹

5.1.2 *Biological activities of terpenoids*

The observation that whole Cannabis extracts may produce effects greater than expected from THC content alone, has led researchers to postulate as to what other components in Cannabis could be responsible for enhancing or modulating the effects of THC. The terpenoids present in Cannabis display a wide range of biological activities that may be involved in regulating the effects of THC as well as producing their own unique pharmacological effects.³⁷ An overview of some of the known biological activities of terpenoids that have been identified in Cannabis is shown in table 3.

Some undesired side effects of THC may be decreased or modulated in the presence of terpenoid compounds. For example, THC is known to cause acetylcholine deficits in the hippocampus, which may lead to short term memory loss. This effect can be alleviated in rats by administering tacrine, an alkaloid which inhibits acetylcholine esterase, the primary enzyme involved in the breakdown of acetylcholine in cholinergic receptors.³⁷ Indeed, tacrine has blocked THC-induced memory loss behavior in rats. Interestingly, many of the terpenoids present in Cannabis display similar acetylcholine esterase inhibition, including pulegone, limonene, limonene oxide, α -terpinene, β -terpinene, terpinen-4-ol, carvacrol, l- and d-carvone,

1,8-cineole, *p*-cymene, fenchone, and pulegone-1,2-epoxide.³⁷ For this reason, terpenoids are investigated for the treatment of Alzheimer's disease.

THC has been known to cause negative psychological reactions such as anxiety and depersonalization.⁶⁵ Some of these effects may again be alleviated by the terpenoids present in Cannabis, because of their sedative and antidepressive effects.³⁷ Cannabis terpenoids such as linalool, citronellol, and α -terpinene were shown to have significant sedative effects, as indicated by decreased activity in a Mice Motility Model after inhalation of these compounds.¹²² Limonene is a common component of Cannabis essential oil,¹¹⁷ and it was shown to have a strong antidepressant effect by inhibiting the secretion of HPA stress hormones and normalization of CD4-CD8 ratios.¹²³ Limonene is also under investigation as an antimutagenic compound due to its multiple anti-carcinogenesis mechanisms. These effects may reduce some of carcinogenic effects of compounds present in Cannabis smoke.³⁷

Table 3. Summary of Terpenoid Biological activity^{37,317}

Terpenoid	Known Properties
β -myrcene	Analgesic, anti-inflammatory, antibiotic, antimutagenic
β -caryophyllene	anti-inflammatory, cytoprotective, antimalarial, CB2 agonist
d-limonene	Immune potentiator, antidepressant, antimutagenic,
linalool	Sedative, antidepressant, anxiolytic, immune potentiator
pulegone	Acetylcholinesterase (AChE) inhibitor, sedative, antipyretic
1,8-cineol	AChE inhibitor, stimulant, antibiotic, antiviral, anti-inflammatory, antinociceptive
α -pinene	anti-inflammatory, bronchodilator, stimulant, antibiotic, antineoplastic, AChE inhibitor
α -terpineol	Sedative, antibiotic, AChE inhibitor, antioxidant, antimalarial
Terpineol-4-ol	AChE inhibitor, antibiotic
<i>p</i> -cymene	Antibiotic, anticandidal, AChE inhibitor

Cannabis and Cannabis extracts are used in pain relief.⁶⁵ Although many of the pain relieving properties of Cannabis have been attributed to cannabinoids, terpenoids present in Cannabis may also exhibit pain relieving effects. One of the most abundant terpenoids in Cannabis is β -myrcene,¹¹⁷ which exhibits a potent analgesic effect as well as anti-inflammatory effect.^{124,125} Other terpenoids present in Cannabis, such as carvacrol, exhibit a potent anti-inflammatory effect, even greater than that of THC.¹²⁶

Cannabis extracts are known to effect blood brain barrier (BBB) permeability,¹²⁷ thereby potentially altering the pharmacokinetics of THC and other cannabinoids. Since terpenoids are well known to interact with lipid membranes, they may be responsible for this observed activity. Terpenoids have also been shown to increase cerebral blood flow,¹²⁸ which may enhance cognitive brain functions in a way similar to ginkgolides in *Ginkgo biloba*.³⁷

Terpenoids known to be present in Cannabis have a variety of antimicrobial effects, including antibacterial, antifungal, antiviral, and antimalarial activity. Besides the general health promoting effect of these antimicrobial activities they may also be important in reducing the dangers of recreational smoking of herbal Cannabis contaminated with microbial organisms.³⁷

A number of studies have investigated the antimicrobial effects of Cannabis essential oil.¹²⁹ One conclusion was that terpenoids from hash oil (obtained from drug-cultivars of Cannabis, high in THC content) displayed an antimicrobial effect which was greater than essential oil derived from fiber cultivars.¹³⁰

Finally, terpenoids present in Cannabis may play an important role in the chemical ecology of the plant. For example, they have been shown to be involved in the pesticidal properties of the Cannabis plant.³⁷ Terpenoids have been detected in the pollen of male Cannabis plants which may play an important role in either attracting organisms involved in pollination, or in repelling harmful organisms.¹³⁴


5.2 Flavonoids

In total 23 flavonoids have been reported from Cannabis.¹³⁵ Some bioactivity studies have been performed on flavonoids from Cannabis, although not nearly as much as on the cannabinoids or terpenoids. Much has been speculated about the role of these compounds in the therapeutic effect of Cannabis. They are often believed to synergistically enhance some beneficial effects, or reduce unwanted side effects of cannabinoids when Cannabis is taken in a crude form. Much remains to be learnt about these flavonoids, not only related to their effect

on consumers of Cannabis but also on their role in the plant, and how various factors affect their biosynthesis and distribution in the plant.

Flavonoids have been extracted from the leaves,^{138,139} flowers,¹⁴⁰ pollen¹⁴¹ and stems¹⁴² of the plant. The aglycones or conjugated O-glycosides of kaempferol, quercetin, apigenin and luteolin have been found, as well as the C-glycosides of vitexin, isovitexin, orientin and their O-glycosides.^{4,136} Two flavonoids are so far unique to the Cannabis plant; these are the prenylated flavonoids called cannflavin A and B,^{137,138} as shown in figure 12.

Figure 12: Structures of cannflavin A and B.



In older studies, flavonoid glycosides were hydrolyzed with acid to yield aglycones, before identification. These were characterized with UV spectral properties and behavior in various chromatographic systems.^{142,144} The result is that for the glycosides, the exact number and linkage positions of the sugar moieties are mostly not known.⁴ In a few later studies additional spectroscopic techniques were used to determine the structures of these flavonoids more precisely.^{141,145}

5.2.1 Biosynthesis of flavonoids in cannabis

Although the flavonoid pathway has been extensively studied in several plants, there is no specific data on the biosynthesis of flavonoids in cannabis. However, the general pathway for

flavone and flavonol biosynthesis as it is expected to occur in cannabis is described by ³⁶¹. There is currently no evidence indicating the presence of flavonoids in glandular trichomes. A few studies have investigated differences in flavonoid content between different strains of Cannabis. Clark *et al.*¹⁶⁸ investigated the flavonoid content of 53 different Cannabis varieties grown from seeds from 9 different countries, and found considerable plant to plant variation. The distribution of flavonoids in different varieties followed a pattern based on agronomic use, with clear differences between high-cannabinoid and low-cannabinoid producing strains. Vanhoenacker *et al.*¹⁶⁹ found that cannabinoid-free Cannabis did not produce prenylated flavonoids in leaves or flowers, indicating that the biosynthesis of flavonoids in Cannabis may be linked to that of cannabinoids, and therefore these two biosynthetic pathways may be competitive. Not much is known about how biotic and abiotic factors influence levels and distribution of flavonoids in Cannabis.

5.2.2 Biological effects of flavonoids

Flavonoids have many roles in the physiology of plants. They provide plant pigmentation and flavor, are involved in plant growth and development, provide resistance to pathogens and predators, as well as protecting against harmful effects of UV radiation.^{146,147}

Flavonoids also show a large variety of pharmacological and biological activities.¹⁴⁸ As phenolic compounds, they can act as metal chelators and free radical scavengers, and more recently much attention has been given to the role of flavonoids as antioxidants.^{149, 150, 151} Flavonoids are able to modify the activities of many enzyme systems in the human body, and have been shown to alter the function of various cell types in mammalian cell systems.¹⁵² Many of these properties are related to immune functions, cellular transformation, and tumor growth and metastasis. Other biological activities reported include anti-bacterial, anti-fungal and antiviral effects.^{153,154}

Segelman *et al.*¹⁵⁷ isolated orientin and two flavone C-glycosides (orientin-2''-O-D-glucopyranoside and vitexin-2''-O-β-D-glucopyranoside) from a Mexican strain of Cannabis. These compounds were tested in a rat Lens Aldose Reductase enzyme assay, and found to have inhibitory properties against this enzyme, that is implicated in the pathogenesis of cataracts in humans with diabetes and galactosemia.

In a recent review of the chemistry and pharmacology of marijuana smoke ¹⁶⁷, no mention is made of flavonoids in Cannabis smoke. Nevertheless, it is likely that some flavonoids are present in Cannabis smoke. Most authors cite the work of Sauer *et al.*¹⁵⁸ who assumed the

estrogenic effect of marijuana smoke condensate was due to the presence of apigenin. Lee *et al.*¹⁶⁶ also tested marijuana smoke condensate for estrogenic effects, and went further by fractionating it to find out which components were responsible for the observed effect. They identified phenol and one phenolic derivative in the active fraction, but no flavonoids were found.

5.2.3 Therapeutic potential

Flavonoids may be important for the overall therapeutic effect of THC and the other cannabinoids by either synergistically enhancing them, or by reducing their side effects.³⁷ Flavonoids may counteract some unwanted effects caused by THC, such as the upregulation of tumor necrosis factor-alpha (TNF- α).³⁴⁰ Flavonoids are particularly adept at inhibiting cytochrome P450 (CYP) monooxygenase enzymes, thereby potentially altering the pharmacokinetics of THC, which is converted into 11-hydroxy-THC by the same enzymes. Such CYP-suppressing flavonoids may therefore act as chemoprotective agents by blocking the conversion of procarcinogens such as benzo[α]pyrene and aflatoxin B1, two harmful agents potentially found in cannabis smoke, as a result of contamination of herbal cannabis with moulds.

Some flavonoids isolated from Cannabis have been tested for pharmacological effects. Cannflavin A and B were found to inhibit prostaglandin E2 in human rheumatoid synovial cells. Cannflavin A did so with 30 times more potency than aspirin.¹³⁸ Cannflavin A inhibited cyclo-oxygenase and lipoxygenase enzymes and thus had anti-inflammatory properties.¹⁵⁵ It is perhaps not surprising that these compounds show strong biological activities, because substitution with a prenyl group increases lipophilicity of flavonoids and give the molecules strong affinity for biological membranes.¹⁵⁶ Prenylated flavonoids are attracting increasing attention from the scientific community because of their potent anti-oxidant and anti-cancer effects, and their potential for treating menopausal problems.³³⁹ Therefore, it is possible that the cannflavins will in the future be shown to possess more biological properties.

Clinical studies on flavonoids have shown that often very little unchanged aglycone is present in human plasma, but that conjugated metabolites such as glucuronic acid conjugates are present at high concentrations.¹⁶⁰ The bioactive forms *in vivo* may thus not be the naturally occurring phytochemical forms but rather their metabolites derived from them after absorption in the body.¹⁶⁵ The uptake of flavonoids and their *in vivo* metabolites are also different for different cell types. Consequently, the concept of oral bioavailability and activity of dietary

flavonoids is clearly a complex topic. Nonetheless it is possible that flavonoids in Cannabis taken orally have potential beneficial effects.

5.3 *Hemp Oil*

When Cannabis is cultivated for the production of fiber or seeds, only specially selected varieties with a very low THC content are legally allowed to be used. In that case, it is usual to use the term hemp instead of Cannabis (see section 1.1). In recent years, scientific knowledge on the composition and benefits of hemp oil has increased significantly. The oil of Cannabis seeds has been promoted as a good source of the healthy polyunsaturated fatty acids, and may be considered a sustainable alternative to fish-oil. As a result, public awareness of these properties is increasing. Cold-pressed, unrefined hemp oil is light green, with a nutty, grassy flavor, while refined hemp oil is clear with little flavor. It is widely used in body care products, lubricants, paints and industrial uses, while its antimicrobial properties and emollient effect make it a useful ingredient for soaps, shampoos and detergents.

5.3.1 *Production methods*

Hemp oil is obtained from mature hemp seeds, grown outdoors.¹⁷⁰ Some classical hemp varieties have been reported to readily yield 500-1000 kg seed/ha, with even higher seed yields being reported from newer cultivars. Hemp is pollinated by wind, which may result in an erratic pattern of pollination, with some flowers being pollinated days before other flowers on nearby plants. As a result, the seeds do not all ripen simultaneously, and at the moment of harvest a proportion of the seeds may still be unripe or green. Because over-ripe seed will fall from the plant and hence will be lost for harvest, it is not economically feasible to wait until all seed is ripe, and a certain proportion of unripe seed in the harvest can not be prevented. Unfortunately, the presence of green seeds may give rise to a decreased oil quality.

After harvest, the seed is dried to reduce its moisture content, which also prevents sprouting during storage. The material is fed in batches to a hydraulic screw press and a high pressure is progressively applied, avoiding large changes in the temperature. Hemp seed contains about 30-35% oil by weight. As about a third of the oil remains in the seed cake, the pressing is usually repeated, although the oil obtained in this way has lower quality.^{170,171} Finally, the oil is filtered to remove solid particles. Chlorophyll and the carotenoid pigments found in mature seeds provide the natural dark green color to the oil.

Most commercial food oils are extracted with the use of organic solvents or elevated temperatures. In contrast, hemp oil is considered to be a relative unstable product, and is mainly extracted by cold-pressing methods. To maintain the native qualities of this product, further refining procedures are usually minimized. Some processing is sometimes applied in order to increase yield. For example, microwave treatment of hemp seed improved oil yield, and increased carotenoid and other pigment contents without causing changes in fatty acid composition.¹⁷² Furthermore, it shifted the melting range of oils to lower temperatures and increased oxidation temperatures, suggesting increased protective effect upon microwave heating.

Hemp oil contains a high proportion of polyunsaturated fatty acids,¹⁷³ and the double bonds that provide such unsaturation can be degraded due to oxidation by exposure to air, light and/or elevated temperatures. At temperatures above 200 °C, undesirable trans-fatty acids are gradually formed, which may lead to formation of aldehydes, causing the oil to become rancid. As a result, it is generally recommended that hemp oil should not be used for frying or baking, but preferably should be consumed cold.^{170,174} In contrast, results obtained by Molleken,¹⁷⁵ who subjected hemp oil to a series of heat treatments before analyzing the fatty acid composition, showed that the stability of hemp oil is much better than generally assumed: trans-fatty acids were not formed under normal cooking conditions, and heated native hemp oils were quite stable under high-temperature conditions (up to 250°C), presumably because of the presence of significant amounts of the antioxidant *gamma*-tocopherol. Nevertheless, industrially produced hemp oil is bottled under a nitrogen atmosphere into dark bottles to prevent oil degradation, and for longer storage, freezing is suggested. Extra addition of tocopherols is recommended as preservative for hemp oil.¹⁷⁶

5.3.2 Composition of hemp oil

Hemp seed typically contains about 25% high quality protein and 35% fat in the form of an excellent quality oil. It has a remarkable fatty acid profile, being high in the desirable omega-3 fatty acids and also delivering some *gamma*-linolenic acid, which is lacking in the average Western diet.¹⁷⁴ Hemp oil is generally considered as healthy, together with other edible oils such as flax oil, linseed oil, fish oil and canola oil. However, only hemp oil typically contains 50-70% linoleic acid (LA, an omega-6 fatty acid) and 15-25% *alpha*-linolenic acid (ALA, an omega-3 fatty acid),¹⁷⁰ which is roughly in the 3-to-1 ratio that matches our nutritional needs (see below). LA and ALA are essential fatty acids, meaning they can not be made by human

metabolism and must therefore be obtained through the diet, as they are necessary for growth and maintenance of cell membranes. Oleic acid and saturated fatty acids both make up about another 10% of the oil.²⁷

Furthermore, hemp oil provides significant amounts of some higher fatty acids such as *gamma*-linolenic acid (GLA; 18:3; omega-6) and stearidonic acid (SDA; 18:4; omega-3).¹⁷⁰ Although work by Ross *et al.*¹⁷⁸ showed no significant difference in the fatty acid composition of the oil generated from drug or fiber type seeds, the content of such higher fatty acids may vary considerably with variety, climate and growing conditions. The content of GLA in hemp oil is 1-6% in most varieties,^{170,175} but the tropical hemp varieties do not show significant quantities of it. The highest concentrations of GLA and SDA in hemp oil were found in varieties adapted to northern latitudes.¹⁷⁵ In some hemp varieties the omega-9 fatty acid eicosenoic acid (EA; 20:1) is present in amounts up to 0.5%,^{170,175} however most varieties typically show less than 0.3%.

Besides fatty acids, moderate to high concentrations of the vitamin E are present in hemp oil as well as small amounts of phytosterols, phospholipids, chlorophyll, carotenes, and several minerals.²⁷

5.3.3 *Therapeutic potential*

Many edible oils (e.g. hemp, sunflower, soybean, pumpkin and canola) contain significant amounts of the health-promoting omega-6 fatty acid LA (figure 13). However, only some of these oils simultaneously provide significant amounts of the omega-3 ALA. It is important to notice that only hemp oil provides a ratio of LA to ALA close to 3:1, which is suggested as optimal for human nutrition.^{170,177,180} Furthermore, hemp oil contains GLA and SDA. No other edible plant oil has these nutritional advantages and consequently, health benefits.

The unbalanced intake of omega-6 and omega-3 fatty acids is associated with many chronic diseases such as cardiovascular disease, diabetes, cancer, obesity, autoimmune diseases, rheumatoid arthritis, asthma and depression.¹⁸¹ The average Western diet provides a ratio of omega-6 to omega-3 of about 15:1. Because the eicosanoids (human lipid messenger molecules involved in many body functions) that are metabolically derived from omega-6 are generally pro-inflammatory, this relative overconsumption of omega-6 fatty acids may lead to a cascade of health compromising effects. These include oxidation of low density lipoprotein, a decrease in bleeding time by decreasing platelet aggregation, a decrease of peripheral blood pressure, interference with the incorporation of polyunsaturated fatty acids in the formation of


membrane phospholipid bilayers, and to allergic and inflammatory disorders and formation of thrombi and atheromas contributing to an increased incidence of cardiovascular disease.¹⁸¹

In contrast, omega-3 fatty acids, through their eicosanoid metabolites, have been shown to result in lower blood pressure and blood cholesterol levels, playing an important role in the prevention and treatment of coronary artery disease, cancer, and hypertension. Moreover, they help normalize fat metabolism and decrease insulin dependence in diabetics. They also increase overall metabolic rate and membrane fluidity, and exhibit anti-inflammatory properties, specifically with regard to relieving arthritis.^{180,182}

Nutritionists suggest that daily requirements should range from 9-18 gram of LA and 6-7 gram of ALA, which would be equivalent to the consumption of 3 to 5 tablespoons of hemp oil. However, individuals who consume a diet high in saturated fatty acids or *trans*-fatty acids will require more, as well as people who are overweight or under great stress.^{104,180}

Figure 13: Typical fatty acid composition of vegetable oils.

Source: [Leson G, Pless P, Roulac J. Hemp Foods and Oils for Health. Sebastopol, CA: Hemptech, 1999].¹⁷⁴ Reprinted with permission.



5.3.4 *Cannabinoid contamination of hemp oil products*

Although no cannabinoids are metabolically produced by the hemp seed itself, they may be detected in hemp oil, because cannabinoids as well as other components present in the resin may be transferred from the flowers and leaves onto the seeds, and subsequently to the oil during pressing. Thorough cleaning of the seeds, including de-hulling, and the use of varieties with a very low THC content (those containing less than 0.3 % THC in the upper third of flowering plants) are ways of preventing such contamination.²⁷ Certified low THC hemp seed is currently available from Canada, Europe, and China and is under development in Australia and the United States. Today hemp is grown throughout the world - except in the United States, where it is illegal to grow the plant but not illegal to manufacture and sell products made from it.


Because hemp oil is produced for applications in food, the fear exists that the oil may be contaminated with significant amounts of the psychoactive component THC. As a result, production fields of hemp are systematically sampled, and also the final hemp oil must be subjected to thorough mandatory testing by certified methods. Depending on the hemp varieties used, the amounts of THC detected can vary. In the case of hemp oil from Chinese and European seeds an excess of 100 ppm have been observed.¹⁷⁷ However, quantities observed in hemp oil are usually so small that there is no possibility of intoxication and hence no potential negative effects on human health. In order to ensure the safety of hemp products (oil and other), strict legal limits have been set for the level of THC allowed, ranging from 10 ppm in Canada to 50 ppm in Switzerland.¹⁸³

Drug tests conducted in the period 1995-1997 showed that consumption of hemp oil from cannabis varieties producing more than 1% THC may in fact result in detectable amounts of THC metabolites in urine, detected by immunoassay screening tests at the 50 ppb cutoff.¹⁸⁴ Other studies show that an ingestion of up to 0.6 mg THC/day, the equivalent to 50-100 ml of typical hemp seed oil, is not likely to produce positive results when analyzing by GC/MS (gas chromatography/ mass spectrometry) methods. This amount is even less likely to produce positive results at the 15 ppb cutoff used in US federal drug testing programs. Use of cosmetics based on hemp oil did not result in positive urine tests for marijuana use. The minimal amounts of THC in hemp oil are probably not absorbed through the skin and/or do not cause any relevant uptake into the bloodstream.


5.4 Other Components Found in Cannabis

Besides the major classes of compounds described above, some other classes are worth mentioning as well. They will be described shortly in the following sections. An excellent review of the functions, occurrence and biosynthetic pathways for the production of these minor components of *Cannabis sativa* has been given by Flores-Sanchez *et al.*³²³

Figure 14: The structures of the Cannabis alkaloids Cannabisativine and Anhydrocannabisativine



(+)-Cannabisativine



Anhydrocannabisativine

5.4.1 Alkaloids and nitrogenous compounds

In cannabis 27 nitrogenous compounds have been detected, of which 10 have been identified as alkaloids.^{4,32} Some of the more unusual constituents of Cannabis include an amide formed

between *p*-hydroxy-(trans)-cinnamic acid and 2-(*p*-hydroxyphenyl)-ethylamine, which was isolated from the roots of Mexican Cannabis, and the spermidine-type alkaloids cannabistatine and anhydro-cannabistatine (see figure 14), isolated from the roots and aerial parts of various Cannabis strains.⁴

Other interesting alkaloids include choline, neurine, L-(+)-isoleucine-betaine and muscarine (protoalkaloids); hordenine (a phenethylamine) and trigonelline (a pyridine). The concentration of choline and neurine from dried roots was only 0.01%.³⁶⁸ The presence of muscarine in cannabis plants has later been questioned.³⁶⁹ Methods for synthesis of cannabistatine³⁷⁰ as well as the biosynthesis of choline and atropine by hairy root cultures of *C. sativa*³⁷¹ have been reported.

Although alkaloids are generally considered to be a most interesting class of compounds for biological activity, there is currently no relevant information on the pharmacological profile of these Cannabis alkaloids. Some studies suggest pharmacological activities of smoke condensate and aqueous or crude extracts containing cannabis alkaloids.^{372,373}

5.4.2 Non-cannabinoid phenols

Twenty five non-cannabinoid (and non-flavonoid) phenols were identified in Cannabis. These include simple phenols such as eugenol and related phenols, dihydrostilbenes or bibenzyl compounds (e.g. canniprene), dihydrophenanthrenes and spiro-indans (e.g. cannabispiran, cannabispirenone). The dihydrostilbenes and spiroindans are closely related, and they possibly have the same biosynthetic origin. Several spiroindans have only been found in Cannabis¹⁸⁵.


Only recently, the phenanthraquinone denbinobin (figure 15) was identified in Cannabis extracts. First isolated from *Ephemerantha lonchophylla*, this compound inhibits nuclear factor- κ B and causes apoptosis in human leukemic cells via reactive oxygen species. Furthermore, in a concentration-dependent manner, it induces apoptosis in human leukemic cells via Akt inactivation, Bad activation, and mitochondrial dysfunction.³¹⁹

5.4.3 Stilbenoids

Nineteen stilbenoids have been identified in cannabis.^{4,32} They have been isolated from stem, leaves and resin.³²³ Studies have reported antibacterial activity for certain cannabis stilbenoids.³⁷⁴ It has been suggested that their biosynthesis could have a common origin, with

dihydroresveratrol as a central intermediate.³²³ However, no comprehensive reports about the biosynthesis of spirans or about the regulation of the stilbenoid pathway in cannabis currently exist.

Figure 15: The structure of the Cannabis phenanthraquinone Denbinobin



5.4.4 Lignanamides and phenolic amides

Cannabis fruits and roots have yielded 11 compounds identified as phenolic amides and lignanamides.³²³ The phenolic amides include *N-trans*-coumaroyltyramine, *N-trans*-feruloyltyramine and *N-trans*-caffeoyltyramine; the lignanamide group includes cannabisin-A, -B, -C, -D, -E, -F, -G and grossamide. In general, lignanamides belong to the lignan group, and the cannabis lignanamides are classified as lignans of the aryl-naphthalene derivative type. The phenolic amides have cytotoxic, anti-inflammatory, antineoplastic, cardiovascular and mild analgesic activity. For the lignanamides grossamide, cannabisin-D and -G a cytotoxic activity was reported.³²³ The presence and accumulation of phenolic amides in response to wounding and UV light suggests a chemical defense against predation in plants.³⁷⁵ For the lignanamides cannabisin-B and -D a potent feeding deterrent activity was reported.³²³ The structures of the lignanamides and phenolic amides from cannabis suggest condensation and polymerization reactions in their biosynthesis starting from the precursors tyramine and CoA-esters of coumaric, caffeic and coniferic acid. However, it has also been suggested that these lignanamides could be isolation artifacts.^{376,377} Further biosynthesis studies are necessary to elucidate their origin.

6. CANNABIS AS A MEDICINE

The clinical potential of the cannabinoids is large; some people suggest that Cannabis could be the “aspirin of the 21st century”, pointing out the impulse secondary metabolites from cannabis may give to contemporary medicine.⁹ However, much of the evidence for the medicinal use of cannabis or cannabinoids is anecdotal and it turns out to be very challenging to confirm many of these findings by clinical trials. Also it is often unknown which constituents are responsible for the effects observed after administration of herbal cannabis or extracts. The lack of appropriate animal models with the complexity of the human brain hampers the study of the behavioral effects of these compounds. Therefore, experimental studies have concentrated on measurable physiological effects, and, as a result, the understanding of the underlying biology is only slowly improving. But despite these limitations, a number of cannabinoids of natural as well as synthetic origin have been developed for clinical use; most often as agonists or antagonists of CB-receptors. These compounds are often the result of extensive studies on structure activity relationships performed on the phytocannabinoids, their chemical derivatives, and their metabolites. The clinical evaluation or development of the non-cannabinoid constituents of Cannabis is minimal.

Although the structure of THC was elucidated by means of NMR-spectroscopy already in 1964, relatively little clinical research took place for a long time. Research on the medicinal potential of cannabinoids got a new impulse after the discovery of the cannabinoid receptors in the 1990s. During the extended period between these two events, the cannabinoid character of a large variety of compounds was assessed through a panel of *in vivo* assays, one of the earliest being the dog ataxia test.²⁵⁷ However, the most widely used set of assays was known as the cannabinoid tetrad,⁶⁴ which comprised four different behavioral tests performed mostly in mice: diminution of temperature (hypothermia), immobility in a multiple photoelectric cell chamber (diminution of locomotion), a ring test or bar test (catalepsy), and a hot-plate or tail-flick test (analgesia). A positive response in all four tests was the criterion to consider a compound as a ‘classical’ cannabinoid. To date, activity in this mouse behavioral battery has been a reliable predictor of psychotomimetic activity in humans. Nowadays, it is understood that the observed effects in the cannabinoid tetrad can in fact be attributed to CB1 activation. Cannabis preparations have been employed in the treatment of numerous diseases, with marked differences in the available supporting data. Clinical studies with single cannabinoids (natural or synthetic) or whole plant preparations (e.g. smoked Cannabis, encapsulated

extract) have often been inspired by positive anecdotal experiences of patients using crude Cannabis products for self-treatment. The antiemetic,²⁵⁸ appetite enhancing,²⁵⁹ analgesic²⁶⁰ and muscle relaxant effects,²⁶¹ and the therapeutic use in Tourette's syndrome,²⁶² were all discovered or rediscovered in this manner. Incidental observations have also revealed therapeutically useful effects. The discovery of decreased intraocular pressure with THC administration, potentially useful in the treatment of glaucoma, was made serendipitously during a systematic investigation of healthy Cannabis users.²⁶³ However, anecdotes as to the efficacy of Cannabis or THC in indications that have not been confirmed in controlled studies have to be judged with caution. Nevertheless, the therapeutic potential of cannabis and the cannabinoids is large.

6.1 *Therapeutic Potential of Cannabinoids*

The therapeutic potential of cannabinoids can be clarified by pointing out the central physiological importance of the endocannabinoid system, as described in section 3. The cannabinoid system is involved in a wide range of physiological functions and might be related to a general stress-recovery system. One yet unproven but intriguing idea is that endocannabinoids may set the 'analgesic tone' of the body, with the level of their production acting as a kind of pain thermostat.²⁹⁴ It is likely that such a system relies on the combined activities of a range of compounds. Strategies to modulate endocannabinoid activity include inhibition of re-uptake into cells and inhibition of their degradation to increase concentration and duration of action. The effect of phytocannabinoids interacting with such an endocannabinoid system could be on multiple levels, other than receptor binding alone. Some of such interactions have already been described.²⁹⁴

The phytocannabinoids make up a significant group of compounds with diverse properties, and even based on the limited data available it may be expected that at least several of them have therapeutic potential. Most known cannabinoids have been tested to describe their relative (psychoactive) potency in comparison to THC, either in receptor binding assays or in THC-specific assays. However, testing non-THC cannabinoids as serious candidates for new leads can sometimes lead to completely counter-intuitive results, as shown in the case of THCV: although its psychoactive potency is roughly similar to THC (about 1/4)^{4,291}, later *in vivo* testing surprisingly showed that THCV should rather be considered an antagonist of THC activity.⁹⁶

An exciting notion is that phytocannabinoids, and possibly non-cannabinoids present in the plant, may exert their effect independent of cannabinoid receptors altogether. In this respect, most studies are focused on the interaction between cannabinoids and the opioid system. It is becoming increasingly clear that crosstalk between the cannabinoid and the opioid system exists¹⁸⁷, but our understanding of this field is only just beginning. Although the brain has more CB1 than opioid-receptors, a review by the US Institute of Medicine has commented on how little we know about cannabinoids in comparison with opiates.²⁹⁷ The obvious analogy between the history of research on opiates and cannabinoids suggests good reason for optimism about the future of cannabinoid drug development.^{298,299}

6.2 *Current Status of Cannabinoid Medicines*

An increasing number of pharmaceutical companies start to pick up the idea of cannabinoids or their antagonists as therapeutic drugs. At present a number of preparations based on the biological activities of the cannabinoids are available, but not all of these have been registered as drugs. Most preparations are pure compounds based on the pharmacological actions of THC. The major ones are shown in figure 16.


The most commonly prescribed cannabinoid-based medicines are Marinol® (synthetic THC in sesame oil, Solvay Pharmaceuticals) and Cesamet® (Nabilone, Valeant Pharmaceuticals International). They are registered for the indication of nausea and vomiting associated with cancer chemotherapy. Marinol is also approved for anorexia and cachexia in HIV/AIDS. The patent on Marinol will expire in 2011, opening the way for the development of generic preparations of synthetic THC.

Although there are clear indications that some effects may vary according to the fact if a cannabinoid is taken alone, or in combination with other cannabinoids, not much work has been done on the activities of combined cannabinoids. However, there is a major exception: Sativex® (GW Pharmaceuticals, UK) is a sublingual spray based on a mixture of two distinct standardized Cannabis extracts. The final mixture contains equal amounts of THC and CBD. Because of the use of whole extracts, non-standardized amounts of ballast components are also present, such as minor phytocannabinoids and terpenoids.²⁸³ It is currently registered only in Canada, but registration is pending in several European countries.


Cannador (European Institute for Oncological and Immunological Research, Germany) is an oral capsule containing a Cannabis extract, whose THC to CBD ratio does not appear to be fully standardized. Although it has been used in several clinical trials, it has not yet been

registered as a drug. It has been clinically tested for reduction of tremor in multiple sclerosis,³⁵³ and post-operative pain management.¹⁰⁹


Figure 16: the structures of several cannabinoid receptor agonists currently in use or under development



HU211 (Dexanabinol)



Ajulemic acid



Rimonabant

Several new cannabinoid-based products are currently under development. Among them are a new prescription anti-obesity drug, Rimonabant (Acomplia®, by Sanofi-Aventis),²⁸⁴ and the potent analgesic ajulemic acid.²⁸⁵ Rimonabant was the first selective CB1 receptor blocker to be approved for use anywhere in the world. It is an inverse agonist for the cannabinoid receptor CB1. Rimonabant was developed based on the observation that recreational Cannabis consumption commonly leads to an insatiable feeling of appetite. Causing the opposite effect, by antagonizing the cannabinoid receptor response, leads to reduction in appetite. It was released in the form of a tablet under the name Acomplia, but has very recently been pulled off the market out of concern over its depressive side effects.

Ajulemic acid (AJA) is a synthetic analog of the human THC metabolite 11-carboxy-THC (see section 3.3). Although the mechanism of AJA action remains largely unknown, it has potent analgesic and anti-inflammatory activity,³⁴¹ without the psychotropic action of THC. Psychoactive effects may be limited as a result of reduced crossing of the blood brain barrier, and greater activity at peripheral rather than central cannabinoid receptors.²⁸⁶ A major advantage of AJA is that, unlike the nonsteroidal anti-inflammatory drugs (NSAIDs), it is not ulcerogenic at therapeutic doses. It has been studied in clinical trials for chronic neuropathic pain.³⁵¹

Dexanabinol, (also known as HU-211) is a dihydroxylated synthetic cannabinoid resembling THC that is devoid of cannabimimetic effects and does not bind to cannabinoid receptors.²⁸⁷ The neuroprotective effect of dexanabinol is related to its unique capacity to act as a non-competitive antagonist of the NMDA receptor, to block COX-2 enzymes, and to prevent inflammation by inhibiting secretion of TNF α and other inflammatory cytokines in the central nervous system.²⁰¹ Dexanabinol may be useful in the treatment of traumatic brain injury.³⁵²

6.3 *Approaches for Further Development*

Extensive information about Cannabis as a medicament goes beyond the possibilities of this article and we can refer readers to several comprehensive books^{27,366} and recent reviews^{108,266,283} on this subject. However, some major developments will be briefly discussed here. The following sections discuss some suggested targets for further development of cannabis compounds as a drug.

Phytocannabinoids, as found naturally occurring in the plant, provide the pharmaceutical developer with a variety of challenges, including low water solubility, variable bioavailability, psychoactive side effects, etc. As a result, current research on synthetic cannabinoids focuses

mainly on new chemical entities (NCEs) that can agonize or antagonize one of the CB receptors specifically, or that can affect the endocannabinoid system otherwise (e.g. FAAH inhibitors). Possible fields of application include obesity, anorexia and neuroprotection. Some of these molecules have proven to be powerful agonists. But although they are extremely useful for nonclinical studies to uncover the functions of the endocannabinoid system, they may be too psychoactive to be tested in human subjects.

6.3.1 Improving the biological availability of cannabinoids

THC is a light yellow resinous oil, sticky at room temperature which hardens upon refrigeration. THC is highly lipophilic, practically insoluble in water,²⁸⁸ having an octanol:water partition coefficient (at pH 7) of at least 6,000:1.³⁵⁰ As a result, it has been difficult to develop effective formulations for human use.⁹⁹ So far, every attempt to make classical cannabinoids more water soluble has yielded only compounds without significant CB binding. Several examples illustrate the difficulties in handling the high lipophilicity of cannabinoids; the synthetic cannabinoid dexanabinol was evaluated in phase I clinical trial by i.v. infusion in cremophor-ethanol vehicle diluted with saline, while Sativex is a sublingual spray containing ethanol and propylene glycol as solubilizers.³⁴² A possible way to handle this obstacle is the creation of water-soluble prodrugs. Examples are glycinate and salts of amino acid esters containing tertiary and quaternary heterocyclic N-atoms.²⁸⁹ Also the use of cyclodextrins as solubilizers has been studied, and seems to be feasible.²⁹⁰

6.3.2 Selective activation of cannabinoid receptors

There is a fundamental problem with using the cannabinoid receptor as a drug target: the main target for most therapeutic activities is CB1 and this is the same receptor that causes most of the adverse effects. Dissociation of the adverse effects from the therapeutic effects of Cannabis may therefore never be truly possible. Furthermore, excessive stimulation of CB1 leads to receptor tolerization and this is a particular problem of strong agonism.³⁰⁵ Also, there may be risks associated with the long-term use of CB-blockers (antagonists): a good example is the increased risk of depression with the prolonged use of Rimonabant.

But although CB1 is generally considered to be centrally active, is also expressed on nerves outside the CNS, e.g. on nerve terminals, dorsal root ganglia and the vasculature. So a possible strategy for drug development is to develop compounds which are excluded from the

blood brain barrier (BBB), in order to selectively activate the peripherally located CB1 receptors. This may limit psychoactivity while producing benefits for disorders such as pain, asthma or glaucoma.

Cannabinoids inhibit pain in virtually every experimental pain paradigm either via CB1 or CB2-like activity, dependent on the type of nociceptive pathway being studied. This finding is consistent with high concentrations of CB1 receptors on primary afferent nociceptors, particularly in the dorsal spinal cord, whereas peripheral CB2 receptors have been implicated in the control of inflammatory pain.²⁷⁰ CB2 selective agents, working on the peripherally located CB2 receptors, without activating the CB1 receptors that may induce a psychoactive effect, may have therapeutic value. Guindon and Hohmann³⁶² reviewed behavioral, neurochemical and electrophysiological data, which identify cannabinoid CB2 receptors as a therapeutic target for treating pathological pain states with limited centrally, mediated side effects. Cheng and Hitchcock³⁶³ reviewed the present development of cannabinoid agonists with an emphasis on selective CB2 agonists and peripherally restricted CB1 or CB1/CB2 dual agonists for treatment of inflammatory and neuropathic pain.

6.3.3 Modulating the endocannabinoid system

Endocannabinoids, through interaction with the CB-receptors, have a range of effects on the nervous system. They are weak agonists and these agents naturally stimulate receptors without much potential for inducing psychoactive effects. For this reason, modulation of the endocannabinoid system is an exciting target for cannabinoid therapy. But although endocannabinoids may be interesting as therapeutic agents, their instability and rapid metabolism limit their utility in preclinical and clinical research. To date, no endocannabinoid agents have been administered to humans.

How many and what functions of the endocannabinoids occur tonically under conditions of physiological homeostasis is at present unclear. The fact that CB1 and CB2 receptor knockout, at least in certain genetic backgrounds, does not produce a strong phenotype in unchallenged animals suggests that this system becomes important mostly under pathological conditions. Indeed, endocannabinoid signaling often undergoes dramatic tissue-specific changes in both animal models of disorders and in human diseases.²²⁶

As discussed in section 3.2, endocannabinoids are made on demand, they act only locally, and are metabolized immediately after action. As a result, the duration of their action is very limited. Compounds that affect the levels of endocannabinoids, by inhibiting membrane

transport or hydrolysis, thereby prolonging their life-span, offer promising potential for further research and pharmaceutical development. During a variety of diseases there are changes in endocannabinoid concentrations at the site of pathology. Targeting of endocannabinoid degradation through inhibition of the reuptake mechanism or enzymes that cause degradation could locally target sites of damage while limiting effects in uninvolved areas. This approach has a simple but important consequence: the effects of endocannabinoids are only prolonged at those sites where they are already produced by existing physiological responses. A more targeted approach would hardly be imaginable.

6.3.4 *Interaction with other neurotransmitter pathways*

An exciting observation is that THC reduces chronic pain in patients who do not get sufficient pain relief from opioids. Many studies have been performed on Cannabis and pain, but they are hard to compare because of the large variety of pain-models used, and the subjective nature of pain. However, a variety of synthetic analogs and derivatives of THC and other cannabinoids have been designed with an improved analgesic effect, but without the psychotropic side effects of THC. A promising development is the combined use of THC with opioids.

Opioids and cannabinoids share several pharmacological effects, including antinociception, hypothermia, inhibition of locomotor activity, hypotension, and sedation²⁵¹ It is therefore not surprising that crosstalk between the two systems has been shown.¹⁸⁷ The coupling of both receptor types, via inhibitory $G_{i/o}$ proteins, to similar intracellular signaling pathways underlies, to some extent, their similarities in actions.³¹⁰ Interactions between the pathways probably explain why antagonists of each receptor type sometimes counteract the pharmacological effects induced by the stimulation of the other type.²⁹⁸ Co-administration of various cannabinoids with morphine produced a greater-than-additive effect with respect to antinociception in mice.³¹¹ Although both cannabinoids and opioids are accompanied by undesirable side effects at high doses, it was found that THC can enhance the potency of opioids such as morphine, thereby dramatically reducing the dose needed for pain control in some clinical indications.^{312,354}

Yet another potential target for interaction with (endo)cannabinoids is ceramide, a ubiquitous sphingolipid second messenger that plays an important role in the control of cell fate. Cannabinoid-induced acute ceramide generation might rely on *de novo* synthesis through induction of sphingomyelin hydrolysis. As a result of this activity, cannabinoids, like other

ceramide-generating agents,³¹³ might be considered as potential therapeutic drugs for the management of malignant tumors.

7. PRACTICAL ASPECTS OF CANNABIS RESEARCH

Thanks to the relatively recent discovery of the human endogenous cannabinoid system, it seems that Cannabis-based medicines may have a bright future. But there are a lot of obstacles to be taken first. Some are a direct result of the nature of the plant and the chemical characteristics of its constituents, but others are clearly the result of social, cultural, and as a result, legal bias towards a hazardous plant. Some of the most important aspects are discussed below.

7.1 *Legal Aspects*

Starting from 1954, the World Health Organization (WHO) has claimed that cannabis and its preparations no longer serve any useful medical purpose and are therefore essentially obsolete. Up to that moment, cannabis legislation had been based on a large number of conventions, causing considerable confusion in the execution of treaties. Under pressure of increasing reports that cannabis was a drug dangerous to society, it was proposed to combine all in single convention, the draft of which was finally accepted by the United Nations in 1961. In following years several complementary treaties were made to strengthen it. Under the "Single Convention on Narcotic Drugs" cannabis and its products were defined as dangerous narcotics with a high potential for abuse and no accepted medicinal value. It reflected the belief that cannabis was a dangerous narcotic with a threat that was equal to the most dangerous opiates, as it was strongly believed that cannabis use could serve as stepping stone to the use of such drugs. Since the Single Convention, the potential danger of cannabis abuse by recreational users has been much higher on the political agenda than any of its benefits as a source for fiber, food or medicines. The distinction between medicinal and recreational use is thereby made only in a few countries.

It can be observed that new scientific insights on cannabis are only slowly and reluctantly incorporated into new legislation. However, in recent years a large variety of scientific and clinical data has become available, further showing the physiological effects of cannabinoids and the endocannabinoid system. And in several Western countries important obstacles for a real acceptance of medicinal cannabis have already been addressed, as serious steps are taken towards decriminalization of cannabis use or even providing medicinal cannabis products to patients. These shifts constitute the first steps away from the dominant drug policy paradigm advocated by the United States, which is punishment-based prohibition, and it signals that the

Single Convention may start to reach its expiry date. The legislation that follows it will depend for a large part on the quality of the research available. However, good arguments will finally not be enough; what is most needed is a change in mentality; in politics, but also in the way research is conducted.

7.2 *Availability of Plant Materials and Reference Standards*

Although a huge number of scientific papers have been published on Cannabis over the past decades, many aspects still remain unclear. The world today is full of Cannabis myth and mystery. A major reason is the unavailability of standardized plant materials. As a result of a prohibition on the breeding of the Cannabis plant, researchers worldwide have virtually no access to fresh plant materials. In fact, most plant material used for Cannabis research comes from customs seizures or governmental agencies. The type of Cannabis (cultivar), the breeding and storage conditions, and age of the plant materials are often unknown to the researcher. Microbiological contamination of such herbal Cannabis has been frequently described. Although it remains a speculation, the production of toxins by these microbes may play a significant role in at least some of the observed adverse effects in medical studies.³⁰

For more than half a century, the medicinal research has been driven by the search for the components responsible for the psychoactive effects of Cannabis. As a result, THC has been in the spotlights for decades, but other Cannabis constituents were largely neglected. By doing so, it is often forgotten that more than 700 different varieties of Cannabis have been described. In many research papers it is assumed that differences between Cannabis cultivars are only defined by the total content of THC (which is defined as THC+THCA). The total fingerprint of other compounds present is usually not reported and very often these compounds were not even analyzed. As a result, such studies can never be repeated, because the (exact) same type of Cannabis can not be obtained by other researchers trying to duplicate the results. It is obvious that there is a serious need for the availability of standardized herbal cannabis, like is currently produced by the Netherlands.³⁰

Finally, independent of the method used for cannabinoid analysis, reliable standards are needed for the compounds to be studied, in order to allow high quality, quantitative research on the pharmacological and medicinal aspects of Cannabis. However, up to very recently, only a few of the major cannabinoids were commercially available (THC, CBD, CBN and ?⁸-THC). Without a doubt, this lack of reference standards has been a great obstacle for the detailed study and understanding of Cannabis. In recent years however, the number of

suppliers of cannabinoid standards has been growing (e.g. Echo pharmaceuticals, Lipomed, THC-pharm, Sigma-Aldrich)

7.3 *Social aspects*

Although the complex chemical nature of the Cannabis plant and its constituents have complicated its study, a significant role was also played by social and cultural views on Cannabis. Although Cannabis has a long history, the 20th century advent of modern purified pharmaceuticals made Cannabis products increasingly less popular with physicians. Only after the biochemical basis of Cannabis activity has been elucidated, in fact only in the last 10-15 years, scientific interest has been revived.

A major argument of health authorities against the medicinal use of herbal Cannabis as currently available has been that it is a highly variable product with respect to composition and (microbiological) contamination. This may be true when comparing different varieties, but the composition of single well-defined varieties of Cannabis can be highly standardized. This fact has been clearly shown by the medicinal Cannabis program currently going on in the Netherlands, where growing under the regime of Good Agricultural Practice (GAP), in combination with technical and hygienic measures, has shown to produce Cannabis of the highest quality.³⁰ Furthermore, procedures for standardized prescription botanical products have been formalized by the FDA, providing a further blueprint for regulatory approval of phytochemicals and botanical medicines.³¹

Cannabis studies often have to deal with problems that are largely unknown to other fields of research. These include difficulties to find funding, get results published, or to obtain permission to perform clinical trials. Also the restrictions on import/export of Cannabis materials and its extracts or pure components can postpone studies for long periods of time. Fortunately, in several Western countries such restrictions are slowly becoming less strict. Still, the continuing fear of potential psycho-active effects of Cannabis frequently interferes with performing (mostly clinical) studies. In fact, the continuous increase in (psychoactive) potency of modern Cannabis varieties is boosting political as well as societal fears of addiction and health problems, and this seems to make the acceptance of Cannabis as a source of potential new medicines even harder.

It is clear that, in time, Cannabis-based medicines should be standardized, efficacious and safe preparations, as much as any other approved medicine. Therefore, the main challenges for the near future are standardization of Cannabis-based medicines, obtaining clinical proof of its

claimed activities, and improving the acceptance among authorities and health-professionals. The dominant view is that the proof of the activities of Cannabis must come from statistically significant randomized clinical trials, acceptable to regulatory bodies in various countries and adhering to the modern scientific method. However, times are changing, and other plant-based medicines, such as Chinese traditional medicine, are gaining ground as part of Western medicine. In some cases, traditional use of such herbal medicine by large groups of patients may be accepted by the authorities as sufficient proof of safety and efficacy. It remains to be seen whether Cannabis can benefit from such developments.



8. REFERENCES

1. World Drug Monitor; United Nations Office on Drugs and Crime: 2006.
2. Clarke, R. C., Marijuana Botany. Ronin Publishing: Berkeley, USA, 1981.
3. Frohne, D.; Jensen, U., Systematik des Pflanzenreichs unter besonderer Berücksichtigung chemischer Merkmale und pflanzlicher Drogen. Gustav Fischer: Stuttgart, 1973; p 100.
4. Turner, C. E.; Elsohly, M. A.; Boeren, E. G., Constituents of *Cannabis sativa* L. XVII. A review of the natural constituents. *J. Nat. Prod.* 1980, 43(2), 169-234.
5. Schultes, R. E.; Hofmann, A., Pflanzen der Götter: Die magischen Kräfte der Rausch- und Giftgewächse. Hallwag Verlag Bern, Switzerland, 1980; p 93.
6. Crombie, L.; Crombie, W. M. L., Cannabinoid formation in *Cannabis sativa* grafted inter-racially, and with two *Humulus* species. *Phytochem.* 1975, 14, 409-412.
7. Fenselau, C.; Kelly, S.; Salmon, M.; Billets, S., The absence of tetrahydrocannabinol from hops. *Fd. Cosmet. Toxicol.* 1976, 14, 35-39.
8. Lehmann, T.; Brenneisen, R., High performance liquid-chromatographic profiling of cannabis products. *J. Liq. Chrom.* 1995, 18, 689-700.
9. Snoeijer, W., A checklist of some Cannabaceae cultivars. Part 1: *Cannabis*. Div. Pharmacognosy, Leiden/Amsterdam Centre for Drug Research: Leiden, The Netherlands, 2001.
10. Schultes, R. E.; Klein, W. M.; Plowman, T.; Lockwood, T. E., Cannabis, an example of taxonomic neglect. *Bot. Mus. Leafl. Harv. Univ.* 1974, 23, 337-367.
11. Anderson, L. C., A study of systematic wood anatomy in *Cannabis*. *Bot. Mus. Leafl. Harv. Univ.* 1974, 24, 29-36.
12. Emboden, W. A., Cannabis – a polytypic genus. *Econ. Bot.* 1974, 28, 304-310.
13. Small, E.; Cronquist, A., A practical and natural taxonomy for Cannabis. *Taxon.* 1976, 25, 405-435.
14. Small, E.; Jui, P. Y.; Lefkovitch, L. P., A numerical taxonomic analysis of Cannabis with special reference to species delimitation. *System. Bot.* 1976, 1, 67-84.
15. Cronquist, A., An integrated system of classification of flowering plants. CUP: New York, 1981; p 193.
16. Beutler, J. A.; Der Marderosian, A. H., Crossbreeding between *Cannabis sativa* and *C. ruderalis*, with analysis of cannabinoid content. *Econ. Bot.* 1978, 32, 378-394.
17. Lawi-Berger, C. Contribution à l'étude chimiotaxonomique du genre Cannabis (Cannabaceae). Dissertation, University of Geneva, Switzerland, 1982.
18. Lawi-Berger, C.; Miège, M. N.; Kapétanidis, I.; Miège, J., Systématique végétale – Contribution à l'étude chimiotaxonomique de *Cannabis sativa* L. *C.R. Acad. Sci. Paris* 1982, 295, 397-402.
19. Brenneisen, R., Psychotrope drogen I. *Cannabis sativa* L. *Pharm. Acta Helv.* 1983, 58 314-320.
20. Grlic, L., A combined spectrophotometric differentiation of samples of cannabis. *Bull. Narcot.* 1968, 20, 25-29.
21. Fetterman, P. S.; Keith, E. S.; Waller, C. W.; Guerrero, O.; Doorenbos, N. J.; Quimby, M. W., Mississippi grown *Cannabis sativa* L.: preliminary observation on chemical definition of phenotype and variations in tetrahydrocannabinol versus age, sex, and plan part. *J. Pharm. Sci.* 1971, 60, 1246-1249.
22. Small, E.; Beckstead, H. D., Common cannabinoid phenotypes in 350 stocks of Cannabis. *Lloydia* 1973, 36, 144-165.

23. Turner, C. E.; ElSohly, M. A.; Cheng, P. C.; Lewis, G., Constituents of Cannabis sativa L., XIV: intrinsic problem in classifying Cannabis based on a single cannabinoid analysis. *J. Nat. Prod.* 1979, 42, 317-319.
24. Brenneisen, R.; Kessler, T., Die Variabilität der Cannabinoidführung von Cannabispflanzen aus Schweizer Kulturen in Abhängigkeit von genetischen und ökologischen Faktoren. *Pharm. Acta Helv.* 1987, 62, 134-139.
25. Balabanova, S.; Parsche, F.; Pirsig, W., First identification of drugs in Egyptian mummies. *Naturwissenschaften* 1992, 79, (8), 358.
26. Zuardi, A. W., History of cannabis as a medicine: a review. *Rev Bras Psiquiatr.* 2006 28, (2), 153-157.
27. Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: Pharmacology, toxicology, and therapeutic potential. Binghamton: Haworth Press; 2002.
28. Conert, H. J.; Jäger, E. J.; Kadereit, J. W.; Schultze-Motel, W.; Wagenitz, G.; Weber, H. E.; Hegi, G., *Illustrierte Flora von Mitteleuropa.* 1992; p 283-295 / 473-474.
29. Gaoni, Y.; Mechoulam, R., Isolation, structure, and partial synthesis of an active constituent of hashish. *JACS* 1964, 86, 646-647.
30. Hazekamp, A., An evaluation of medicinal grade cannabis in The Netherlands. *Cannabinoids* 2006, 1, (1), 1-9.
31. Guidance for industry: botanical drug products; US Food and Drug Administration, Center for Drug Evaluation and Research: Rockville, MD, USA, 2004; p 48.
32. Ross, S.; ElSohly, M. A., Constituents of Cannabis sativa L. XXVIII A review of natural constituents: 1980-1994. *Zagazig journal of pharmaceutical sciences* 1995, 4, 1-10.
33. Kim, E. S.; Mahlberg, P. G., Secretory vesicle formation in the secretory cavity of glandular trichomes of Cannabis sativa L. (Cannabaceae). *Mol. Cells.* 2003, 15(3), 387-395.
34. Sirikantaramas, S.; Taura, F.; Tanaka, Y.; Ishikawa, Y.; Morimoto, S.; Shoyama, Y., Tetrahydrocannabinolic acid synthase, the enzyme controlling marijuana psychoactivity, is secreted into the storage cavity of the glandular trichomes. *Plant & cell physiology* 2005 46, (9), 1578-1582.
35. Sirikantaramas, S.; Taura, F.; Morimoto, S.; Shoyama, Y., Recent advances in Cannabis sativa research: biosynthetic studies and its potential in biotechnology. *Curr. Pharm. Biotechnol.* 2007 8, (4), 237.
36. Mechoulam, R., Plant cannabinoids: a neglected pharmacological treasure trove. *Br. J. Pharmacol.* 2005, 146, (7), 913-915.
37. McPartland, J. M.; Russo, E. B., Cannabis and cannabis extracts: greater than the sum of their parts. *Journal of Cannabis Therapeutics* 2001, 1, 103-132.
38. Russo, E. B.; McPartland, J. M., Cannabis is more than simply delta(9)-tetrahydrocannabinol. *Psychopharmacology (Berl)* 2003, 165(4), 431-432.
39. Mechoulam, R.; Ben-Zvi, Z.; Shani, A.; Zemler, H.; Levy, S., *Cannabinoids and cannabis activity.* Oxford University Press: London, 1972.
40. Radwan, M. M.; Ross, S. A.; Slade, D.; Ahmed, S. A.; Zulfikar, F.; Elsohly, M. A., Isolation and characterization of new cannabis constituents from a high potency variety. *Planta Med* 2008, 74, (3), 267-272.
41. Adams, R.; Baker, B. R.; Wearn, R. B., Structure of cannabinol. III. Synthesis of cannabinol, 1-hydroxy-3-n-amy-6,6,9-trimethyl-6-dibenzopyran. *JACS* 1940, 62, (8), 2204-2207.
42. Ross, S. A.; Mehmedic, Z.; Murphy, T. P.; Elsohly, M. A., GC-MS analysis of the total delta9-THC content of both drug- and fiber-type cannabis seeds. *J. Anal. Toxicol.* 2000, 24(8), 715-717.

43. Field, B. I.; Arndt, R. R., Cannabinoid compounds in South African *Cannabis sativa* L. *J. Pharm. Pharmacol.* 1980, 32, 21-24.
44. Hemphill, J. K.; Turner, J. C.; Mahlberg, P. G., Cannabinoid content of individual plant organs from different geographical strains of *Cannabis sativa* L. *J. Nat. Prod.* 1980, 43, 112-122.
45. Eddy, N. B., The question of cannabis. Bibliography United Nations Commission on Narcotic Drugs, E/CN7/49. 1965.
46. Gaoni, Y.; Mechoulam, R., The structure and synthesis of cannabigerol, a new hashish constituent. *Proc. Chem. Soc.* 1964, 82.
47. Mechoulam, R.; Gaoni, Y., Hashish. IV. The isolation and structure of cannabinolic, cannabidiolic, and cannabigerolic acids. *Tetrahedron* 1965, 21, 1223-1229.
48. Mechoulam, R.; Gaoni, Y., Recent advances in the chemistry of hashish. *Fortsch. Chem. Org. Naturst.* 1967, 25, 175-213.
49. Mechoulam, R., Marijuana chemistry. Recent advances in cannabinoid chemistry open the area to more sophisticated research. *Science* 1970, 168, 1159-1166.
50. Mechoulam, R., Marijuana. Academic press: New York, 1973.
51. Shoyama, Y.; Yamauchi, T.; Nishioka, I., Cannabis V. Cannabigerolic acid monomethyl ether and cannabinolic acid. *Chem. Pharm. Bull.* 1970, 18, 1327-1332.
52. Shoyama, Y.; Yagi, M.; Nishioka, I.; Yamauchi, T., Biosynthesis of cannabinoid acids. *Phytochem.* 1975, 14, 2189-2192.
53. Turner, C. E.; Hadley, K., Constituents of *Cannabis sativa* L. II: Absence of cannabidiol in an African variant. *J. Pharm. Sci.* 1973, 62, 251-258.
54. Fellermeier, M.; Zenk, M. H., Prenylation of olivetolate by a hemp transferase yields cannabigerolic acid, the precursor of tetrahydrocannabinol. *FEBS Letters* 1998, 427, 283-285.
55. Fellermeier, M.; Eisenreich, W.; Bacher, A.; Zenk, M. H., Biosynthesis of cannabinoids. Incorporation experiments with ¹³C-labeled glucoses. *Eur. J. Biochem.* 2001, 268, 1596-1604.
56. Taura, F.; Morimoto, S.; Shoyama, Y.; Mechoulam, R., First direct evidence for the mechanism of Δ^1 -tetrahydrocannabinolic acid biosynthesis. *Journal of the American Chemical Society* 1995, 117(38), 9766-9767.
57. Taura, F.; Morimoto, S.; Shoyama, Y., Purification and characterization of cannabidiolic acid synthase from *Cannabis sativa* L. *Journal of Biological Chemistry* 1996, 271(29), 17411-17416.
58. Morimoto, S.; Komatsu, K.; Taura, F.; Shoyama, Y., Purification and characterization of cannabichromenic acid synthase from *Cannabis sativa* & *J. Phytochem.* 1998, 49(6), 1525-1529.
59. Veress, T.; Szanto, J. I.; Leisztner, L., Determination of cannabinoid acids by high-performance liquid chromatography of their neutral derivatives formed by thermal decarboxylation in an open reactor. *J. Chromatogr.* 1990, 520, 339-347.
60. ElSohly, M. A.; ElSohly, H. N.; Turner, C. E., Cannabis: new constituents and their pharmacological action. *Topics in pharmaceutical sciences* 1983, 429-439.
61. Razdan, R. K., Recent advances in the chemistry of cannabinoids. *Progr. Org. Chem.* 1973, 8, 78-101.
62. Crombie, L.; Ponsford, R.; Shani, A.; Yagnitinsky, B.; Mechoulam, R., Hashish components. Phytochemical production of cannabicyclol from cannabichromene. *Tetrahedron Lett.* 1968, 55, 5771-5772.
63. Di Marzo, V., *Cannabinoids*. Springer: New York, 2004.
64. Martin, B. R., Cellular effects of cannabinoids. *Pharmacol Rev* 1986, 38, 45-74.

65. Williamson, E. M.; Evans, F. J., Cannabinoids in clinical practice. *Drugs* 2000, 60(6), 1303-1314.
66. McPartland, J., Advantages of polypharmaceutical herbal Cannabis compared to single-ingredient, synthetic tetrahydrocannabinol. In *Biosource hemp: third international symposium*, Nova Institut, G., Ed. Wolfsburg, Germany, 2000.
67. Onaivi, E. S.; Ishiguro, H.; Gong, J. P.; Patel, S.; Meozzi, P. A.; Myers, L.; Perchuk, A.; Mora, Z.; Tagliaferro, P. A.; Gardner, E.; Brusco, A.; Akinshola, B. E.; Hope, B.; Lujilde, J.; Inada, T.; Iwasaki, S.; Macharia, D.; Teasensfitz, L.; Arinami, T.; Uhl, G. R., Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. *PLoS ONE* 2008 20, (3), e1640.
68. Parker, L. A.; Burton, P.; Sorge, R. E.; Yakiwchuk, C.; Mechoulam, R., Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. *Psychopharm.* 2004, 175, (360-366).
69. Perez-Reyes, M., Marijuana smoking: factors that influence the bioavailability of tetrahydrocannabinol. *NIDA Res Monogr* 1990, (99), 42-62.
70. Domino, E. F., *Cannabinoids and the cholinergic system*. Humana press: Totowa, NJ, 1999.
71. Adams, I. B.; Martin, B. R., Cannabis: pharmacology and toxicology in animals and humans. *Addiction* 1996, 91, (11), 1585-1614.
72. Zuurman, L.; Roy, C.; Schoemaker, R.; Hazekamp, A.; den Hartigh, J.; Bender, J. C. M. E.; Verpoorte, R.; Pinquier, J. L.; Cohen, A. F.; van Gerven, J. M. A., Effect of intrapulmonary THC administration in humans. *J Psychopharmacol* 2008.
73. Favrat, B.; Ménétrey, A.; Augsburger, M.; Rothuizen, L. E.; Appenzeller, M.; Buclin, T.; Pin, M.; Mangin, P.; Giroud, C., Two cases of "cannabis acute psychosis" following the administration of oral cannabis. *BMC Psychiatry* 2005 5, 17.
74. Järvinen, T.; Pateb, D. W.; Laine, K., Cannabinoids in the treatment of glaucoma *Pharmacology & Therapeutics* 2002, 95, (2), 203-220.
75. Costa, B., On the pharmacological properties of delta-9-Tetrahydrocannabinol (THC). *Chemistry & Biodiversity* 2007, 4, 1664-1677.
76. McKallip, R. J.; Nagarkatti, M.; Nagarkatti, P. S., Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. *J. Immunol.* 2005, (174), 3281-3289.
77. Tselnicker, I.; Keren, O.; Hefetz, A.; Pick, C. G.; Sarne, Y., A single low dose of tetrahydrocannabinol induces long-term cognitive deficits. *Neurosci Lett.* 2007 411, (2), 108-111.
78. Zuardi, A. W.; Shirakawa, I.; Finkelfarb, E.; Karniol, I. G., Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. *Psychopharmacology (Berl)* 1982, 76, (3), 245-250.
79. Zuardi, A. W.; Morais, S. L.; Guimaraes, F. S.; Mechoulam, R., Anti-psychotic effect of cannabidiol. *Journal of Clinical Psychiatry* 1995, 56, 485-486.
80. Malfait, A. M.; Gallily, R.; Sumariwalla, P. F.; Malik, A. S.; Andreanos, E.; Mechoulam, R.; Feldmann, M., The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. *PNAS USA* 2000, 97, (17), 9561-9566.
81. Kathmann, M.; Flau, K.; Redmer, A.; Tränkle, C.; Schlicker, E., Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. *Naunyn-Schmiedeberg's Archives of Pharmacology* 2006, 375, (5), 354-361.

82. Murillo-Rodríguez, E.; Millán-Aldaco, D.; Palomero-Rivero, M.; Mechoulam, R.; Drucker-Colín, R., Cannabidiol, a constituent of *Cannabis sativa*, modulates sleep in rats. *FEBS Lett.* 2006 580, (18), 4337-4345.
83. de Souza Crippa, J. A.; Zuardi, A. W.; Garrido, G. E. J.; Wichert-Ana, L.; Guarnieri, R.; Ferrari, L.; Azevedo-Marques, P. M.; Hallak, J. E. C.; McGuire, P. K.; Busatto, G. F., Effects of cannabidiol (CBD) on regional cerebral blood flow. *Neuropsychopharmacology* 2004, 29, 417-426.
84. McAllister, S. D.; Christian, R. T.; Horowitz, M. P.; Garcia, A.; Desprez, P. Y., Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. *Mol Cancer Ther* 2007, 6, (11), 2921-2927.
85. Massi, P.; Vaccani, A.; Ceruti, S.; Colombo, A.; Abbracchio, M. P.; Parolaro, D., Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. *JPET* 2004, 308, (3), 838-845.
86. Ligresti, A.; Moriello, A. S.; Starowicz, K.; Matias, I.; Pisanti, S.; De Petrocellis, L.; Laezza, C.; Portella, G.; Bifulco, M.; Di Marzo, V., Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. *J Pharmacol Exp Ther* 2006, 318, (3), 1375-1387.
87. Bornheim, L. M.; Kim, K. Y.; Li, J.; Perotti, B. Y.; Benet, L. Z., Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. *Drug Metab Dispos* 1995 23, (8), 825-831.
88. Bornheim, L. M.; Grillo, M. P., Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator. *Chem Res Toxicol* 1998 11, (10), 1209-1216.
89. Grlic, L., A comparative study on some chemical and biological characteristics of various samples of cannabis resin. *Bulletin on Narcotics* 1976, 14, 37-46.
90. Ungerleider, J. T.; Andrysiak, T., Therapeutic issues of marijuana and THC (tetrahydrocannabinol). *Int J Addict* 1985, 20, 691-699.
91. Yamaguchi, T.; Kubota, T.; Watanabe, S.; Yamamoto, T., Activation of brain prostanoid EP3 receptors via arachidonic acid cascade during behavioral suppression induced by Delta8-tetrahydrocannabinol. *J Neurochem* 2004 88, (1), 148-154.
92. Devane, W. A.; Dysarz, F. A.; Johnson, M. R.; Melvin, L. S.; Howlett, A. C., Determination and characterization of a cannabinoid receptor in rat brain. *Mol. Pharmacol.* 1988, 34, 605-613.
93. Baek, S. H.; Han, D. S.; Yook, C. N.; Kim, Y. C.; Kwak, J. S., Synthesis and antitumor activity of cannabigerol. *Arch Pharm Res* 1996, 19, (3), 228-230.
94. Herring, A. C.; Kaminski, N. E., Cannabinoid-mediated inhibition of nuclear factor-kappaB, cAMP response element-binding protein, and interleukin-2 secretion by activated thymocytes. *J Pharmacol Exp Ther* 1999, 291, 1156-1163.
95. Musty, R. E.; Deyo, R. A., Cannabichromene (CBC) extract alters Behavioral Despair on the Mouse Tail Suspension test of depression. In *International Cannabinoid Research Society, 2003 Symposium on the Cannabinoids*, Burlington, VT, 2003; p 146.
96. Thomas, A.; Stevenson, L. A.; Wease, K. N.; Price, M. R.; Baillie, G.; Ross, R. A.; Pertwee, R. G., Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. *Br. J. Pharmacol.* 2005, 146(7), 917-926.
97. Ma, Y. L.; Weston, S. E.; Whalley, B. J.; Stephens, G. J., The phytocannabinoid delta-9-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum. *Br J Pharmacol* 2008.

98. Hazekamp, A.; Bastola, K.; Rashidi, H.; Bender, J.; Verpoorte, R., Cannabis tea revisited: A systematic evaluation of the cannabinoid composition of cannabis tea. *J Ethnopharm* 2007, 113, 85-90.
99. Hazekamp, A.; Ruhaak, R.; Zuurman, L.; van Gerven, J.; Verpoorte, R., Evaluation of a vaporizing device (Volcano®) for the pulmonary delivery of tetrahydrocannabinol. *J. Pharm. Sci.* 2006, 95, (6), 1308-1317.
100. Ederly, H.; Grunfeld, Y.; Porath, G.; Ben-Zvi, Z.; Shani, A.; Mechoulam, R., Structure-activity relationships in the tetrahydrocannabinol series. Modifications on the aromatic ring and its side-chain. *Arzneimittelforschung* 1972, 22, (11), 1995-2003.
101. Hazekamp, A.; Simons, R.; Peltenburg-Looman, A.; Sengers, M.; van Zweden, R.; Verpoorte, R., Preparative isolation of cannabinoids from *Cannabis sativa* by centrifugal partition chromatography. *J Liq Chrom Rel Technol* 2004, 27, (15), 2421-2439.
102. Verhoeckx, K. C.; Korthout, H. A.; van Meeteren-Kreikamp, A. P.; Ehlert, K. A.; Wang, M.; van der Greef, J.; Rodenburg, R. J.; Witkamp, R. F., Unheated *Cannabis sativa* extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. *Int. Immunopharmacol.* 2006, 6, (4), 656-665.
103. Shoyama, Y.; Fujita, T.; Yamauchi, T.; Nishioka, I., Cannabichromenic acid, a genuine substance of cannabichromene. *Chem Pharm Bull (Tokyo)* 1968 16, (6), 1157-1158.
104. Leizer, C.; Ribnicky, D.; Poulev, A.; Dushenkov, S.; Raskin, I., The composition of hemp seed oil and its potential as an important source of nutrition *Journal of Nutraceuticals, Functional & Medical Foods* 2000, 2, (4).
105. Morimoto, S.; Tanaka, Y.; Sasaki, K.; Tanaka, H.; Fukamizu, T.; Shoyama, Y.; Taura, F., Identification and characterization of cannabinoids that induce cell death through mitochondrial permeability transition in *Cannabis* leaf cells. *J Biol Chem* 2007 282, (28), 20739-20751.
106. Perras, C., Sativex for the management of multiple sclerosis symptoms. *Issues Emerg. Health Technol.* 2005, 72, 1-4.
107. Nadulski, T.; Pragst, F.; Weinberg, G.; Roser, P.; Schnelle, M.; Fronk, E. M.; Stadelmann, A. M., Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC versus standardized cannabis extract. *Ther. Drug Monit.* 2005, 27, (6), 799-810.
108. Ben Amar, B., Cannabinoids in medicine: a review of their therapeutical potential. *J. Ethnopharm.* 2006, 105, 1-25.
109. Holdcroft, A.; Maze, M.; Dore, C.; Tebbs, S.; Thompson, S., A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. *Anesthesiology* 2006, 104, (5), 1040-1046.
110. Raharjo, T. J.; Verpoorte, R., Methods for cannabinoids analysis in biological materials: a review. *Phytochem. Anal.* 2004, 15(2), 79-94.
111. Lurie, I. S.; Meyers, R. P.; Conner, T. S., Capillary electrochromatography of cannabinoids. *Anal. Chem.* 1998, 70, (15), 3255-3260.
112. Backstrom, B.; Cole, M. D.; Carrott, M. J.; Jones, D. C.; Davidson, G.; Coleman, K., A preliminary study of the analysis of *Cannabis* by supercritical fluid chromatography with atmospheric pressure chemical ionisation mass spectroscopic detection. *Sci. Justice* 1997, 37, (2), 91-97.

113. Stolker, A. A.; van Schoonhoven, J.; de Vries, A. J.; Bobeldijk-Pastorova, I.; Vaes, W. H.; van den Berg, R., Determination of cannabinoids in cannabis products using liquid chromatography-ion trap mass spectrometry. *J. Chromatogr. A* 2004, 1058(1-2), 143-151.
114. Hazekamp, A.; Giroud, C.; Peltenburg, A.; Verpoorte, R., Chromatographic and spectroscopic data of cannabinoids from *Cannabis sativa* L. *J. Liq. Chrom. Rel. Technol.* 2005, 28, (15), 2361-2382.
115. Stahl, E.; Kunde, R., New substances from essential oil of *Cannabis sativa*. *Tetrahedron Letters* 1973, 30, 2841-2844.
116. Brenneisen, R.; ElSohly, M. A., Chromatographic and spectroscopic profiles of cannabis of different origins: Part I. *J. Forens. Sci.* 1988, 33, 1385-1404.
117. Ross, S. A.; ElSohly, M. A., The volatile oil composition of fresh and air-dried buds of *Cannabis sativa*. *Journal of Natural Products* 1996, 59, (1), 49-51.
118. Meier, C.; Mediavilla, V., Factors influencing the yield and quality of hemp (*Cannabis sativa* L.) essential oil. *Journal International Hemp Association* 1998, 5, (1), 16-20.
119. Hillig, K. W., A chemotaxonomic analysis of terpenoid variation in *Cannabis*. *Biochemical Systematics And Ecology* 2004, 32, (10), 875-891.
120. Carlini, E. A.; Karniol, I. G.; Renault, P. F.; Schuster, C. R., Effects of marijuana in laboratory animals and in man. *Br. J. Pharmacol.* 1974 50, (2), 299-309.
121. Fairbairn, J. W.; Pickens, J. T., Activity of cannabis in relation to its delta'-trans-tetrahydro-cannabinol content. *Br. J. Pharmacol.* 1981, 72, (3), 401-409.
122. Buchbauer, G.; Jirovetz, L.; Jäger, W.; Plank, C.; Dietrich, H., Fragrance compounds and essential oils with sedative effects upon inhalation. *J. Pharm. Sci.* 1993, 82, (6), 660-664.
123. Komori, T.; Fujiwara, R.; Tanida, M.; Nomura, J., Potential antidepressant effects of lemon odor in rats. *Eur. Neuropsychopharmacol.* 1995, 5, (4), 477-480.
124. Lorenzetti, B. B.; Souza, G. E.; Sarti, S. J.; Santos Filho, D.; Ferreira, S. H., Myrcene mimics the peripheral analgesic activity of lemongrass tea. *J. Ethnopharmacol.* 1991, 34, (1), 43-48.
125. Rao, V. S.; Menezes, A. M.; Viana, G. S., Effect of myrcene on nociception in mice. *J. Pharm. Pharmacol.* 1990, 42, (12), 877-878.
126. Burstein, S.; Varanelli, C.; Slade, L. T., Prostaglandins And Cannabis .3. Inhibition Of Biosynthesis By Essential Oil Components Of Marijuana. *Biochemical Pharmacology* 1975, 24, (9), 1053-1054.
127. Agrawal, A. K.; Kumar, P.; Gulati, A.; Seth, P. K., Cannabis induced neurotoxicity in mice: effect of cholinergic (muscarinic) receptors and blood barrier permeability. *Res. Commun. Subst. Abuse* 1989, 10, 155-168.
128. Nasel, C.; Nasel, B.; Samec, P.; Schindler, E.; Buchbauer, G., Functional imaging of effects of fragrances on the human brain after prolonged inhalation. *Chem. Senses* 1994, 19, (4), 359-364.
129. Novak, J.; Zitterl-Eglseer, K.; Deans, S. G.; Franz, C. M., Essential oils of different cultivars of *Cannabis sativa* L. and their antimicrobial activity. *Flavour And Fragrance Journal* 2001, 16, (4), 259-262.
130. Fournier, G.; Paris, M. R.; Fourniat, M. C.; Quero, A. M., Bacteriostatic Activity of *Cannabis-Sativa* L Essential Oil. *Annales Pharmaceutiques Francaises* 1978, 36, (11-1), 603-606.
131. Maruzzella, J. C.; Sicurella, N. A., Antibacterial activity of essential oil vapors. *Journal of the American Pharmaceutical Association* 1960, 49, 692-694.

132. Novotny, M.; Merli, F.; Wiesler, D.; TSaeed, T., Composition of the basic fraction of marijuana and tobacco condensates: A comparative study by capillary GC/MS. *Chromatographia* 1982, 15, (9), 564-568.
133. Savelev, S.; Okello, E.; Perry, N. S.; Wilkins, R. M.; Perry, E. K., Synergistic and antagonistic interactions of anticholinesterase terpenoids in *Salvia lavandulaefolia* essential oil. *Pharmacol. Biochem. Behav.* 2003, 75, (3), 661-668.
134. Rothschild, M.; Bergstrom, G.; Wangberg, S. A., *Cannabis sativa*: volatile compounds from pollen and entire male and female plants of two variants, Northern Lights and Hawaiian Indica. *Botanical Journal of the Linnean Society* 2005, 147, (4), 387-397.
135. ElSohly, M. A.; Slade, D., Chemical constituents of marijuana: The complex mixture of natural cannabinoids. *Life Sciences* 2005, 78, (5), 539-548.
136. Brenneisen, R., Chemistry and Analysis of Phytocannabinoids and Other Cannabis Constituents. In *Forensic Science and Medicine: Marijuana and the Cannabinoids*, ElSohly, M. A., Ed. Humana Press Inc.: Totowa, New Jersey, 2006; pp 17-49.
137. Barrett, M. L.; Gordon, D.; Evans, F. J., Isolation from *Cannabis-Sativa L* of Cannflavin - a Novel Inhibitor of Prostaglandin Production. *Biochemical Pharmacology* 1985, 34, (11), 2019-2024.
138. Barrett, M. L.; Scutt, A. M.; Evans, F. J., Cannflavin-a and Cannflavin-B, Prenylated Flavones from *Cannabis-Sativa L*. *Experientia* 1986, 42, (4), 452-453.
139. Paris, R. R.; Paris, M. R., Flavonoids of Marihuana (*Cannabis-Sativa L*). *Comptes Rendus Hebdomadaires Des Seances De L Academie Des Sciences Serie D* 1973, 277, (21), 2369-2371.
140. Choi, Y. H.; Hazekamp, A.; Peltenburg-Looman, A. M. G.; Frederich, M.; Erkelens, C.; Lefeber, A. W. M.; Verpoorte, R., NMR assignments of the major Cannabinoids and cannabiflavonoids isolated from flowers of *Cannabis sativa*. *Phytochemical Analysis* 2004, 15, (6), 345-354.
141. Ross, S. A.; ElSohly, M. A.; Sultana, G. N. N.; Mehmedic, Z.; Hossain, C. F.; Chandra, S., Flavonoid glycosides and cannabinoids from the pollen of *Cannabis sativa L*. *Phytochemical Analysis* 2005, 16, (1), 45-48.
142. Gellert, M.; Novak, I.; Szell, M.; Szendrei, K., Glycosidic components of *Cannabis sativa L*. I. Flavonoids. In *Secretariat, U.*, Ed. 1974.
143. Paris, M.; Boucher, F.; Cosson, L., Constituents of *Cannabis-Sativa Pollen*. *Economic Botany* 1975, 29, (3), 245-253.
144. Paris, R. R.; Henri, E.; Paris, M., Sur les c-flavonoïdes du *Cannabis sativa L*. *Plantes Medicinales et Phytotherapie* 1976, 10, 144-54.
145. Segelman, A. B.; Segelman, F. P.; Star, A. E.; Wagner, H.; Seligmann, O., *Cannabis-Sativa L* (Marihuana) .8. Structure of 2 C-Diglycosylflavones from *Cannabis-Sativa*. *Phytochemistry* 1978, 17, (4), 824-826.
146. Bravo, L., Polyphenols: Chemistry, dietary sources, metabolism, and nutritional significance. *Nutrition Reviews* 1998, 56, (11), 317-333.
147. Treutter, D., Significance of flavonoids in plant resistance and enhancement of their biosynthesis. *Plant Biology* 2005, 7, (6), 581-591.
148. Middleton, E., Biological properties of plant flavonoids: An overview. *International Journal of Pharmacognosy* 1996, 34, (5), 344-348.
149. Braca, A.; Fico, G.; Morelli, I.; De Simone, F.; Tome, F.; De Tommasi, N., Antioxidant and free radical scavenging activity of flavonol glycosides from different *Aconitum* species. *Journal of Ethnopharmacology* 2003, 86, (1), 63-67.
150. Fraga, C. G., Plant polyphenols: How to translate their in vitro antioxidant actions to in vivo conditions. *Iubmb Life* 2007, 59, (4-5), 308-315.

151. Pietta, P. G., Flavonoids as antioxidants. *Journal of Natural Products* 2000, 63, (7), 1035-1042.
152. Middleton, E.; Kandaswami, C.; Theoharides, T. C., The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and cancer. *Pharmacological Reviews* 2000, 52, (4), 673-751.
153. Cushnie, T. P. T.; Lamb, A. J., Antimicrobial activity of flavonoids. *International Journal of Antimicrobial Agents* 2005, 26, (5), 343-356.
154. Ozcelik, B.; Orhan, I.; Toker, G., Antiviral and antimicrobial assessment of some selected flavonoids. *Zeitschrift Fur Naturforschung C-a Journal of Biosciences* 2006, 61, (9-10), 632-638.
155. Evans, A. T.; Formukong, E. A.; Evans, F. J., Actions of Cannabis Constituents on Enzymes of arachidonate metabolism: anti-inflammatory potential. *Biochemical Pharmacology* 1987, 36, (2035-7).
156. Botta, B.; Vitali, A.; Menendez, P.; Misiti, D.; Delle Monache, G., Prenylated flavonoids: Pharmacology and biotechnology. *Current Medicinal Chemistry* 2005, 12, (6), 713-739.
157. Segelman, A. B.; Segelman, F. P.; Varma, S. D.; Wagner, H.; Seligmann, O., Cannabis-Sativa L (Marihuana) .9. Lens Aldose Reductase Inhibitory Activity of Marihuana Flavone C-Glycosides. *Journal of Pharmaceutical Sciences* 1977, 66, (9), 1358-1359.
158. Sauer, M. A.; Rifka, S. M.; Hawks, R. L.; Cutler, G. B.; Loriaux, D. L., Marijuana - Interaction with the Estrogen-Receptor. *Journal of Pharmacology and Experimental Therapeutics* 1983, 224, (2), 404-407.
159. McPartland, J. M.; Pruitt, P. L., Side effects of pharmaceuticals not elicited by comparable herbal medicines: The case of tetrahydrocannabinol and marijuana. *Alternative Therapies in Health and Medicine* 1999, 5, (4), 57-62.
160. Walle, T., Absorption and metabolism of flavonoids. *Free Radical Biology And Medicine* 2004, 36, (7), 829-837.
161. Ross, J. A.; Kasum, C. M., Dietary flavonoids: Bioavailability, metabolic effects, and safety. *Annual Review of Nutrition* 2002, 22, 19-34.
162. Arts, I. C. W.; Sesink, A. L. A.; Faassen-Peters, M.; Hollman, P. C. H., The type of sugar moiety is a major determinant of the small intestinal uptake and subsequent biliary excretion of dietary quercetin glycosides. *British Journal of Nutrition* 2004, 91, (6), 841-847.
163. Felgines, C.; Texier, O.; Morand, C.; Manach, C.; Scalbert, A.; Regerat, F.; Remesy, C., Bioavailability of the flavanone naringenin and its glycosides in rats. *American Journal of Physiology-Gastrointestinal and Liver Physiology* 2000, 279, (6), G1148-G1154.
164. Reutrakul, V.; Ningnuek, N.; Pohmakotr, M.; Yoosook, C.; Napaswad, C.; Kasisit, J.; Santisuk, T.; Tuchinda, P., Anti HIV-1 flavonoid glycosides from *Ochna integerrima*. *Planta Medica* 2007, 73, (7), 683-688.
165. Spencer, J. P. E.; El Mohsen, M. M. A.; Rice-Evans, C., Cellular uptake and metabolism of flavonoids and their metabolites: implications for their bioactivity. *Archives of Biochemistry and Biophysics* 2004, 423, (1), 148-161.
166. Lee, S. Y.; Oh, S. M.; Chung, K. H., Estrogenic effects of marijuana smoke condensate and cannabinoid compounds. *Toxicology and Applied Pharmacology* 2006, 214, (3), 270-278.
167. Elsohly, H. N.; Elsohly, M. A., Marijuana smoke condensate: chemistry and pharmacology. In *Marijuana and the cannabinoids*, Elsohly, M. A., Ed. Humana press: Totowa, New Jersey, 2007.

168. Clark, M. N.; Bohm, B. A., Flavonoid variation in Cannabis L. . Botanical Journal of the Linnean Society 1979, 79, 249-257.
169. Vanhoenacker, G.; Van Rompaey, P.; De Keukeleire, D.; Sandra, P., Chemotaxonomic features associated with flavonoids of cannabinoid-free cannabis (*Cannabis sativa* subsp *sativa* L.) in relation to hops (*Humulus lupulus* L.). Natural Product Letters 2002, 16, (1), 57-63.
170. Deferne, J. L.; Pate, D. W., Hempseed oil: A source of valuable essential fatty acids. Journal of the International Hemp Association 1996, 3, (1), 4-7.
171. Jones, K. Nutritional and medicinal guide to hemp seed; Rainforest Botanical Laboratory: 1995.
172. Oomah, B. D.; Busson, M.; Godfrey, D. V.; Drover, J. C. G., Characteristics of hemp (*Cannabis sativa* L.) seed oil. Food Chemistry 2002, 76, 33-43.
173. Wirtshafter, D., Bioresource Hemp. 2nd ed.; 1995.
174. Leson, G.; Pless, P.; Roulac, J., Hemp foods and oils for health. Hemptech: Sebastopol, CA, 1999.
175. Molleken, H.; Theimer, R., Survey of minor fatty acids in Cannabis sativa L. Fruits of various origins. Journal of the International Hemp Association 1997, 4, (1), 13-18.
176. McEvoy, C.; Edwards, M.; Snowden, M., An overview of antioxidant, preservative and solvent excipients used in the pharmaceutical industry. Pharmaceutical Technology Europe 1996, 8, (6), 36-40.
177. Callaway, J. C., Hempseed as a nutritional resource: an overview. Euphytica 2004, 140, 65-72.
178. Ross, S. A.; ElSohly, H. N.; ElKashoury, E. A.; ElSohly, M. A., Fatty acids of cannabis seeds. Phytochem. Anal. 1996, 7, 279-283.
179. Callaway, J. C.; Tennila, T.; Pate, D. W., Occurrence of "omega-3" stearidonic acid (cis-6,9,12,15-octadecatetraenoic acid) in hemp (*Cannabis sativa* L.) seed. Journal of the International Hemp Association 1996, 3, (2), 61-64.
180. Erasmus, U., Fats that heal, fats that kill. Alive Books: Burnaby, British Columbia, Canada, 1999.
181. Simopoulos, A. P., Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomedicine and Pharmacotherapy 2006, 60, (9), 502-507.
182. Simopoulos, A. P., Omega-3 fatty acids in inflammation and autoimmune diseases. Journal of the American College of Nutrition 2002, 21, (6), 495-505.
183. Grotenhermen, F.; Karus, M.; Lohmeyer, D. Derivation of THC limits for food, part II. www.naihc.org/hemp_information/content/nova_report/part2.html
184. Callaway, J. C.; Weeks, R. A.; Raymon, L. P.; Walls, H. C.; Hearn, W. L., A positive urinalysis from hemp (*Cannabis*) seed oil. Journal of Analytical Toxicology 1997, 21, (4), 319-320.
185. Raman, A.; Joshi, A., 3. The chemistry of cannabis. CRC Press: 1998.
186. Di Marzo, V.; Melck, D.; Bisogno, T.; De Petrocellis, L., Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 1998, 21, 521-528.
187. Corchero, J.; Manzanares, J.; Fuentes, J. A., Cannabinoid/opioid crosstalk in the central nervous system. Crit. Rev. Neurobiol. 2004, 16, 159-172.
188. Straiker, A.; Mackie, K., Cannabinoids, electrophysiology, and retrograde messengers: challenges for the next 5 years. AAPS Journal 2006, 8, (2), E272-E276.
189. King, L. A.; Carpentier, C.; Griffiths, P., Cannabis potency in Europe. Addiction 2005, 100, 884-886.

190. Mechoulam, R.; Devane, W. A.; Glaser, R., Cannabinoid geometry and biological activity. CRC press: Boca Raton, 1992; p 1-33.
191. Mechoulam, R.; Braun, P.; Gaoni, Y., A stereospecific synthesis of (-) dl and (-) d6-tetrahydrocannabinoids. *J Am Chem Soc* 1967, 89, 4552-4554.
192. Razdan, R. K., The total synthesis of cannabinoids. Wiley: New York, 1981; p 185-262.
193. Dewey, W. L., Cannabinoid pharmacology. *Pharmacol. Rev.* 1986, 38, 151-178.
194. Pertwee, R. G., The central neuropharmacology of psychotropic cannabinoids. *Pharmacol. Ther.* 1988, 36, 189-261.
195. Mechoulam, R.; Feigenbaum, J. J.; Lander, N.; et al., Enantiomeric cannabinoids: stereospecificity of psychotropic activity. *Experientia* 1988, 44, 762-764.
196. Little, P. J.; Compton, D. R.; Mechoulam, R.; et al., Stereochemical effects of 11-OH delta 8-THC-dimethylheptyl in mice and dogs. *Pharmacol Biochem Behav* 1989, 32, 661-666.
197. Jarbe, U. C.; Hiltunen, A. J.; Mechoulam, R., Stereospecificity of the discriminative stimulus functions of the dimethylheptyl omologs of 11-hydroxy-delta 8-tetrahydrocannabinol in rats and pigeons. *Pharmacol Exp ther* 1989, 250, 1000-1005.
198. Howlett, A. C. A.; M., C. T.; Wilken, G. H.; et al., Stereochemical effects of 11-OH-delta-8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. *Neuropharmacology* 1990, 29, 161-165.
199. Devane, W. A.; Hanus, L.; Breuer, A.; et al., Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* 1992, 258, 1946-1949.
200. Mechoulam, R.; Hanus, L.; Martin, B. R., The search for endogenous ligands of the cannabinoid receptor. *Biochem Pharmacol* 1994, 48, 1537-1544.
201. Darlington, C. L., Dexanabinol: a novel cannabinoid with neuroprotective properties. *Idrugs* 2003, 6, 976-979.
202. Howlett, A. C., Cannabinoid inhibition of adenylat-cyclase. *Biochemistry of the response in neuroblastoma cell membranes.* *Mol. Pharmacol.* 1985, 27, 429-436.
203. Howlett, A. C.; Qualy, J. M.; Khachatrian, L. L., Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. *Mol. Pharmacol.* 1986, 29, 307-313.
204. Howlett, A. C., Cannabinoid inhibition of adenylat cyclase, relative activity of constituents and metabolites of marihuana. *Neuropharmacol.* 1987, 26, 507-512.
205. Bidaut-Russell, M.; Devane, W. A.; Howlett, A. C., Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain. *J. Neurochem.* 1990, 55, 21-26.
206. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I., Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature* 1990, 346, 651-654.
207. Mackie, K.; Hille, B., Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. *Proc. Natl. Acad. Sci. USA* 1992, 89, 3825-3829.
208. Velasco, G.; Galve-Roperh, I.; Sánchez, C.; Blázquez, C.; Haro, A.; Guzmán, M., Cannabinoids and ceramide: two lipids acting hand-by-hand. *Life Sci.* 2005, 77, 1723-1731.
209. Munro, S.; Thomas, K. L.; Abu-Shaar, M., Molecular characterization of a peripheral receptor for cannabinoids. *Nature* 1993, 365(6441), 12-13.
210. van Sickle, M. D.; Duncan, M.; Kingsley, P. J.; Mouihate, A.; Urbani, P.; Mackie, K.; Stella, N.; Makriyannis, A.; Piomelli, D.; Davison, J. S.; Marnett, L. T.; DiMarzo, V.; Pittman, Q. J.; Patel, K. D.; Sharkey, K. A., Identification and functional characterization of brainstem cannabinoid CB2 receptors. *Science* 2005, 310, 329-332.

211. Molina-Holgado, F.; Pinteaux, E.; Moore, J. D.; Molina-Holgado, E.; Guaza, C.; Gibson, R. M.; Rothwell, N. J., Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. *J. Neurosci.* 2003, 23(16), 6470-6474.
212. Cabral, G. A.; Raborn, E. S.; Griffin, L.; Dennis, J.; Marciano-Cabral, F., CB2 receptors in the brain: role in central immune function. *Br J Pharmacol* 2008, 153, (2), 240-251.
213. Smart, D.; Gunthorpe, M. J.; Jerman, J. C.; Nasir, S.; Gray, J.; Muir, A. I.; Chambers, J. K.; Randall, A. D.; Davis, J. B., The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). *Br. J. Pharmacol.* 2000, 129, 227-230.
214. Zygmunt, P. M.; Petersson, J.; Andersson, D. A.; Chuang, H.; Sjørgård, M.; DiMarzo, V.; Julius, D.; Högestätt, E. D., Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. *Nature* 1999, 400(6743), 452-457.
215. Pertwee, R. G., Pharmacological actions of cannabinoids. *Handb. Exp. Pharmacol.* 2005, 168, 1-51.
216. De Petrocellis, L.; Melck, D.; Bisogno, T.; Milone, A.; Di Marzo, V., Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in feeding response. *Neuroscience* 1999, 92(1), 377-387.
217. McPartland, J. M.; Pruitt, P., Sourcing the code: searching for the evolutionary origins of cannabinoid receptors, vanilloid receptors, and anandamide. *Journal of Cannabis Therapeutics* 2002, 2(1), 73-104.
218. Begg, M.; Pacher, P.; Bátkai, S.; Osei-Hyiaman, D.; Offertáler, L.; Mo, F. M.; Liu, J.; Kunos, G., Evidence for novel cannabinoid receptors. *Pharmacol Ther* 2005 106, (2), 133-145.
219. Ryberg, E.; Larsson, N.; Sjögren, S.; Hjorth, S.; Hermansson, N. O.; Leonova, J.; Elebring, T.; Nilsson, K.; Drmota, T.; Greasley, P. J., the orphan receptor GPR55 is a novel cannabinoid receptor. *Br J Pharmacol* 2007, 152, (7), 1092-1101.
220. Makriyannis, A., The role of cell membranes in cannabinoid activity in cannabinoid receptors. Academic press: London, 1995; p 87-115.
221. Oddi, S.; Spagnuolo, P.; Bari, M.; D'Agostino, A.; Maccarrone, M., Differential modulation of type 1 and type 2 cannabinoid receptors along the neuroimmune axis. *Int. Rev. Neurobiol.* 2007, 82, 327-337.
222. Mechoulam, R.; Ben-Shabat, S.; Hanus, L.; Ligumsky, M.; Kaminski, N. E.; Schatz, A. R.; Gopher, A.; Almog, S.; Martin, B. R.; Compton, D. R.; Pertwee, R. G.; Griffin, G.; Bayewitch, M.; Barg, J.; Vogel, Z., Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochemical Pharmacology* 1995, 50, (83-90).
223. Mechoulam, R.; Fride, E.; Di Marzo, V., Endocannabinoids (review). *Eur. J. Pharmacol.* 1998, 359, 1-18.
224. Pertwee, R. G., The pharmacology of cannabinoid receptors and their ligands: an overview. *Int. J. Obes. (Lond.)* 2006, 30 Suppl 1, S13-18.
225. Di Marzo, V.; T., B.; De Petrocellis, L., Endocannabinoids and related compounds: walking back and forth between plant natural products and animal physiology. *Chemistry & Biology* 2007, 14, 741-756.
226. Di Marzo, V.; Petrosino, S., Endocannabinoids and the regulation of their levels in health and disease. *Curr. Opin. Lipidol.* 2007, 18, 129-140.
227. McFarland, M. J.; Barker, E. L., Anandamide transport. *Pharmacol. Ther.* 2004, 104, 117-135.

228. Koutek, B.; Prestwich, G. D.; Howlett, A. C.; Chin, S. A.; Salehani, D.; Akhavan, N.; Deutsch, D. G., Inhibitors of arachidonoyl ethanolamide hydrolysis. *J. Biol. Chem.* 1994, 269, 22937-22940.
229. Shrestha, R.; Dixon, R. A.; Chapman, K. D., Molecular identification of a functional homologue of the mammalian fatty acid amide hydrolase in *Arabidopsis thaliana*. *J. Biol. Chem.* 2003, 278, 34990-34997.
230. Chapman, K. D., Occurrence, metabolism, and prospective functions of N-acyl ethanolamines in plants. *Prog. Lipid. Res.* 2004, 43, 302-327.
231. Peat, M. A., Distribution of delta-9-tetrahydrocannabinol and its metabolites. *Advances in analytical toxicology* 1989, 2, 186-217.
232. Wall, M. E., Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. *Clinical pharmacology and therapeutics* 1983, 34, 352-363.
233. Huestis, M. A., Pharmacokinetics and metabolism of the plant cannabinoids, delta-9-tetrahydrocannabinol, cannabidiol and cannabinol. *Handb Exp Pharmacol* 2005, 168, 657-690.
234. Yamamoto, I.; Watanabe, K.; Narimatsu, S.; Yoshimura, H., Recent advances in the metabolism of cannabinoids. *The International Journal of Biochemistry & Cell Biology* 1995, 27, (12), 1365.
235. Mechoulam, R., Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression Prostaglandins, leukotrienes and essential fatty acids 2002, 66, (2-3), 93-99.
236. Vinciguerra, V.; et al., Inhalation of marijuana as an antiemetic for cancer chemotherapy. *New York state journal of medicine* 1988, 85, 525-527.
237. Chang, A. E.; et al., Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate: a prospective randomized evaluation. *Annals of internal medicine* 1979, 91, 819-824.
238. Hepler, R. S.; Petrus, R., Experiences with administration of marijuana to glaucoma patients. *Plenum Medical Book Company: New York*, 1976; p 63-76.
239. Grinspoon, L.; Bakalar, J. B.; Zimmer, L.; Morgan, J. P., Marijuana addiction. *Science* 1997 277, (5327), 749.
240. Mattes, R. D.; et al., Bypassing the first-pass effect for the therapeutic use of cannabinoids. *Pharmacology Biochemistry and Behavior* 1993, 44, 745-747.
241. Mattes, R. D.; et al., Cannabinoids and appetite stimulation. *Pharmacology biochemistry behavior* 1994, 49, 187-195.
242. Wall, M. E.; Perez-Reyes, M., The metabolism of delta-9-tetrahydrocannabinol and related cannabinoids in man. *Journal of Clinical Pharmacology* 1981, 21, 178-189S.
243. Hiller, F. C.; Wilson, F. J. J.; Mazumder, M. K.; Wilson, J. D.; Bone, R. C., Concentration and particle size distribution in smoke from marijuana cigarettes with different delta-9-tetrahydrocannabinol content. *Fundam. Appl. Toxicol.* 1984, 4, 451-454.
244. Matthias, P.; Tashkin, D. P.; Marques-Magallanes, J. A.; Wilkins, J. N.; Simmons, M. S., Effects of varying marijuana potency on deposition of tar and delta-9-THC in the lung during smoking. *Pharmacol. Biochem. Behav.* 1997, 58, 1145-1150.
245. Joy, J. E. *Marijuana and medicine: assessing the scientific base*; Institute of Medicine: 1999.
246. Agurell, S.; et al., Pharmacokinetics and metabolism of delta-1-tetrahydrocannabinol and other cannabinoids with emphasis on man. *Pharmacological Reviews* 1986, 38, 21-43.

247. Ohlsson; et al., Plasma delta-9-THC concentrations and clinical effects after oral and intravenous administrations and smoking. *Clinical pharmacology and therapeutics* 1980, 28, 409-416.
248. Abrams, D. I.; Vizoso, H. P.; Shade, S. B.; Jay, C.; Kelly, M. E.; Benowitz, N. L., Vaporization as a smokeless cannabis delivery system: a pilot study. *Clin. Pharmacol. Ther.* 2007 82, (5), 572-578.
249. Noyes, R.; Brunk, S. F.; Avery, D. H.; Canter, A., The analgesic properties of delta-hydrocannabinol and codeine. *Clinical pharmacology and therapeutics* 1975, 18, 84-89.
250. Campbell, F. A.; Tramer, M. R.; Carroll, D.; Reynolds, D. J.; Moore, R. A.; McQuay, H. J., Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. *British Medical Journal* 2001, 323, 13-16.
251. Cichewicz, D. L., Synergistic interactions between cannabinoid and opioid analgesics. *Life Sci.* 2004, 74, 1317-1324.
252. Lichtman, A. H.; Martin, B. R., The selective cannabinoid antagonist SR141716A blocks cannabinoid-induced anti-nociception in rats. *Pharmacology Biochemistry and Behavior* 1997, 57, 7-12.
253. Fuentes, J. A.; Ruiz-Gayo, M.; Manzanares, J.; Vela, G.; Reche, I.; Corchero, J., Cannabinoids as potential new analgesics. *Life Sciences* 1999, 65, 675-685.
254. Fox, A.; Kessingland, A.; Gentry, C.; McNair, K.; Patel, S.; Urban, L.; James, I., The role of central and peripheral cannabinoid 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. *Pain* 2001, 92, 91-100.
255. Johnson, M. R.; Melvin, L. S.; Althuis, T. H.; Brinda, J. S.; Harbert, C. A.; Milne, G. M.; Weissman, A., Selective and potent analgetics derived from cannabinoids. *Journal of Clinical Pharmacology* 1981, 21, 271s-282s.
256. Monnet-Tschudi, F.; Hazekamp, A.; Perret, N.; Zurich, M. G.; Mangin, P.; Giroud, C.; Honegger, P., Delta-9- tetrahydrocannabinol accumulation, metabolism and cell-type specific adverse effects in aggregating brain cell cultures. *Toxicology and Applied Pharmacology* 2008, 228, 8-16.
257. Walton, R. P.; Martin, L. F. K., J.H., The relative activity of various purified products obtained from American grown hashish. *J. Pharmacol. Exp. Ther.* 1938, 62, 239.
258. Dansak, D. A., As an antiemetic and appetite stimulant in cancer patients. McFarland & Co.: Jefferson, NC, 1997; p 69-83.
259. Plasse, T. F.; Gorter, R. W.; Krasnow, S. H.; Lane, M.; Shepard, K. V.; Wadleigh, R. G., Recent clinical experience with dronabinol. *Pharmacology, Biochemistry and Behaviour* 1991, 40(3), 695-700.
260. Noye, R.; Baram, D. A., Cannabis analgesia. *Comprehensive Psychiatry* 1974, 15(6), 531-535.
261. Clifford, D. B., Tetrahydrocannabinol for tremor in multiple sclerosis. *Annals of Neurology* 1983, 13(6), 669-671.
262. Muller-Vahl, K. R.; Kolbe, H.; Schneider, U.; Emrich, H. M., Cannabis in movement disorders. *Forsch. Komplementarmed.* 1999, 6 Suppl 3, 23-27.
263. Hepler, R. S.; Frank, I. R., Marijuana smoking and intraocular pressure. *JAMA.* 1971, 217(10), 1392.
264. Milligan, G.; Bond, R. A.; Lee, M., Inverse agonism: pharmacological curiosity or potential therapeutic strategy? *Trends in Pharmacological Sciences* 1995, 16, 10-13.
265. Mackie, K.; Stella, N., Cannabinoid receptors and endocannabinoids: evidence for new players. *AAPS Journal* 2006, 8, E298-E306.
266. Goutopoulos, A.; Makriyannis, A., From cannabis to cannabinergics: new therapeutic opportunities. *Pharmacol. Ther.* 2002, 95, 103-117.

267. Palmer, S. L.; Thakur, G. A.; Makriyannis, A., Cannabinergic ligands. *Chem. Phys. Lipids* 2002, 121, 3-19.
268. Thakur, G. A.; Nikas, S. P.; C., L.; Makriyannis, A., Structural requirements for cannabinoid receptor probes. *Handb. Exp. Pharmacol.* 2005, 168, 209-246.
269. Thakur, G. A.; Duclos jr, R. I.; Makriyannis, A., Natural cannabinoids: templates for drug discovery. *Life Sciences* 2005, 78, 454-466.
270. Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mechoulam, R.; Pertwee, R. G., International union of pharmacology: XXVII, classification of cannabinoid receptors. *Pharmacol. Rev.* 2002, 54, 161-202.
271. Thakur, G. A.; Nikas, S. P.; Makriyannis, A., CB1 receptor ligands. *Mini. Rev. Med. Chem.* 2005, 5, (631-640).
272. Huffman, J. W.; Liddle, J.; Yu, S.; Aung, M. M.; Abood, M. E.; Wiley, J. L.; Martin, B. R., 3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. *Bioorg. Med. Chem.* 1999, 7, (12), 2905-2914.
273. Rhee, M. H., Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylyl cyclase. *J. Med. Chem.* 1997, 40, 3228-3233.
274. Huffman, J. W.; Miller, J. R.; Liddle, J.; Yu, S.; Thomas, B. F.; Wiley, J. L.; Martin, B. R., Structure-activity relationships for 1',1'-dimethylalkyl-delta8-tetrahydrocannabinols. *Bioorg. Med. Chem.* 2003, 11, 1397-1410.
275. Huffman, J. W.; Bushell, S. M.; Miller, J. R.; Wiley, J. L.; Martin, B. R., 1-methoxy-, 1-deoxy-11-hydroxy- and 11-hydroxy-1-methoxy-delta(8)-tetrahydrocannabinols: new selective ligands for the CB2 receptor. *Bioorg. Med. Chem.* 2002, 10, 4119-4129.
276. Melvin, L. S.; Milne, G. M.; Johnson, M. R.; Subramaniam, B.; Wilken, G. H.; Howlett, A. C., Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. *Mol. Pharmacol.* 1993, 44, 1008-1015.
277. Tong, W.; Collantes, E. R.; Welsh, W. J.; Berglund, B. A.; Howlett, A. C., Derivation of a pharmacophore model for anandamide using constraint conformational searching and comparative molecular field analysis. *J. Med. Chem.* 1998, 41, 4207-4215.
278. Picone, R. P.; Khanolkar, A. D.; Xu, W.; Ayotte, L. A.; Thakur, G. A.; Hurst, D. P.; Abood, M. E.; Reggio, P. H.; Fournier, D. J.; Makriyannis, A., (-)-7'-isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with the cysteine in helix six and activates the CB1 cannabinoid receptor. *Mol. Pharmacol.* 2005, 68, 1623-1635.
279. Ryan, W. J.; Banner, W. K.; Wiley, J. L.; Martin, B. R.; Razdan, R. K., Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain. *J. Med. Chem.* 1997, 40, 3617-3625.
280. Khanolkar, A. D.; Makriyannis, A., Structure-activity relationships of anandamide, an endogenous cannabinoid ligand. *Life Sciences* 1999, 65, 607-616.
281. Reggio, P. H.; Traore, H., Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase. *Chem. Phys. Lipids* 2000, 108, 15-35.
282. Klein, T. W.; Newton, C. A., Therapeutic potential of cannabinoid-based drugs. *Adv Exp Med Biol* 2007, 601, 395-413.
283. Russo, E. B.; Guy, G. W., A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. *Med. Hypotheses* 2006, 66, 234-246.

284. Gaal, L. F. v.; Rissanen, A. M.; Scheen, A. J.; Ziegler, O.; Rossner, S., Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. *Lancet* 2005, 365, 1389-1397.
285. Burstein, S. H.; Karst, M.; Schneider, U.; Zurier, R. B., Ajulemic acid: a novel cannabinoid produces analgesia without a "high". *Life Sci.* 2004, 75(12), 1513-1522.
286. Salim, K.; Schneider, U.; Burstein, S.; Hoy, L.; Karst, M., Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. *Neuropharmacology* 2005 48, (8), 1164-1171.
287. Feigenbaum, J. J.; Bergmann, F.; Richmond, S. A.; Mechoulam, R.; Nadler, V.; Kloog, Y.; Sokolovsky, M., Nonpsychotropic Cannabinoid Acts as a Functional N-Methyl-D-Aspartate Receptor Blocker. *Proceedings of the National Academy of Sciences of the United States of America* 1989, 86, (23), 9584-9587.
288. Garrett, E. R.; Hunt, C. A., Physicochemical properties, solubility, and protein binding of delta9-tetrahydrocannabinol. *J. Pharm. Sci.* 1974, 63, 1056-1064.
289. Stern, E.; Lambert, D. M., Medicinal chemistry endeavors around the phytocannabinoids. *Chem Biodivers* 2007 4, (8), 1707-1728.
290. Hazekamp, A.; Verpoorte, R., Structure elucidation of the tetrahydrocannabinol complex with randomly methylated-beta-cyclodextrin. *Eur. J. Pharm. Sci.* 2006, 29, (5), 340-347.
291. Hollister, L. E., Structure-activity relationships in man of cannabis constituents, and homologues and metabolites of delta-9-tetrahydrocannabinol. *Pharmacol.* 1974, 11, 3-11.
292. Herring, A. C.; Faubert Kaplan, B. L.; Kaminski, N. E., Modulation of CREB and NF-kappaB signal transduction by cannabinol in activated thymocytes. *Cell. Signal.* 2001, 13, 241-250.
293. Jan, T. R.; Rao, G. K.; Kaminski, N. E., Cannabinol enhancement of interleukin-2 (IL-2) expression by T cells is associated with an increase in IL-2 distal nuclear factor of activated T cell activity. *Mol. Pharmacol.* 2002, 61, 446-454.
294. Watts, G., High hopes for cannabinoid analgesia. *BMJ* 2004, 329, 257-258.
295. Baker, D.; Pryce, G.; Giovannoni, G.; Thompson, A. J., The therapeutic potential of cannabis. *Lancet Neurology* 2003, 2, 291-298.
296. Russo, E. B., Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? *Neuro Endocrinol Lett* 2004 25, (1-2), 31-39.
297. Joy, J. E.; Watson, S. J.; Besnon Ja, e., *Marijuana and medicine*. National academy press: Washington DC, 1999.
298. Vigano, D.; Rubino, T.; Parolaro, D., Molecular and cellular basis of cannabinoid and opioid interactions. *Pharmacol. Biochem. Behav.* 2005, 81(2), 360-368.
299. Pertwee, R. G., Cannabinoid pharmacology: the first 66 years. *Br. J. Pharmacol.* 2006, 147 Suppl 1, S163-171.
300. Hajos, N.; Katona, I.; Naiem, S. S.; MacKie, K.; Ledent, C.; Mody, I.; Freund, T. F., Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. *Eur. J. Neurosci.* 2000, 12, 3239-3249.
301. Shen, M.; Piser, T. M.; Seybold, V. S.; Thayer, S. A., Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. *J. Neurosci.* 1996, 16, 4322-4334.

302. Glass, M.; Dragunow, M.; Faull, R. L., The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. *Neuroscience* 2000, 97, 505-519.
303. Fowler, C. J., Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents: non-psychoactive cannabinoids, 'entourage' compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid psychotropic effects. *Brain res. brain res. rev.* 2003, 41, 26-43.
304. Panikashvili, D.; Shein, N. A.; Mechoulam, R.; Trembovler, V.; Kohen, R.; Alexandrovich, A.; Shohami, E., The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. *Neurobiol Dis* 2006 22, (2), 257-264.
305. Kumar, R. N.; Chambers, W. A.; Pertwee, R. G., Pharmacological actions and therapeutic uses of cannabis and cannabinoids. *Anaesthesia* 2001, 56, 1059-1068.
306. Ofek, O.; Karsak, M.; Leclerc, N.; Fogel, M.; Frenkel, B.; Wright, K.; Tam, J.; Attar-Namdar, M.; Kram, V.; Shohami, E.; Mechoulam, R.; Zimmer, A.; Bab, I., Peripheral cannabinoid receptors, CB2, regulates bone mass. *Proc. Natl. Acad. Sci. USA* 2006, 103, (696-701).
307. Fowler, C. J.; Tiger, G.; Stenstrom, A., Ibuprofen inhibits rat brain deamidation of anandamide at pharmacologically relevant concentrations. Mode of inhibition and structure-activity relationship. *J. Pharmacol. Exp. Ther.* 1997, 283, 729-734.
308. Bisogno, T.; Cascio, M. G.; Saha, B.; Mahadevan, A.; Urbani, P.; Minassi, A.; Appendino, G.; Saturnino, C.; Martin, B.; Razdan, R.; Di Marzo, V., Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. *Biochim. Biophys. Acta* 2006, 1761, 205-212.
309. Gertsch, J., Immunomodulatory lipids in plants: plant fatty acid amides and the human endocannabinoid system. *Planta Med.* 2008, in print.
310. Howlett, A. C., Cannabinoid receptor signalling. *Handb. Exp. Pharmacol.* 2005, 168, 53-79.
311. Smith, P. B.; Welch, S. P.; Martin, B. R., Interaction between d9-tetrahydrocannabinol and kappa opioids in mice. *Journal of Pharmacology and Experimental Therapeutics* 1994, 268, 1382-1387.
312. Williams, I. J.; Edwards, S.; Rubo, A.; Haller, V. L.; Stevens, D. L.; Welch, S. P., Time course of the enhancement and restoration of the analgesic efficacy of codeine and morphine by delta9-tetrahydrocannabinol. *Eur. J. Pharmacol.* 2006, 539(1-2), 57-63.
313. Radin, N. S., Killing tumours by ceramide-induced apoptosis: a critique of available drugs. *Biochemical Journal* 2003, 371, 243-256.
314. Adams Jr, T. C.; Jones, L. A., Phytosterols of Cannabis smoke. *J Agric Food Chem* 1975, 23, (2), 352-353.
315. Raduner, S.; Majewska, A.; Chen, J. Z.; Xie, X. Q.; Hamon, J.; Faller, B.; Altmann, K. H.; Gertsch, J., Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. *J. Biol. Chem.* 2006, 281, 14192-14206.
316. Gertsch, J.; Raduner, S.; Altmann, K. H., New natural noncannabinoid ligands for cannabinoid type-2 (CB2) receptors. *J. Recept. Signal Transduct. Res.* 2006, 26, (5-6), 709-30.
317. Gertsch, J.; Leonti, M.; S., R.; Racz, I.; Chen, J. Z.; Xie, X. Q.; Altmann, K. H.; Karsak, M.; Zimmer, A., Beta-caryophyllene is a dietary cannabinoid. *PNAS USA* 2008, 105, (26), 9099-9104

318. Woelkart, K.; Salo-Ahen, O. M.; Bauer, R., CB receptor ligands from plants. *Curr. Top. Med. Chem.* 2008, 8, (3), 173-186.
319. Kuo, C. T.; Hsu, M. J.; Chen, B. C.; Chen, C. C.; Teng, C. M.; Pan, S. L.; Lin, C. H., Denbinobin induces apoptosis in human lung adenocarcinoma cells via Akt inactivation, Bad activation, and mitochondrial dysfunction. *Toxicol. Lett.* 2008, 177, (1), 48-58.
320. Walker, J.; Huang, S., Cannabinoid analgesia. *Pharmacol. Ther.* 2002, 95, 127-135.
321. Sharp, D., Highs and lows of cannabis. *Lancet* 2004, 363, 344.
322. Ahmed SA; Ross SA, Slade D, Radwan MM, Zulfiqar F, Elsohly MA. Cannabinoid ester constituents from high-potency Cannabis sativa. *J Nat Prod.* 2008 Apr;71(4):536-42.
323. Flores-Sanchez JJ, Verpoorte R. Secondary metabolism in cannabis. *Phytochem Rev* (2008) 7:615-639
324. Devane WA, Breuer A, Sheskin T, Järbe TU, Eisen MS, Mechoulam R. A novel probe for the cannabinoid receptor. *J Med Chem.* 1992 May 29;35(11):2065-9.
325. DiMarzo V. CB(1) receptor antagonism: biological basis for metabolic effects. *Drug Discov Today.* 2008 Dec;13(23-24):1026-41.
326. Meiri E, Jhangiani H, Vredenburg JJ, Barbato LM, Carter FJ, Yang HM, Baranowski V. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. *Curr Med Res Opin.* 2007 Mar;23(3):533-43.
327. Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Christensen B. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. *J Clin Oncol.* 2002 Jan 15;20(2):567-73.
328. Esfandyari T, Camilleri M, Busciglio I, Burton D, Baxter K, Zinsmeister AR. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. *Am J Physiol Gastrointest Liver Physiol.* 2007 Jul;293(1):G137-45
329. Avraham Y, Ben-Shushan D, Breuer A, Zolotarev O, Okon A, Fink N, Katz V, Berry EM. Very low doses of delta 8-THC increase food consumption and alter neurotransmitter levels following weight loss. *Pharmacol Biochem Behav.* 2004 Apr;77(4):675-84.
330. Colasanti BK. A comparison of the ocular and central effects of delta 9-tetrahydrocannabinol and cannabigerol. *J Ocul Pharmacol.* 1990 Winter;6(4):259-69.
331. Appendino G, Gibbons S, Giana A, Pagani A, Grassi G, Stavri M, Smith E, Rahman MM. Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. *J Nat Prod.* 2008 Aug;71(8):1427-30.
332. Formukong EA, Evans AT, Evans FJ. The inhibitory effects of cannabinoids, the active constituents of Cannabis sativa L. on human and rabbit platelet aggregation. *J Pharm Pharmacol.* 1989 Oct;41(10):705-9.
333. Nahas G, Trouve R. Effects and interactions of natural cannabinoids on the isolated heart. *Proc Soc Exp Biol Med.* 1985 Nov;180(2):312-6.
334. Shook JE, Burks TF. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. *J Pharmacol Exp Ther.* 1989 May;249(2):444-9.
335. Akinshola BE, Chakrabarti A, Onaivi ES. In-vitro and in-vivo action of cannabinoids. *Neurochem Res* (1999) 24(10):1233-1240.
336. Formukong EA, Evans AT, Evans FJ. Analgesic and antiinflammatory activity of constituents of Cannabis sativa L. *Inflammation* 12(4), 1988, 361-371

337. Davis WM, Hatoum NS. Neurobehavioral actions of cannabichromene and interactions with delta 9-tetrahydrocannabinol. *Gen Pharmacol.* 1983;14(2):247-52.
338. Petri, G. (1988) in *Biotechnology in Agriculture and Forestry: Medicinal and Aromatic Plants I* (Bajaj, Y. P. S., ed) Vol. 4, pp. 333–349, Springer-Verlag, Heidelberg, Germany
339. Stevens JF, Page JE. Xanthohumol and related prenylflavonoids from hops and beer: to your good health! *Phytochemistry.* 2004 May;65(10):1317-30.
340. Gerritsen ME, Carley WW, Ranges GE, Shen CP, Phan SA, Ligon GF, Perry CA. Flavonoids inhibit cytokine-induced endothelial cell adhesion protein gene expression. *American Journal of Pathology* 1995; 147(2):251-272
341. Zurier RB, Sun YP, George KL, Stebulis JA, Rossetti RG, Skulas A, Judge E, Serhan CN. Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4. *FASEB J.* 2009 Jan 5 [Epub ahead of print]
342. Scully C. Cannabis; adverse effects from an oromucosal spray. *Br Dent J.* 2007 Sep 22;203(6):E12
343. Reiter A, Hake J, Meissner C, Rohwer J, Friedrich HJ, Oehmichen M. Time of drug elimination in chronic drug abusers. Case study of 52 patients in a “low-step” detoxification ward. *Forensic Sci. Int.* 2001; 119: 248-253
344. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. *Clin. Pharmacokinet.* 2003; 42: 327-360
345. Van der Kooy F, Pomahacova B, Verpoorte R. Cannabis smoke condensate II: influence of tobacco on tetrahydrocannabinol levels. *Inhal Toxicol.* 2009 Feb;21(2):87-90.
346. Henquet C, Rosa A, Krabbendam L, Papiol S, Fananás L, Drukker M, Ramaekers JG, van Os J. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. *Neuropsychopharmacology.* 2006 Dec;31(12):2748-57.
347. Williams SJ, Hartley JP, Graham JD. Bronchodilator effect of delta1-tetrahydrocannabinol administered by aerosol of asthmatic patients. *Thorax.* 1976 Dec;31(6):720-3.
348. Mahlberg PG, Kim ES. Accumulation of cannabinoids in glandular trichomes of *Cannabis* (Cannabaceae). *J Ind Hemp* 2004; 9:15-36
349. JM McPartland, M Glass, RG Pertwee. Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. *British Journal of Pharmacology* (2007) 152, 583–593
350. Thomas BF, Compton DR, Martin BA. Characterization of the lipophilicity of natural and synthetic analogs of delta-9-tetrahydrocannabinol and its relationship to pharmacological potency. *Journal of pharmacology and experimental therapeutics* 1990;255(2):624-630
351. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. *JAMA.* 2003 Oct 1;290(13):1757-62
352. Maas AI, Murray G, Henney H 3rd, Kassem N, Legrand V, Mangelus M, Muizelaar JP, Stocchetti N, Knoller N; Pharms TBI investigators. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. *Lancet Neurol.* 2006 Jan;5(1):38-45.
353. Fox P, Bain PG, Glickman S, Carroll C, Zajicek J. The effect of cannabis on tremor in patients with multiple sclerosis. *Neurology.* 2004 Apr 13;62(7):1105-9.

354. Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, Jamison RN. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. *J Pain*. 2008 Mar;9(3):254-64
355. Russo, EB. History of Cannabis and Its Preparations in Saga, Science, and Sobriquet. *Chemistry and biodiversity* 2007;4:1614-1648
356. Corrigan D, Lynch JJ (1980) An investigation of potential staining reagents for the glandular trichomes of *Cannabis sativa*. *Planta Medica*: 163-169
357. Debruyne, D., Albessard, F., Bigot, M. C., and Moulin, M. (1994) Comparison of three advanced chromatographic techniques for cannabis identification. *Bull. Narc.* 46, 109-121.
358. Pothier, J., Galand, N., and Viel, C. (1992) Rapid characterization of stupeficient and toxic substances by pressurized thin-layer chromatography. *J. Toxicol. Clin. Exp.* 12, 495-501.
359. Oroszlan, P., Verzar-Petri, G., Mincsovcis, E., and Szekely, T. (1987) Separation, quantitation and isolation of cannabinoids from *Cannabis sativa* L. by overpressured layer chromatography. *J. Chromatogr.* 388, 217-224.
360. Bailey, K. (1979) The value of the Duquenois test for cannabis—a survey. *J. Forens. Sci.* 24, 817-841.
361. Flores-Sanchez IJ (2008) Polyketide synthases in *Cannabis sativa* L.. Dissertation, Univ. Leiden, The Netherlands
362. Guindon J, Hohmann AG. (2008) Cannabinoid CB2 receptors: A therapeutic target for the treatment of inflammatory and neuropathic pain. *Br J Pharmacol.* 153, 319-334.
363. Cheng Y, Hitchcock SA. (2007) Targeting cannabinoid agonists for inflammatory and neuropathic pain. *Expert Opin Investig Drugs* 16, 951-965.
364. Bohlmann F, Hoffmann E (1979) Cannabigerol-ähnliche verbindungen aus *Helichrysum umbraculigerum*. *Phytochemistry* 18, 1371-1374.
365. Asakawa Y, Takikawa K, Toyota M, Takemoto T (1982) Novel bibenzyl derivatives and ent-cuparene-type sesquiterpenoids from *Radula* species. *Phytochemistry* 21, 2481-2490.
366. Mechoulam R, editor. *Cannabinoids as therapeutics*. Basel: Birkhaeuser Verlag; 2005. p. 272.
367. Pertwee, R.G., The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. *Br. J. Pharmacol.* 2008, 153, 199-215.
368. Turner CE, Mole ML. Chemical components of *Cannabis sativa*. *JAMA*. 1973;225(6):639
369. Mechoulam, R. Alkaloids in *Cannabis sativa* L. In: *The alkaloids: chemistry and pharmacology*. Vol. 34. Brussi A., ed. Academic Press Inc, USA. 77-93
370. Hamada, T. New development of photo-induced electron transfer and total synthesis of natural product. *Journal of the Pharmaceutical Society of Japan* 2005, 125, 1-16.
371. Wahby, I.; Arráez-Román, D.; Segura-Carretero, A.; Ligeró, F.; Caba, J.M.; Fernández-Gutiérrez, A. Analysis of choline and atropine in hairy root cultures of *Cannabis sativa* L. by capillary electrophoresis-electrospray mass spectrometry. *Electrophoresis* 2006, 27, 2208-2215.
372. Johnson, J.M.; Lemberger, L.; Novotny, M.; Forney R.B.; Dalton W.S.; Maskarinec M.P. (1984) Pharmacological activity of the basic fraction of marihuana whole smoke condensate alone and in combination with delta-9- tetrahydrocannabinol in mice. *Toxicol Appl Pharmacol* 72: 440-448.

373. Klein F.K. and Rapoport H. (1971) Cannabis alkaloids. *Nature* 232: 258-259.
374. Molnar J., Csiszar K., Nishioka I. and Shoyama Y. (1986) The effects of cannabispino compounds and tetrahydrocannabinolic acid on the plasmid transfer and maintenance in *E. coli*. *Acta Microbiol. Hung.* 33: 221-231.
375. Back, K.; Jang, S.M.; Lee, B.C.; Schmidt, A.; Strack, D.; Kim, K.M. Cloning and Characterization of a Hydroxycinnamoyl-CoA:Tyramine N-(Hydroxycinnamoyl)Transferase Induced in Response to UV-C and Wounding from *Capsicum annuum*. *Plant and Cell Physiology* 2001, 42(5), 475-481.
376. Ayres, D.C., Loike, J.D. (1990) Chemistry and Pharmacology of natural products. Lignans: Chemical, biological and clinical properties. Phillipson J.D., Ayres D.C. and Baxter H., eds. Cambridge University Press, UK.
377. Lewis N.G. and Davin L.B. (1999) Lignans: Biosynthesis and function. In: Comprehensive natural products chemistry. Barton D.H.R., Nakanishi K. and Meth-Cohn O., eds. Vol. 1. Polyketides and other secondary metabolites including fatty acids and their derivatives. Sankawa U., ed. Elsevier Science Ltd., Oxford, UK. 639-712.